IERMA0181~ - EPIC · oo~S04 . Target Fee --Incentive Arrangement: Maximum Fee: Minimum Fee: (Share Ratio: Government/Contractor) DASG60-98-C-000 1 P00254 Page 3 of 12 (b )(4) (b )(4)

AMENDMENT OF SOUCITATIONIMODIFICATION OF CONTRACT

~MENDMENTIMODIFICA'DON NO. REQ.NO.

FO0253 6. ISSUED BY·

U8A8MOCIARSTRAT SMOC-ROC

CODE <.:.:.;:...;.;;:;:.::;..... __ -17. ADMINISTERED BY (Ifotlo""than - DCMARAYTHEON

POBOX 1800 HUNTSIIIU AI.. 3e11D7·3801

5DAPfILE HiLl ORIIIE MlST2FR2 TEWCllBURY MA 01818

8. NAME AND ADDRESS OF CONTRACTOR (No., ~reet, Colllty, ~atc and Zip Code) RAYTHEON COMPANY 360 LOY.aL ST. ANDO\IERMA0181~

10.o\.M2D. OF CONTRACTIORDERNO. ll'ougvo98-c.ooo1

nUnDored lolioilalion ia ~ .. -ut IKth in Item 14. 1hobourond dlla l!*itad "r~p' o~ i. not ClIlDllded. O. nu.1 IckDowledsa ra"pl orlbi ....... 01 .... ' priorto tha bour Ind dlla Ipeoiled in tba lolicllalion or _ .-.ncIad by One oftbe 1fI1IowiDS .-thoda: (I) By eOJqlllllinB It_ 8 IIId 15, .. 01 retumins ""pi. ortba _dlllml; (b) BylClcnowledsi. reoeipl oftbi. _01_1 OlD ... oopy oflbl 0. ,ubnitted; or (e) By lapll1lllleltaror toles_which inelud~ce to die .olicitalion.nd _dillin, nunDln. FAILURE OF YOURACKNOWLEDOMENTTO BE RECEIVED AT1HE PLACE DESIGNA mD FOR 1HE RECElPTOF OFFERS PRIOR '10 lHE HOUR AND DATE SPECIFIBD MAY RESUL TIN

REJECTION OF YOUR OFFBR. Ifby virtul ofthil_dllllllt YOII deaiteto chuBe In 0. "rudy .ubnilted, luch chinS. n)' b ..... a by Ielesnmor lellar, provided _h talosnunor lottar 1liiie .. ra ..... ce to the lolimtatioa .nd Ihilllllllldll'Et, .. d i. received prior to the opllllins hour ud dale epecifed.

ACCOUNTING AND APPROPRIATION DATA (lfrequircd)

13. THIS ITEM APPLIES ONLY TO MODIFICA IT MODlFIESTHECONTRACfIORDER

THIS CHANGE ORDER IS ISSUED PURSUANT TO: (SPecifY althorlty) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM lOA.

TO REFLECT THE ADMINISTRATIVE \..nIU'I'..E.i> (such as chanlCS in paying P~ANT TOTHE AUTHORITY OF FAR

OTHER (~ecify type of modification and authority)

E. IMPORT ANT: Contractor [!] is not, 0 is required to signlhis <bcument 8Ild rctlR copies to the issuing oftlce.

14. DESCRIPTION OF AMENDMENTIMODIFICATION (Organized by UO' section headings, including solicitation/contract SIiljcct matter Wiere feasible.) Modification Control Number: ___

The purpose of this rrodlflcatlon is~Mxflflcation POO251. ACANMK, fromCM GFEBSO01015913300001 to CIt GFEBSOO1015913300030. All other tem. and concltlona renaln the lame and no addIIIonai fundilg hal been provided.

II provided hlmn, alii.",. and ocnditioal oftbe doculllDllt reimJced ia IItm9A or lOA, II

\. NAME AND TITLE OF SlCIIIER (Type or print)

IS8.00NTRACTORIOFFEROR I SC. DATE SIGNED

(b )(6)

30·105·04 APPROVED BY OIRM 11-84

OOd.'501 STANDARD FORM 30 (Rev. 10·83) Prescribed by GSA FAR (48 CFR) 53.243

SECTION SF 30 BLOCK 14 CONTINUA nON PAGE

(End of Summary of Changes)

OO~50~

DASG60-98-C-OOO 1 P00253

Page 2 of2

AMENDMENT OF SOLICITATIONIMODIFICATION OF CONTRACT

USASMDClAASTRAT SMOC·RDC PO !lOX 1!Dl HUNT$'v1J.£ It. 39107.:311)1

DCMA RAYTHEON "API'\,,( HIll. ORNE ,.,,"'" lEWIS8URY 1M 01878

AND AO[)RFS'\OF mNTRACfOR (No .• Sh eet, County, !ialc and Zip Co~) RAYTHEON COMP.IHY 3eOlCW'aL.1T. ANOO'JER MA018'1(l.4O)

v

(SEE ITEM II)

l OA. MOO. OF CONTRACfK>ROER NO. 0l.SG60-98-COOO1

lOB. DATED (SEE ITEM 13)

I I , , i ... ' .... d.d II Hlllnb ;m I,em 14. ThehourOlld datupacilod brrocclp. " fUji, o iUJllended, D 101l0t e>IIendtd .

Oltr ""a. tdno .. (cod lle '-;pl oflbi • ...,lIdlllmt priono tbo bour IIIId dote . , ,,,,' Ied i. dle.olici, .. i()n Or" ...... ded by one oftb ,l>lIo"'08 _bodt: (0) By ...,,,,,1"'08 II .... , .. 01 I ".lIIId reI"",ill8 ___ O(Ipi .. ortbe _dIJo:OI: (b) By ICkQowledaioi rltCelpl ofthi.ln"ClIdmeoot on cICb copy oflbc ob n brritted:

or(e) By .epant. letIoror telIS""" .... kkb iBcl,,"" • rri_ to Ibuolici latiOfl W _01""", n ...... , FAILURE OF YOURACXNOWlEOOMllNTlO 8E RECEM!O "TTHE PLACE DESIGNATED FOR 1M!> RECEIPTOf OFfERS PRIO R 10 nil! HOUR AND 010 TE SPECIFIED MA Y RElIU l TIN

REEC'nON OF YOUR OFFEL Ifby y;lt"oorth,. omeod ..... ' yOil d"',..lo ...... lOll 0. 1I....ty .. haiRed, l udl dlq. -.y be...scby 1eI ...... or lemr, pravide:l -=h td q"""'" Ielter ..... eo ......... to the oolicilot;"" .. d this _dmtnt. tnd ;1 received prior lO!!Ie opaili>a hour _d dote . pea,*,.

See Schedule

CIIANGE ORDER ITBM 14 ARE MADE IN THE CONT RAcr ORDER NO. IN ITEM l OA.

as changes in payins I

THIS SUPPLEMEm AL A<JtEEMENT IS ENTERED INTO PURSUANT TO AlffHORlT Y OF:

Contractor isnOI, is reqJiredlo sign this OOCI.IneDI andretWl oop;es to the issuillg offlCC.

. DESCRIPTION (Organized by UCF sectioo beadings, incilking solicitationloontract subject matter ""'ere feasible.) Modification Control Number: (b)( 6)

To issue a change order training due to replacement of sotjiers conductilg the LUT as oulli\ed In a:AM-CAB-B letters, JLENS-2012· 012 and JJ..eS.2012-018, dated Mlrch 30, 2012 and Aprl2S, 2012, respectively. The required trairlng is as foBow s: Genie Man-Lift Trairling, lAah Test and Training Range (LITlRj , 12 students: fight Ci'ector Training, ~ 6 students; and Maintainer Course Training, lJTTR 17 students .

. , -to NAME AND TITLE OF SIGlER (Type or print)

COm'RACfORlOFFEROR DATE SIGNED

(b)(6)

I )0 (Rev. 10-83) APPROVED BY OIRM 11-84 Prescribed by GSb.

FAR (43 CPR) 53.24)

SECTION SF 30 BLOCK 14 CONTINUATION PAGE

SUMMARY OF CHANGES

1. SECTION A - SOLICITATION/CONTRACT FORM

DASG60-98-C-000 1 P00254

Page 2 of12

The total cost of this contract was increased by $724,879.00 from $1,920,203,430.00 to $1,920,928,309.00.

2. SECTION B - SUPPLIES OR SERVICES AND PRICES

SUBCLIN 0017 AA

The target cost has increased by from to ,:====~ The target profit/fee has increased by from to. 7 The total cost of this line item has increased by $724,879.00 from $1,682.454.983.00 to

$1,683,179,862.00.

This includes an increase in target cost of :onsisting of cost and a lcrease in facilities capital cost of money, and an increase in target fee target cost less facilities capital cost of money.

CLIN 0030 The total cost of this line item has increased by •••• tr,O~J ••••• to t ••••••••

• As stated in Modification P00251, CLIN 0030 has been established for the sole purpose of obligating GFEBS funding for performance of SubCLIN 0017 AA. The value of CLIN 0030 equates to the amount of GFEBS funding obligated for performance of SubCLIN 00 17 AA and should not be considered additional contract value. Informational SubCLINs under CLIN 0030 will be established each time additioanl GFEBS funding is obligated. CLIN 0030 and its SubCLINS will not be segregated from SubCLIN 0017AA, identified, accounted for, invoiced, analyzed, or reported separately from SubCLIN 0017, including EVMS. All scope remains under SubCLIN 0017 AA with associated incentive events and flat zones.

SUBCLIN 003002 is added as follows:

ITEM NO SUPPLIES/SERVICES QUANTITY 003002

GFEBS Funding for SubCLIN 0017AA

CPIF

FOB: Destination

ACRNMX CIN: GFEBSOOlO17438300030

UNIT UNlTPRICE

B-17. INCENTIVE FEE FOR SUBCLIN 00 17AA1CLIN 0018 (SEEH-19):

AMOUNT

$719,132.00

In accordance with FAR 52.216-7, entitled "Allowable Cost and Payments", and FAR 52.216-10, entitled "Incentive Fee", the total amount for reimbursement of cost and fee for performance under SubCLIN 0017 AAlCLlN 0018 are set forth below:

Target Cost

oo~S04

Target Fee --Incentive Arrangement: Maximum Fee: Minimum Fee:

(Share Ratio: Government/Contractor)

DASG60-98-C-000 1 P00254

Page 3 of 12

(b )(4)

(b )(4)

Underrun: __ or the amount by which the total allowable cost is less than the target cost until maximum fee is attained.

(b )(4)

Overrun: ••• the amount by which the total allowable cost exceeds the target cost until minimum (b) (4) fee is attained.

FAR 52.216-10, INCENTIVE, paragraph (e)(1), is stated as follows:

(e) Fee Payable.

(1) The fee payable under this contract shall be the target fee increased b_nts for every dollar that the total allowable cost is less than the target cost or decreased b~ts for every doilail1lat the total allowable cost exceeds the target cost. In no event shall the fee be greater th~ent or less th~cent ofthe target cost.

B-18. TARGET COST. TARGET FEE. I'.1INIMUM INCENTIVE FEE. MAXIMUM INCENTIVE FEE.

AND INCENTIVE ARRANGEMENT FOR SUBCLIN 0017AA/CLIN 0018:

SUBCLIN 0017 AA - (Two SDD ]LENS Systems)

a. Target cost:

b. Target fee:

c. Minimum incentive fee:

d. Maximum incentive fee:

e. Total target cost and target fee: $1,683,179,862

3. SECTION G - CONTRACT ADMINISTRATION DATA

Accounting and Appropriation

Summary for the Payment Office

As a result of this modification, the total funded amount for this document was increased by $719,132.00 from $1,876,986,879.63 to $1,877,706,011.63.

SUBCLIN 003002 (GFEBS funding for SubCLIN 00 17AA):

Funding on SUBCLlN 003002 is initiated as follows:

ACRN:MX

elN: GFEBSOOI017438300030

oo~5D5

(b )(4)

(b )(4)

(b )(4) (b )(4) (b )(4) (b )(4) (b )(4)

Acctng Data: 02120122013204000001 171722550030003242A.0000013.1.1

Increase: $719,132.00

Total: $719,132.00

Cost Code: A5XFJ

DASG60-98-C-000 1 P00254

Page 4 of12

6100.9000021001

Target Cost, Target Fee, and total for the above increase of$719,132 is distributed as follows and includes an increase in target cost os 7 cost and f facilities capital cost of money) and an increase in target fee of_

Target Cost Target Fee Total

IMPLEMENTATION OF AND EXPLANATION OF THERELATIONSillP OF THE LIMITATION OF FUNDS (LOF) CLAUSE TO FEE OBLIGATIONS, subparagraph c., is revised to read as follows:

SUBCLIN 0017 AA : THIS CUMULATIVE PRIOR MODIFICATION TOTAL·

(I) Amount Required for Full Funding, Including Fee: $1,682,454,983 $724,879 $ 1,683,179,862

(2) Amount Allotted Under the LOF Clause for Payment of Costs: $

(3) Amount Separately Obligated for Payment of Fee:

(4) Total Amount Allotted and Obligated: $1,643,784,189.27 5719,132 51,644,503,321.27 (5) Net Amount Required for Full Funding $ 38,670,793.73 5 5,747 $ 38,676,540.73

• These figures take into consideration the negotiated total value of SubCLIN 0017 AA (This does not include SubCLIN 17 AH)

4. SECTION H - SPECIAL CONTRACT REQUIREMENTS is revised as follows:

Paragraph H-19, INCENTIVE FEE STRUCTURE AND PAYMENT FOR CLIN 0017. SYSTEM DEVELOPMENT AND DEMONSTRATION (SDD), subparagraph c., is revised as follows:

a. General.

SubCLIN 0017AA, System Development and Demonstration (SDD), is a cost-plus-incentive-fee (CPIF) Line Item with cost and schedule incentives as described below. Paragraph H-19(b) applies only to the Cost Incentive and Paragraph the Schedule Incentive. The contrac~rice amount of$I,683,179,862 includes a target cost includes ~f cost of facilities capital cost of money) and «-I~ i~ftarget cost ess facilities capital cost of money.

b. Cost Incentive.

ill The tariet fee.payable under SubCLIN 0017AA i ••• fthe target cost less facilities capital cost of money an amount equal to_

(b )(4) u,)..{

llo)LIf:

lb)u(.

l~)L~

DASG60-98-C-OOO I P00254

Page 5 of 12

(2) The maximum fee payable under SubCLIN 0017 AA is~the target cost less facilities capital cost of •• In amount equal to •••• ,

~ fee payable under SubCLIN 0017 AA ~f the target cost less facilities capital cost of money ___ anamountequalto_ '

(4) Fee will be adjusted for actual cost that is less than or more than the target cost stated above using a share ratio o~Government /~ontractor for actual costs less than the target cost, and a ratio o~ovemment / ~ontractor for actual costs greater than the target cost range applied according to Paragraph H-19( c)( I).

(5) Nothing stated in this clause shall take precedence over the clause 52.216-10 - Incentive Fee contained in this contract.

c. Schedule and Performance Incentive.

(1) A maximum ••••• '''flat zone" will be established at the target cost value oq & iith the conduct of milestones "flat zone" over which the contractor will earn target fee is for eligible costs from $ to the milestones set forth below are conducted. (Note: As of the effective date of P00253, only of the maximwi t zone" has been acknowledged as earned.)

(a) fthe maximum benefit of the "flat zone", earned by the conduct of the SOD System Functional Review NL T 2nd Quarter, Fiscal Year 2007. (It is hereby acknowledged by the government that

".,.n .. "n ""'1.U1'''~''''' the requirement for this flat zone and earned the "Flat Zone" schedule incentive of Final determination of incentive fee n .. "n.P,,,t

Reference letter,

(b __ fthe maximum benefit of the "flat zone", earned by the conduct of SDD Orbit Critical Design review NL T 2nd Quarter, Fiscal Year 2009. (It is hereby acknowledged by the government that Rapheon completed the requirement for this flat zone and earned the "Flat Zone" schedule incentive of 2 Final determination of incentive fee the "Flat Zone" amount will be made of the contract. Reference letter -(c) _1IIIto of the maximum benefit of the "flat zone", earned by the conduct of the Developmental Test I (DT-I) in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDn Contract, Section H-19(c), dated 1111111. (It is hereby acknowledged by the government that Rarheon completed ge requirement for this flat zone and earned a "Flat Zone" schedule incentive of

,( of the available , m Final determination of incentive fee payment utilizing the "Flat Zone" amount will be made at the conclusion 0 t e contract.)

maximwn benefit of the "flat zone", earned by the conduct of the Electromagnetic Environmental in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDD Contract, Section H-19(c), dated 1111111.

(e) _S of the maximum benefit of the "flat zone", earned by the conduct of the Integrated Fire Control Event in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDD Contract, Section H-19( c), dated 1111111.

[h)t§l-) (PJL~)

Qo)i80 (b)l'k)

~1t

(9y~) (b~) ~L¥'

(b )(4) (b)0

(b )(4 )PP)l'

(f) of the maximum benefit of the "flat zone", earned by the conduct of the Functional (b) ( 4) I};l ) L l Configuration Audit (FCA) #1 in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDD Contract, Section H-19(c). dated J 111/11.

00;)..507

DASG60-98-C-000 1 P00254

Page 6 of12

(3) For Earned Value and cost reporting purposes, the target cost value of$I,463,647,573 will be used.

d. Changes issued under FAR 52.243-2, Changes - Cost Reimbursement

In the event of a change issued under FAR 52.243-2, Changes - Cost Reimbursement, it is agreed that changes to the perfonnance and schedule incentive may be considered a part of the equitable adjustment. In the event that any Options to CLlN 0017 are added and exercised. the incentive fee for cost and schedule/performance applicable to the Option will be incorporated in accordance with the incentive fee structure of this provision.

5. The following is an update to Modification P00252 showing a summary of funding by ACRN through Modification P00254:

ACRN FUNDING

AA 440,100.00 AB 2,298,235.00 AC 17,832,987.00 AD 0.00 AE 7,500,000.00 AF 3,300,000.00 AG 17,192,400.00 AH 700,000.00 AJ 200,000.00 AK 85,000.00 AL 45,000.00 AM 17,045,000.00 AN 5,800.00 AP 20,779,000.00 AQ 105,000.00 AR 35,000.00 AS 0.00 AT 6,984,678.52 AU 7,970,000.00 AV 0.00 AW 100,000.00 AX 3,396,000.00 AY 550,000.00 AZ 19,412,000.00 BA 24,527,878.00 BB 146,000.00 BC 72,000.00 BD 85,000.00 BE 100,000.00 BF 100,000.00 BG 1,975,321.00 BH 38,018,908.00 BJ 7,896,673.34 BK 260,000.00 BL 0.00

OOd.)OV

DASG60-98-C-000 1 P00254

Page 7 of12

BM 125,000.00 BN 103,000.00 BP 10,199,288.50 BU . 350,000.00

BV 9,000.00 BW 84,896,852.00 BX 1,146,000.00 BY 3,880,000.00 BZ 190,000.00 KL 118,250.00 KM 192,793,000.00 KN 0.00 KQ 92,811.00 KR 0.00 KS 0.00 KT 386,377,998.00 KU 2,203,183.00 KV 65,000.00 KW 20,000.00 KX 60,000.00 KY 25,000.00 KZ 25,000.00 LA 13,508.00 LB 12,500.00 LC 200,000.00 LD 7,943,648.00 LE 1,173,850.00 LF 10,000.00 LG 62,000.00 LH 400,000.00 LJ 7,476.00 LK $281,575,897.00 LL $173,798.00 LM $1,410,376.00 LN $630,061.00 LP $83,200.00 LQ $235,566.00

LR $125,000.00 LS $6,069,616.00 LT $530,377.00 LU $9,100,000.00 LV $1,957,265.00

LW $255,567.00 LX $68,000.00 LY $264,807,424.52 LZ $1,751,384.00

MA $2,982,442.00

MB $375,000.00

MC $2,283,481.00

MD $8,573.00

oo!l50Q

DASG60-98-C-000 1 P00254

Page 8 of12

ME $0.00 MF $270,514,880.00 MG $6,262,095.00 MH $213,390.00 MJ $858,495.00 MK $56,076.00 ML $116,044.00 MM $1,618,600.00 MN $2,573,000.00 MP $250,000.00 MQ $691,421.00 MR $0.00 MS $700,000.00 MT $16,289,524.00 MU $7,864,499.00 MY $39,921,199.75 MW $10,000,000.00 MX 553,693,415.00

6. The following is an update to Modification P00252 showing a summary of funding by CLlN by ACRN through Modification P00254:

CLlN 0001 CLINOOOI

CLINOO03 CLINOO03 CLINOO03 CLIN 0003 CLIN 0003 CLINOO03 CLIN 0003 CLIN0003 CLIN 0003 CLIN 0003 CLINOO03 CLINOO03 CLIN 0003 CLIN 0003

CLIN0005 CLIN0005 CLIN0005 CLIN 0005

AA AD

AB AC AD AE AF AG AH AM AN AP AS AT AW AY

BA BB BC BD

FUNDING AMT CLIN TOTAL

440,100.00 0.00 _____ _

2,298,235.00 17,832,987.00

0.00 7,500,000.00 3,300,000.00

17,192,400.00 700,000.00

17,045,000.00 5,800.00

20,779,000.00 0.00

6,984,678.52 100,000.00

440,100.00

550,000.00 _____ _

24,527,878.00 146,000.00 72,000.00 85,000.00

00&510

94,288,100.52

DASG60-98-C-OOO 1 P00254

Page 9 of12

CLINOO05 BE 100,000.00 CLINOO05 BF 100,000.00 CLINOO05 BG 1,975,321.00 CLINOO05 BH 38,018,908.00 CLINOO05 BL 0.00 CLINOO05 BZ 0.00

65,025,107.00

CLINOO07AA BP 10,199,288.50

10,199,288.50

CLINOO09AA AQ 45,106.00 CLINOO09AA AV 0.00 CLINOO09AA BK 256,545.00 CLINOO09AA BM 125,000.00 CLINOO09AA BN 21,315.00

447,966.00

CLINOO09AB AJ 200,000.00 CLINOO09AB AK 85,000.00 CLINOO09AB AL 45,000.00 CLINOO09AB AQ 59,894.00 CLINOO09AB AR 35,000.00 CLINOO09AB BK 3,455.00 CLINOO09AB BN 81,685.00 CLINOO09AB BU 350,000.00 CLINOO09AB BV 9,000.00

869,034.00

CLIN0013 AU 7,970,000.00 CLINOO13 AX 3,396,000.00 CLINOO13 AY 0.00 CLINOO13 AZ 19,412,000.00 CLINOO13 BI 7,896,673.34

38,674,673.34

CLIN0017 BW 0.00 CLIN0017 KM 0.00

0.00

CLIN0017AA BY 3,880,000.00 CLIN0017AA BX 1,146,000.00 CLINOO17AA BW 84,896,852.00 CLIN0017AA BZ 0.00 CLINOO17AA KM 192,793,000.00 CLINOO17AA KN 0.00 CLINOO17AA KQ 66,151.00

ooa511

DASG60-98-C-000 1 P00254

Page 10 of 12

CLINOO17AA KS 0.00 CLINOO17AA KT 386,204,200.00 CLINOOI7AA KU 2,203,183.00 CLINOO17AA KY 0.00 CLINOO17AA LC 200,000.00 CLINOO17AA LD 7,943,648.00 CLINOO17AA LE 0.00 CLINOO17AA LH 400,000.00 CLINOO17AA LJ 7,476.00

CLINOO17AA LK 281,575,897.00

CLINOOl7AA LQ 235,566.00

CLINOOl7AA LS 6,069,616.00 CLINOO17AA LT 530,377.00

CLINOO17AA LU $9,100,000.00

CLINOO17AA LV $1,957,265.00

CLINOOl7AA LW $255,567.00

CLINOOl7AA LX $68,000.00

CLINOO17AA LY $264,807,424.52

CLINOO17AA MB $375,000.00

CLINOOl7AA MC $2,283,481.00

CLINOO17AA MD $8,573.00

CLINOO17AA ME $0.00

CLINOO17AA MF $270,514,880.00

CLINOO17AA MH $213,390.00

CLINOO17AA MJ $858,495.00

CLINOO17AA MK $56,076.00

CLINOO17AA ML $116,044.00

CLINOOl7AA MM $1,618,600.00

CLINOO17AA MN $2,573,000.00

CLINOO17AA MP $250,000.00

CLINOO17AA MQ $691,421.00

CLINOO17AA MR $0.00

CLINOOl7AA MS $700,000.00

CLINOOl7AA MT $16,289,524.00

CLINOO17AA MY $39,921,199.75

CLINOO17AA MW $10,000,000.00

CLINOOl7AA MX $53,693,415.00

1,644,503,321.27

CLIN 0017AB KL 118,250.00 ------118,250.00

DASG60-98-C-OOO 1 POO254

Page 11 of12

CLINOO17AC BZ 190,000.00

190,000.00

CLINOO17AD KN 0.00 CLINOO17AD KS 0.00

0.00

CLINOO17AE LL 173,798.00

173,798.00

CLINOO17AH KT 173,798.00

173,798.00

CLIN0020AA KN 0.00 CLIN0020AA KQ 26,660.00

26,660.00

CLIN0021AA KW 0.00

0.00

CLIN0021AB KV 0.00 CLIN0021AB LB 0.00 CLIN0021AB KX 0.00 CLIN0021AB KY 0.00

0.00

CLIN0021AC KZ 0.00 CLIN0021AC LA 0.00

0.00

CLIN0022 KW 0.00

0.00

CLIN0023 KX 60,000.00 CLIN0023 KY 25,000.00 CLIN0023 KV 65,000.00 CLIN0023 LB 12,500.00 CLIN0023 LF 10,000.00 CLIN0023 LR $125,000.00

297,500.00

CLIN0024 LA 13,508.00 CLIN0024 LG 62,000.00 CLIN0024 KZ 25,000.00 CLIN0024 KW 20,000.00

OOQ.513

CLINOO24 LP

CLINOO25 LE CLINOO25 LM

CLINOO25 MA

CLINOO26 LN

CLINOO27 LZ

CLINOO28 LM

CLINOO28 MA

CLINOO28 MG

CLINOO28 MU

CLIN 003001 * MX

CLIN003002* MX

83,200.00

1,173,850.00 1,080,404.00

0.00

630,061.00

1,751,384.00

329.972.00 2,982,442.00 6,262,095.00

$7.864.499

$52,974,283.00

$719,132.00

203,708.00

2,254,254.00

630,061.00

1,751,384.00

17,439,008.00

DASG60-98-C-000 1 P00254

Page 12 of 12

* eLIN 0030 has been established for the sole purpose of obligating GFEBS funding for performance of SubCLIN 0017 AA. Informational SubCLINs under CLIN 0030 will be established each time additioanl GFEBS funding is obligated. For pruposes of this funding update, funding obligated under CLIN 0030 will also be reflected under SubCLIN 0017 AA and should not be counted twice with regards ot the total contract funding obligated.


OOQ.51l£

AMENDMENT OF SOLICITATIONIMODIFICA nON OF CONTRACT

\MENDMENT/MODIFICA nON NO

R)0255

6. ISSUED BY

USASMOC/ARSTRAT SMOC·ROC POBOX 1500 HUNTSVIUE AL. :lSIIl7-3801

8. NAME AND ADDRESS OF RAYTHEON COMPANY 350 LO\I\EU. ST. ANOOVER MA0181o-+KlO

. EFFECTIVE DATE 4. REQUISITION/PURCHASE REQ. NO.

CODE 7. ADMlNISlERED BY {Ifotherthan item '---------1 OCMA RAYTHEON

50 APPLE HIU. DRIVE MlST2FR2 TEW<SBURY MA01878

(No., Street, County, State and Zip Code)

lOA. MOD. OF CONTRACT IORDER NO. MSG60-98-C-0001

above nUDbercd solicitation is ammded as set fOrth in Item 14. The hour and date specified ilrreceipt ofO. o i. not e>cIended.

0. 11118t acknowledge receipt ofthi. IIIJlOIldment prior to the hour and date specified in the solicitation or as IIIJlOIlded by one ofth. ililowing methods:

(8) By couplcting It oms 8 and IS, and returning copies oflbe urendment; (b) By acknowledging receipt ofthi. ammdm:nt on each copy oflbe 0. Bubnitted;

or (c) By sepllIllte l.tter or telegram wbich includ~ce to the solicitation and IIIIIOndmont nunbers. FAll.URE OF YOURACKNOWLEDGMENTTO BE RECEIVED ATmE PLACE DESIGNATED FOR mE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DAlE SPECIFIED MAY RESULT IN

REJECnON OF YOUR OFFER Ifby virtue oflbi. ammdmmt you de.ire to cbange an 01lOr a1roady subnitted, such chang. lIllY be lDIde by telegramor letter, provided each telcgramorletter11llke. ref:rence to tbe solicitation and this amendment, and i. reteived prior to the opening hoursnd date specified.

12. ACCOUNTING AND APPROPRIATION DATA (Ifre~d)

See Schedule

13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACTS'ORDERS. IT MODIFIES THE CONTRACTIORDERNO. AS DESCRIBED IN ITEM 14.

THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM lOA.

TO REFLECT THE ADMlNISfRATIVE CHANCJES(such as changes in paying IN TO THE AlITHORITY OF FAR

. THIS SUPPLEMENT AL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:

(Specify type of modification and authority) lERAL: FAR 52.232-22, "Linitation of Funds"

E. IMPORT ANT: Contractor 00 is not, 0 is required to sign this Iklcument and return copies to the issuing office.

14. DESCRIPTION OF AMENDMENT !MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter Vlbere feasible.) Modification Control Number: _

To increase Incremental funding in the armunt'!l!5,747.

\. NAME AND TITLE OF SIGNER (Type or print)

(b )(6)

ISB. CONTRACTOR/OFFEROR ISC. DATE SIGNED 16C. DATE SI{S)(6

24-May-2012

30-105-04 APPROVED BY OIRM 11-84 CX)~515

Sf ANDARD FORM 30 (Rev. 10-83) Prescribed by GSA FAR (48 CFR) 53.243


SUMMARY OF CHANGES


CLIN0030

DASG60-98-C-OOO 1 P00255

Page 2 ofl0

The total cost of this line item has increased by $5,747.00 from $53,693,415.00 to $53,699,162.00. *

* As stated in Modification P0025l, CLIN 0030 has been established for the sole purpose of obligating GFEBS funding for performance of SubCLIN 0017 AA. The value of CLIN 0030 equates to the amount of GFEBS funding obligated for performance of SubCLIN 0017 AA and should not be considered additional contract value. Informational SubCLINs under CLIN 0030 will be established each time additioanl GFEBS funding is obligated. CLIN 0030 and its SubCLINS will not be segregated from SubCLIN 0017 AA, identified, accounted for, invoiced, analyzed, or reported separately from SubCLIN 0017, including EVMS. All scope remains under SubCLIN 0017 AA with associated incentive events and flat zones.



GFEBS Funding for SubCLIN 0017

CPIF FOB: Destination

ACRNMX CIN: GFEBSOOI017438400030

UNIT


AccoWlting and Appropriation

Summary.for the Payment Office

UNIT PRICE

As a result of this modification, the total funded amount for this document was increased by $5,747.00 from $1,877,706,011.63 to $1,877,711,758.63.

SUBCLIN 003003: Funding on SUBCLIN 003003 is initiated as follows:

ACRN:MX

CIN: GFEBSOOIOl7438400030

Acctng Data: 02120122013204000001 171722550030003242A.0000013.1.1 6100.9000021001

Increase: $5,747.00

Total: $5,747.00

Cost Code: A5XFJ

AMOUNT

$5,747.00

DASG60-98-C-000 1 P00255

Page 3 of 10

Target Cost, Target Fee, and total for the above increase of istributed as follows and includes an increase in target cost os ~f cost and .-r facilities capital cost of money) and an increase in target fee of $403.

IMPLEMENTATION OF AND EXPLANATION OF THE RELATIONSHIP OF THE LIMITATION OF FUNDS (LOF) CLAUSE TO FEE OBLIGATIONS, subparagraph c., is revised to read as follows:

SUBCLIN 0017 AA : TIllS CUMULATIVE PRIOR MODIFICATION TOTAL·

(1) Amount Required for Full Funding, Including Fee: $1,683,179,862 $ 0 $ 1,683,179,862

(2) Amount Allotted Under the LOF Clause for Payment of Costs:


(4) Total Amount Allotted and Obligated: $1,644,503,321.27 $1,644,509,068.27 (5) Net Amount Required for Full Funding $ 38,676,540.73 $

* These figures take into consideration the negotiated total value of SubCLIN 00 17 AA (This does not include SubCLIN 17 AH)


AA AB AC AD AE AF AG AH AI AK AL AM AN AP AQ AR AS

FUNDING

440,100.00 2,298,235.00

17,832,987.00 0.00

7,500,000.00 3,300,000.00

17,192,400.00 700,000.00 200,000.00

85,000.00 45,000.00

17,045,000.00 5,800.00

20,779,000.00 105,000.00 35,000.00

0.00

OOd.5/7

38,670,793.73

(b )(4) ~

(b}f~)

DASG60~98-C-000 1 P00255

Page 4 of10

AT 6,984,678.52 AU 7,970,000.00

AV 0.00 AW 100,000.00 AX 3,396,000.00 AY 550,000.00 AZ 19,412,000.00 BA 24,527,878.00 BB 146,000.00 BC 72,000.00 BD 85,000.00 BE 100,000~00

BF 100,000.00 BG 1,975,321.00 BH 38,018,908.00 BJ 7,896,673.34 BK 260,000.00 BL 0.00 BM 125,000.00 BN 103,000.00 BP 10,199,288.50 BU 350,000.00 BV 9,000.00 BW 84,896,852.00 BX 1,146,000.00 BY 3,880,000.00 BZ 190,000.00 KL 118,250.00 KM 192,793,000.00 KN 0.00 KQ 92,811.00 KR 0.00 KS 0.00 KT 386,377,998.00 KU 2,203,183.00 KV 65,000.00 KW 20,000.00 KX 60,000.00 KY 25,000.00 KZ 25,000.00 LA 13,508.00 LB 12,500.00 LC 200,000.00 LD 7,943,648.00 LE 1,173,850.00 LF 10,000.00 LG 62,000.00 LH 400,000.00 U 7,476.00 LK $281,575,897.00

OOa$lg

DASG60-98-C-000 1 P00255

Page 5 of 10

LL $173,798.00 LM $1,410,376.00 LN $630,061.00 LP $83,200.00 LQ $235,566.00 LR $125,000.00 LS $6,069,616.00 LT $530,377.00 LV $9,100,000.00 LV $1,957,265.00 LW $255,567.00 LX $68,000.00 LV $264,807,424.52 LZ $1,751;384.00 MA $2,982,442.00 MB $375,000.00 MC $2,283,481.00 MD $8,573.00 ME $0.00 MF $270,514,880.00 MG $6,262,095.00 MH $213,390.00 MJ $858,495.00 MK $56,076.00 ML $116,044.00 MM $1,618,600.00 MN $2,573,000.00 MP $250,000.00 MQ $691,421.00 MR $0.00 MS $700,000.00 MT $16,289,524.00 MU $7,864,499.00 MY $39,921,199.75 MW $10,000,000.00 MX 553,699,162.00

4. The following is an update to Modification P00254 showing a summary of funding by CLIN by ACRN through Modification P00255:

CLINOOOI CLINOOOI

CUNOOO3 CLIN0003 CLIN0003

AA AD

AS AC AD


440,100.00 0.00 _____ _

2,298,235.00 17,832,987.00

0.00

440,100.00

DAS060-98-C-000 1 P00255

Page 6 of10

CLINOO03 AE 7,500,000.00 CLINOO03 AF 3,300,000.00 CLINOO03 AO 17,192,400.00 CLINOO03 AH 700,000.00 CLINOO03 AM 17,045,000.00 CLINOO03 AN 5,800.00 CLINOO03 AP 20,779,000.00 CLINOO03 AS 0.00 CLINOO03 AT 6,984,678.52 CLIN 0003 AW 100,000.00 CLINOO03 AY 550,000.00

94,288,100.52

CLIN 0005 BA 24,527,878.00 CLINOO05 BB 146,000.00 CLINOO05 BC 72,000.00 CLlNOO05 BD 85,000.00 CLIN 0005 BE 100,000.00 CLINOO05 BF 100,000.00 CLIN 0005 BO 1,975,321.00 CLINOO05 BH 38,018,908.00 CLINOO05 BL 0.00 CLINOO05 BZ 0.00

65,025,107.00

CLINOO07AA BP 10,199,288.50

10,199,288.50

CLINOO09AA AQ 45,106.00 CLINOO09AA AV 0.00 CLINoo09AA BK 256,545.00 CLINoo09AA BM 125,000.00 CLINOO09AA BN 21,315.00

447,966.00

CLINOO09AB AJ 200,000.00 CLINOO09AB AK 85,000.00 CLINOO09AB AL 45,000.00 CLINOO09AB AQ 59,894.00 CLINOO09AB AR 35,000.00

CLfNOO09AB BK 3,455.00 CLfNOO09AB BN 81,685.00 CLfN0009AB BU 350,000.00 CLINOO09AB BV 9,000.00

869,034.00

CLINOO13 AU 7,970,000.00

OO~5aO

DASG60-98-C-000 1 P00255

Page 7 of 10

CLIN 0013 AX 3,396,000.00 CLINOO13 AY 0.00 CLINOOl3 AZ 19,412,000.00 CLIN 0013 BJ 7,896,673.34

38,674,673.34

CLINOO17 BW 0.00 CLINOO17 KM 0.00

0.00

CLINOO17AA BY 3,880,000.00 CLINOO17AA BX 1,146,000.00 CLINOO17AA BW 84,896,852.00 CLINOO17AA BZ 0.00 CLlNOO17AA KM 192,793,000.00 CLINOO17AA KN 0.00 CLINOO17AA KQ 66,151.00 CLINOO17AA KS 0.00 CLINOO17AA KT 386,204,200.00 CLINOO17AA KV 2,203,183.00 CLINOO17AA KY 0.00 CLINOO17AA LC 200,000.00 CLlNOO17AA LD 7,943,648.00 CLINOO17AA LE 0.00 CLINOO17AA LH 400,000.00 CLINOO17AA LJ 7,476.00

CLINOO17AA LK 281,575,897.00 CLINOO17AA LQ 235,566.00

CLINOO17AA LS 6,069,616.00 CLlNOO17AA LT 530,377.00 CLINOO17AA LV $9,100,000.00

CLINOO17AA LV $1,957,265.00

CLINOO17AA LW $255,567.00

CLINOO17AA LX $68,000.00

CLINOO17AA LY $264,807,424.52


CLINOO17AA MC $2,283,481.00


CLINOO17AA ME $0.00

CLINOO17AA MF $270,514,880.00





CLINOO17AA MM $1,618,600.00

OO~S~,

CLINOO17AA MN

CLINOO17AA MP

CLINOO17AA MQ CLINOO17AA MR

CLINOO17AA MS CLINOO17AA MT

CLINOO17AA MY

CLINOO17AA MW

CLINOO17AA MX

CLIN0017AB KL

CLINOO17AC BZ

CLIN0017AD KN CLINOO17AD KS

CLIN0017AE LL

CLIN0017AH KT

CLIN0020AA KN CLIN0020AA KQ

CLIN0021AA KW

CLIN0021AB KV CLINOO21AB LB CLIN0021AB KX CLIN0021AB KY

CLIN0021AC KZ CLIN0021AC LA

$2,573,000.00 =====-==

$250,000.00 =-=======

$691,421.00 --===-=

$0.00 =====-__ $700,000.00 _=====

$16,289,524.00 ======

$39,921,199.75 ======

$10,000,000.00 -=====

553,699,162.00 ====-===

1,644,509,068.27

118,250.00

118,250.00

190,000.00

190,000.00

0.00 0.00

0.00

173,798.00 173,798.00

173,798.00

173,798.00

0.00 26,660.00

26,660.00

0.00

0.00

0.00 0.00 0.00 0.00

0.00

0.00 0.00

OCd.5~

DASG60-98-C-000 1 P00255

Page 8ofiO

DASG60-98-C-000 1 P00255

Page 9 ofl0

0.00

CLIN0022 KW 0.00

0.00

CLIN0023 KX 60,000.00 CLINOO23 KY 25,000.00 CLIN0023 KV 65,000.00 CLIN0023 LB 12,500.00 CLIN0023 LF 10,000.00 CLIN0023 LR $125,000.00

297,500.00

CLIN0024 LA 13,508.00 CLIN0024 LG 62,000.00 CLIN0024 KZ 25,000.00 CLIN0024 KW 20,000.00

CLIN0024 LP 83,200.00

203,708.00

CLIN0025 LE 1,173,850.00 CLIN0025 LM 1,080,404.00

CLIN0025 MA 0.00

2,254,254.00

CLIN0026 LN 630,061.00

630,Q61.00

CLIN0027 LZ 1,751,384.00

1,751,384.00

CLIN 0028 LM 329,972.00

CLIN0028 MA 2,982,442.00

CLIN0028 MG 6,262,095.00

CLIN0028 MU $7,864,499

17,439,008.00

CLIN 003001* MX $52,974,283.00

CLIN003002* MX $719,132.00

eLIN 000303* MX 55,747.00

DASG60-98-C-OOO 1 P00255

Page 10 oflO

• CLIN 0030 has been established for the sole purpose of obligating GFEBS funding for performance of SubCLIN 0017 AA. Informational SubC~INs under CUN 0030 will be established each time additioanl GFEBS funding is obligated. For pruposes of this funding update, funding obligated under CLIN 0030 will also be reflected under SubCLIN 0017 AA and should not be counted twice with regards to the total contract funding obligated.


AMENDM~T OF SOLICITATIONIMOnDICATION OF CONTRACT

U8A8MDC",RSTRAT &Moe·ROC PO BOX 1111lO HUNTSVIlLE PL. 315807-:1801

NO.

CODE

8. NAME AND I'UJLI",~OF CONTRACTOR (No., Street, County, State IndZip Code) RAYTH£aII COMPANY 350 LOV.a..L ST. ANDOVER iliA 0181G-4«lO

.bov.nlllltNncl.olioitllion i. IIIIIIIdeci u.1t Iblth III Item 14. lh.hourlllddat.lp8Cifed fIr ..... pI oro. O"lIIIlt .w.owled., neapt oftbi ....... dment prior to the hour IIld daI'opeoiiad in tho .oIloltllioll or U lIIIIaded by oao ofthe flllowi ... lllltbod.}- .• - ... C.) By coapt_II ... Itam B ... d 15.1114 Nlumilll copi .. oflho -m-t; (b) By ",*Ilowl.tains receipt ofthil _4_t 011 eoch copy oftbeo •• ubnittad;

or (0) By •• pnl.letterortol ........ whi ... illc1ud~OI to the .olioitlllion IIId _adnlmt n"'" FAR.URE OF YOURACKNOWLBDOMENTTO BE RECEIVED AT1HB pLACH DESIONAll!D POR,1HB RECSIPTOl'OPJIERlI PRIOR TO tHE HOUR AND DAlB SPBCll'IED MAY RESULT IN

REJEC'ItON 01' YOU1l0PFBR. [fby virtu. ofthi. _dna! you deal .. to ahaqo III 0."na4y lubniltec!,l1Ioh oh .... ~ b ....... by loI"IrIIlIor Iltler. p..,.,idecl eeoh 1I1 ........ or lett. rmIc ....... 00 10 tho .0Ucic-IIon IIld thi. _4 ... t .... 4 Ie roooiTo4 priorto tho opoDiog "0111:1041 datl.pooifad,

AND APPROPRIATION See Schedule

13. nns ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACflVORDERS. IT MODIFIES THE CONTRAer/ORDER NO. AS DESCRIBED IN ITEM 14.

THIS CHANGE ORDER IS I~D PURSUANT TO: (*ecify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM lOA.

<u>n. \ '>II""U~ type of modification IJId authority) 52.232-22, ·untBtIon or Fundi"

Contractor 1Kl ill not, is required to IIign this tbcumcnt lind return copies to tbe ilSlling office.

14. DESCRIPTION OF AMENDMENT /MODIFICATION (Orl!llllized by UCF section headinp. including solicitation/contract suQjcct-mattcr ~cre feuibIe.) Modification Control Number: _

To provide Incranwntal funding In the amount or $16,000,000 .

• A. NAME AND TITLE OF !lONER (Type or print)

UB.

30-105-04 APPROVED BY OIRM 11-84

OOci.Sa..S

PAGES

10


SUMMARY OF CHANGES


CLIN0030

DASG60-98-C-OOO 1 P00256

Page 2 ofl0

The total cost of this line item has increased by $16,000,000.00 from $53,699,162.00 to $69,699,162.00.*

* As stated in Modification P00251, CLIN 0030 has been established for the sole purpose of obligating GFEBS funding for performance of SubCLIN 0017 AA. The value of eLIN 0030 equates to the amount of GFEBS funding obligated for performance of SubCLIN 0017 AA and should not be considered additional contract value. Informational SubCLINs under CLIN 0030 will be established each time additioanl GFEBS funding is obligated. CLIN 0030 and its SubCLINS will not be segregated from SubCLIN 00 1 7AA, identified, accounted for, invoiced, analyzed, or reported separately from SubCLIN 0017, including EVMS. All scope remains under SubCLIN 0017 AA with associated incentive events and flat zones.



GFEBS Funding for SubCLIN 0017AA

CPlF

FOB: Destination

UNIT UNIT PRICE AMOUNT

ACRNMX CIN:GFEBSOOIOI9081700030

$16,000,000.00




As a result of this modification, the total funded amount for this document was increased by $ I 6,000,000.00 from $1,877,711,758.63 to $1,893,711,758.63.


ACRN:MX

CIN: GFEBSOOI019081700030

Acctng Data: 02120122013204000001171722550030003242A.0000013.1.1 6100.9000021001

Increase: $16,000,000.00

Total: $16,000,000.00

Cost Code: A5XFJ

DASG60-98-C-000 1 P00256

Page 3 of 10

Target Cost, Target Fee, and total for the above increase ofl •• increase in target cost os 2 t __ f cost

is distributed as follows and includes an facilities capital cost of money) and an

increase in target fee of 5

IMPLEMENTATION OF AND EXPLANATION OF THE RELATIONSHIP OF THE LIMITATION OF FUNDS (LOF) CLAUSE TO FEE OBLIGATIONS, subparagraph C., is revised to read as follows:

SUBCLIN0017AA : THIS CUMULATIVE PRIOR MODIFICATION TOTAL'"

(I) Amount Required for Full Funding, Including Fee: $1,683,179,862 $ 0 $ 1,683,179,862

(2) Amount Allotted Under the LOF Clause for Payment of Costs: • (3) Amount Separately Obligated for Payment of Fee: $ $

(4) Total Amount Allotted and Obligated: $1,644,509,068.27 $16,000,000 51,660,509,068.27 (5) Net Amount Required for Full Funding $ 38,670,793.73 (516,000,000) $

... These figures take into consideration the negotiated total value of SubCLIN 0017 AA (This does not include SubCLIN 17 AH)


ACRN FUNDING

AA 440,100.00 AB 2,298,235.00 AC 17,832,987.00 AD 0.00 AE 7,500,000.00 AF 3,300,000.00 AG 17,192,400.00 AH 700,000.00 AJ 200,000.00 AK 85,000.00 AL 45,000.00 AM 17,045,000.00 AN 5,800.00 AP 20,779,000.00 AQ 105,000.00

oo~5~1

22,670,793.73

lbJLf (b )(4)

(b}fd,

DASG60-98-C-000 1 P00256

Page 4 of10

AR 35,000.00 AS 0.00 AT 6,984,678.52 AU 7,970,000.00 AV 0.00 AW 100,000.00 AX 3,396,000.00 AY ,~ 550,000.00

AZ 19,412,000.00 BA 24,527,878.00 BB 146,000.00 BC 72,000.00 BD 85,000.00 BE 100,000.00 BF 100,000.00 BG 1,975,321.00 BH 38,018,908.00 BJ 7,896,673.34 BK 260,000.00 BL 0.00 BM 125,000.00 BN 103,000.00 BP 10,199,288.50 BU 350,000.00 BV 9,000.00 BW 84,896,852.00 BX 1,146,000.00 BY 3,880,000.00 BZ 190,000.00 KL 118,250.00 KM 192,793,000.00 KN 0.00 KQ 92,811.00 KR 0.00 KS 0.00 KT 386,377,998.00 KU 2,203,183.00 KV 65,000.00 KW 20,000.00 KX 60,000.00 KY 25,000.00 KZ 25,000.00 LA 13,508.00

LB 12,500.00 LC 200,000.00 LD 7,943,648.00 LE 1,173,850.00 LF 10,000.00

LG 62,000.00 LH 400,000.00

ood5QE

DASG60-98-C-OOO 1 P002S6

Page 5 of 10

LJ 7,476.00 LK $281,575,897.00 LL $173,798.00 LM $1,410,376.00 LN $630,061.00 LP $83,200.00 LQ $235,566.00 LR $125,000.00 LS $6,069,616.00 LT $530,377.00 LU $9,100,000.00 LV $1,957,265.00 LW $255,567.00 LX $68,000.00 LY $264,807,424.52 LZ $1,751,384.00 MA $2,982,442.00 MB $375,000.00 MC $2,283,481.00 MD $8,573.00 ME $0.00 MF $270,514,880.00 MG $6,262,095.00 MH $213,390.00 MJ $858,495.00 MK $56,076.00 ML $116,044.00 MM $1,618,600.00 MN $2,573,000.00 MP $250,000.00 MQ $691,421.00 MR $0.00 MS $700,000.00 MT $16,289,524.00 MU $7,864,499.00 MV $39,921,199.75 MW $10,000,000.00 MX $69,699,162.00


CLINOOOI CLINOOOI

CLIN 0003

AA AD

AB


440,100.00 0.00 _____ _

440,100.00

2,298,235.00

DASG60-98-C-000 1 P00256

Page 6 ofl0

CLINOO03 AC 17,832,987.00 CLINOO03 AD 0.00 CLINOO03 AE 7,500,000.00 CLINOO03 AF 3,300,000.00 CLINOO03 AG 17,192,400.00 CLINOO03 AH 700,000.00 CLINOO03 AM 17,045,000.00 CLIN 0003 AN 5,800.00 CLIN 0003 AP 20,779,000.00 CLINOOO3 AS 0.00 CLINOOO3 AT 6,984,678.52 CLINOO03 AW 100,000.00 CLINOO03 AY 550,000.00

94,288,100.52

CLINOO05 BA 24,527,878.00 CLINOO05 BB 146,000.00 CLINOO05 BC 72,000.00 CLINOO05 BD 85,000.00 CLINOO05 BE 100,000.00 CLINOO05 BF 100,000.00 CLINOO05 BG 1,975,321.00 CLINOO05 BH 38,018,908.00 CLINOO05 BL 0.00 CLINOO05 BZ 0.00

65,025,107.00

CLINOO07AA BP 10,199,288.50

10,199,288.50


447,966.00

CLINOO09AB AJ 200,000.00 CLINOO09AB AK 85,000.00 CLINOO09AB AL 45,000.00 CLINOO09AB AQ 59,894.00 CLINOOO9AB AR 35,000.00 CLINOOO9AB BK 3,455.00 CLINOOO9AB BN 81,685.00 CLINOO09AB BU 350,000.00 CLINOOO9AB BV 9,000.00

869,034.00

OO~'53D

DASG60-98-C-000 1 P00256

Page 7 oflO

CLIN 0013 AU 7,970,000.00 CLINOO13 AX 3,396,000.00 CLIN 0013 AY 0.00 CLIN 0013 AZ 19,412,000.00 CLIN 0013 BJ 7,896,673.34

38,674,673.34

CLIN 0017 BW 0.00 CLIN 0017 KM 0.00

0.00

CLIN OO17AA BY 3,880,000.00 CLIN 0017AA BX 1,146,000.00 CLINOO17AA BW 84,896,852.00 CLINOO17AA BZ 0.00 CLIN 0017AA KM 192,793,000.00 CLIN 0017AA KN 0.00 CLIN 0017AA KQ 66,151.00 CLIN 0017AA KS 0.00 CLIN 0017AA KT 386,204,200.00 CLINOO17AA KU 2,203,183.00 CLINOO17AA KY 0.00 CLINOO17AA LC 200,000.00 CLIN 0017AA LD 7,943,648.00 CLINOO17AA LE 0.00 CLINOO17AA LH 400,000.00 CLINOO17AA LJ 7,476.00

CLINOO17AA LK 281,575,897.00

CLINOO17AA LQ 235,566.00

CLIN 0017AA LS 6,069,616.00

CLINOO17AA LT 530,377.00

CLIN 0017AA LU $9,100,000.00

CLINOO17AA LV $1,957,265.00



CLIN 0017AA LY $264,807,424.52

CLIN 0017AA MB $375,000.00

CLINOO17AA MC $2,283,481.00


CLINOO17AA ME $0.00

CLINOO17AA MF $270,514,880.00




OO~531

CLlNOO17AA ML

CLlNOO17AA MM

CLINOO17AA MN

CLIN0017AA MP

CLIN 0017AA MQ CLINOO17AA MR

CLINOO17AA MS CLINOO17AA MT CLINOO17AA MY

CLIN00l7AA MW CLINOO17AA MX

CLINOOl7AB KL

CLINOO17AC BZ

CLINOO17AD KN CLINOO17AD KS

CLINOO17AE LL

CLINOO17AH KT

CLINOO20AA KN CLIN0020AA KQ

CLINOO21AA KW

CLIN0021AB KV CLIN0021AB LB CLIN0021AB KX CLIN0021AB KY

$116,044.00 ======

$1,618,600.00 =========

$2,573,000.00 ========

$250,000.00 =_==-===== $691,421.00 -==--====

$0.00 ............ -====== $700,000.00

====== $16,289,524.00

====== $39,921,199.75 ======-_ $10,000,000.00 ======== 569,699,162.00

====== 1,660,509,068.27

118,250.00

118,250.00

190,000.00

190,000.00

0.00 0.00

0.00

173,798.00

173,798.00

173,798.00

173,798.00

0.00 26,660.00

26,660.00

0.00

0.00

0.00 0.00 0.00 0.00

0.00

OO~S3~

DASG60-98-C..QOO 1 P00256

Page 8 of 10


Page 9 of 10


0.00

CLIN0022 KW 0.00

0.00

CLIN0023 KX 60,000.00 CLINOO23 KY 25,000.00 CLIN0023 KV 65,000.00 CLIN0023 LB 12,500.00 CLIN0023 LF 10,000.00 CLIN0023 LR $125,000.00

297,500.00

CLINOO24 LA 13,508.00 CLIN0024 LG 62,000.00 CLINOO24 KZ 25,000.00 CLIN0024 KW 20,000.00

CLIN0024 LP 83,200.00

203,708.00

CLIN0025 LE 1,173,850.00 CLIN0025 LM 1,080,404.00

CLIN0025 MA 0.00

2,254,254.00

CLIN0026 LN 630,061.00

630,061.00

CLIN0027 LZ 1,751,384.00

1,751,384.00

CLIN0028 LM 329,972.00

CLIN0028 MA 2,982,442.00

CLIN0028 MG 6,262,095.00

CLIN0028 MU $7,864,499

17,439,008.00

CLIN 003001* MX $52,974,283.00

CLIN003002* MX $719,132.00

CLIN 000303* MX $5,747.00

eLIN 000304* MX $16,000,000.00

69,699,162.00

QOd-5:33

DASG60-98-C-000l P00256

Page 10 oflO

• CLIN 0030 has been established for the sole purpose of obligating GFEBS funding for performance of SubCLIN 0017 AA. Informational SubCLINs under CLIN 0030 will be established each time additioanl GFEBS funding is obligated. For pruposes of this funding update, funding obligated under CLIN 0030 will also be reflected under SubCLIN 0017 AA and should not be counted twice with regards to the total contract funding obligated.


AM 53'-1

AMENDMBN'l' OF SOUClTA110NIMOODlCA110N OJ' CONTltACI'

ulle .... 1111 ......... nlI. n.'" De..., ................... ......

a. .. I ............. 'I.,. .. ~ ................................ dII .... I ... III' ...... .,_ ••• n ............ : (ll)1Iy .... I8a ......... "............ eap' •• fllle-'-'r. .... ., ..................... -'-IOII ... ..., .............. .. • r(e)., ...... IIIW., ............. IuIa~ •• I .. IIIIIakIIIaa .. ___ III ..... 'AIWUOPYOU.ACKNOWUDGMINT1Oaa ItICEMaJAT'IIIIIPLAaD ... NAUDIIOII.11I.8KIIPTO'0fRIII .... 1011IIHClURANDDAlIi.IaPllDMAYRllULTIN ua:no .. OFYOUACJFIIB.llllyv .... ' .. , ...... ,... ........ ct-. • ., ........ , ............. .., ..... ., ... _I ..... ........................ __ ......... Jc1IM .......................... pdar ........... IIoUrIId ..... ....

-ahIaIII in payin.

14. DBICRInION OF AMENDMENTIMODIFICATION (0riIaiIIII1Ir to __ hIIdInII. ~ •• lcilatlolllcon .. "'" 1Ml_ ........ ) . MocIIIcMlan OmtIOI H_E •

lbprclVldlthli.' ..... f\Jrdvtl .. 1IIIUIt Df.te,ooo.lIOO; IDrtlVlle8eclDnff.1t.taNllYERES'IRJCI\EAN)MVII!NI'PDRa.N CIOt1. 8V8IB'tII~ AtGIIMNnM'IDII(8DD) fD nadPi .. 1IIt.pat hllnlMtcdlrla lDeIII. _ PllfarftWlOe CIIR from IbIl ..... "-0mIId (Jq .-1It .. Ainotlanlll ~AudI(FQ\)'" eMntmilD ......... __ lnalnllrecdlrllfD __ .. IIIt.patlncldlna~ In """'rec ... 1D ..... IlclalnJDhiJde .............. _ ...... ~ .... nwlHmlD~"~ Ult(aR.)B1J1)4. Alot.- ....... CGi .... ,..,u,.".....

P..mr.dlly CB\ FAR('" a'R) 53.243

PM.

16


SUMMARY OF CHANGES


CLIN 0030

DASG60-98-C-000 1 P00257

Page 2 of 15

The total cost of this line item has increased by $16,000,000.00 from $69,699,162.00 to $85,699,162.00.*

• As stated in Modification P00251, CLIN 0030 has been established for the sole purpose of obligating GFEBS funding for performance of SubCLIN 00 17 AA. The value of CLIN 0030 equates to the amount of GFEBS funding obligated for performance of SubCLIN 0017 AA and should not be considered additional contract value. Informational SubCLINs under CLIN 0030 will be established each time additioanl GFEBS funding is obligated. CLIN 0030 and its SubCLINS will not be segregated from SubCLIN 0017AA, identified, accounted for, invoiced, analyzed, or reported separately from SubCLIN 0017, including EVMS. All scope remains under SubCLIN 0017 AA with associated incentive events and flat zones.



GFEBS Funding for SubCLIN 0017 AA

CPIF

FOB: Destination


ACRNMX $16,000,000.00 CIN: GFEBSOOI015913300030




As a result of this modification, the total funded amount for this document was increased by $16,000,000.00 from $1,893,711,758.63 to $1,909,711,758.63.


ACRN:MX

eIN: GFEBSOOI015913300030

Acctng Data: 0212012201320400000 1171722550030003242A.OOOOO 13.1.1

Increase: $16,000,000.00

Total: $16,000,000.00

6100.9000021001

Cost Code: A5XFJ

Target Cost, Target Fee, and total for the above increase in target cost os increase in target fee of


OASG60-98-C-000 1 P00257

Page 3 of 15

~~'=lliiS.d~istributed as follows and includes an lSI • facilities capital cost of money) and an

IMPLEMENTATION OF AND EXPLANATION OF THE RELATIONSIDP OF THE LIMITATION OF FUNDS (LOF) CLAUSE TO FEE OBLIGATIONS, subparagraph c., is revised to read as follows:

SUBCLIN 0017 AA : THIS CUMULATIVE PRIOR MODIFICA nON TOTAL·

(I) Amount Required for Full Funding, Including Fee: $1,683,179,862 $ 0 $ 1,683,179,862

(2) Amount Allotted Under the LOF Clause ~)(4) for Payment of Costs:

(3) Amount Separately Obligated for Payment of Fee: $ ..

(4) Total Amount Allotted and Obligated: $1,660,509,068.27 516,000,000 51,676,509,068.27 (5) Net Amount Required for Full Funding $ 22,670,793.73 (516,000,000) 5

* These figures take into consideration the negotiated total value of SubCLIN 0017 AA (This does not include SubCLIN 17 AH)


Paragraph H-19, INCENTIVE FEE STRUCTURE AND PAYMENT FOR CLIN 0017, SYSTEM DEVELOPMENT AND DEMONSTRATION (SOD), subparagraph C., is revised as follows:


6,670,793.73

b)(4)

(1) A maximum 'flat zone" will be established at the estimated cost value of with the (b)( 4 ) conduct of milestones below. The "flat zone" over which the contractor will earn target fee is for eligible costs from _to nce the program milestones set forth below are conducted. (Note: As of the (b)( 4 ) effective date of Modification P002S7, only ofthe maximum flat zone" has been acknowledged as earned.)

(a) 2 . ,-. of the maximum benefit of the "flat zone", earned by the conduct of the SOD System Functional Review NLT2iid Quarter, Fiscal Year 2007. (It is hereby acknowledged by the government that : • 1 •.• I • II' . ted the requirement for this flat zone and earned the "Flat Zone" schedule incentive of

Final determination of incentive fee payment utilizing the "Flat Zone" amount will be made at the conclusion of the contract. Reference letter, dated 5 March 2007 from

(b) S ,~fthe maximum benefit of the "flat zone", earned by the conduct ofSOO Orbit Critical Design review NL T 2nd Quarter, Fiscal Year 2009. (It is hereby acknowledged by the government that Raytheon completed the requirement for this flat zone and earned the "Flat Zone" schedule incentive 0_. Final determination of incentive fee payment utilizing the "Flat Zone" amount will be made at the conclusion of the

ooaS3'7

(b )(4)

[b')..l£;) lQlD)

Cb~)

(],1t>

contract. Reference letter, dated 12 January 2009, from

2 a -

DASG60-98-C-OOO 1 P00257

Page 4 of 15

(c) I of the maximum benefit of the "flat zone", earned by the conduct ofthe Developmental Test 1 (DT -1) in accordance with the criteria set forth in Section J attachment entitled Flat Zone Perfonnance Criteria for JLENS SOD Contract, Section H-19{c), dated 081t0/12. (It is hereby acknowledged by the government that Raytheon co:teted the requirement for this flat zone and earned a "Flat Zone" schedule incentive of $ , or of the available Final detennination of incentive fee payment utilizing the "Flat Zone" amount will be made at the conclusion of the contract.)

(d) of the maximum benefit ofthe "flat zone", earned by the conduct of the Electromagnetic Environmental Effects (E3) Testing in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDD Contract, Section H-19(c), dated 08/10/12.

(e) of the maximum benefit of the "flat zone", earned by the conduct of the Integrated Fire Control Event in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SOD Contract, Section H-19(c), dated 08/10/12. (It is hereby acknowledged by the government ~n completed tbe requirement for this flat zone and earned a "Flat Zone" schedule incentive of"'-oi ofthe available j • Final determination of incentive fee payment utilizing the "Flat Zone" will be at the conclusion of the *NOTE: Tbe

(t) 7· -. of the maximum benefit of the "flat zone", earned by the conduct of the Functional Configuration Audit (FCA) # 1 in accordance with the criteria set forth in Section J attachment entitled Flat Zone

l~l~) ~l0

~f-v

(0)Ll£)

u:>'itf) (b)(3)(A) (i)&Title 10 Sec 130 (a) (b)

Performance Criteria for JLENS SDn Contract, Section H-19(c), dated 08/10/12. *Note: has been10 Sec 130 (a)(b)

(b)(3)(A)

(g) _ of the maximum benefit of the "flat zone", earned bytbe conduct of (i)&Title Lb){~ Developmental Test 2 (DT -2) in accordance with the criteria set forth in Section J attachment entitled F1at10 Sec 130 Zone Performance Criteria for JLENS SDn Contract, Section H-19(c), dated 08110/12. • (a)(b)

(h) ~ of the maximum benefit of the "flat zone", earned by the conduct of the Early User u,)Ltf) Test (previously defined as Limited User Test) in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDD Contract, Section H-19(c), dated 08/10/12. *

(i) -. of the maximum benefit of the "flat zone", earned by the conduct of the Final Lb)l <1:) Functional Configuration Audit (FCA) in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDD Contract, Section H-19{c), dated 08110/12. •

• These additional incentives are added to the contract contingent upon agreement to a pending contract ceiling increase. Should the parties not be able to reach agreement on such increase, the Government reserves the right to rescind the incentives.

(3) For Earned Value and cost reporting purposes, the estimated cost value o_ill be used.


In the event of a change issued under FAR 52.243-2, Changes - Cost Reimbursement, it is agreed that changes to the performance and schedule incentive may be considered a part of the equitable adjustment. In the event that any Options to CLIN 0017 are added and exercised, the incentive fee for cost and schedule/performance applicable to

DASG60-98-C-OOO 1 P00257

Page 5 of 15

the Option will be incorporated in accordance with the incentive fee structure of this provision.

4. SECTION J - LIST OF DOCUMENTS, EXHIBITS AND OTHER ATTACHMENTS

The following has been revised:

Contract Security Classification Specification (DD Form 254), Revision 13 (Added per Modification P0023S)

JLENS Software Source Code Specifically Negotiated License, License Number lLENS-SWLA-OI (Added per Modification POO 166)

CLINOOI7: JLENS System Development and Demonstration (SDD) Program Statement of Work (Revised by Incorporating CSDR Plans dated 20 Febr 2007 in Appendix C per Modification P00136)

JLENS System Development and Demonstration (SDD) Program Statement of Work (Added per Modification POO 187)

JLENS System Development and Demonstration (SDD) Program Statement of Work, Revision 2 (Added per Modification P00207)

JLENS System Development and Demonstration (SOD) Program Statement of Work, Revision 3 (Added per Modification P00239)

JLENS System Development and Demonstration (SOD) Program Statement of Work (Added per Modification P00240)

Contract Data Requirements List (DD Form 1423) Exhibit A with Distribution List & Data Item Nos. BOOI through B062 (Replace Data Item Nos. B026 and B027, only Per Modification P00136) (Replace Data Item Nos. B048 and B049, only Per Modification P00143 & to add statement in Section A of Modification POOI43) (Replace Data Item No. B033 only, per Modification POO 161)

Contract Data Requirements List (DD Form 1423) Exhibit A. Data Item Nos. BOOI and BOl4 (Added per Modification POO 187)

14 Apr 11

04 Sep 08

30Nov06-Revised 20 Feb 07

Revised 06 Apr 09

Revised 09 Mar 10

Revised 01 Sep 11

Revised 26 Sep 11

March 08

01 Dec 06

Revised 05 Apr 07

Revised 24 Oct 07

Revised 11 JuI 08

Revised 07 May 09

#OFPAGES

13

8

37

38

36

36

36

63

2

(b )(3) (A) (i)&Title lO Sec 130 (a)(b)

(

(

( ,

Contract Data Requirements List (DO Fonn 1423) Exhibit A, Data Item Nos. 8002 through B062 (less 80 [4 ) (Added per Modification POD 187)

Contract Data Requirements List (DO Fonn 1423) Exhibit At Data Item Nos. BOOI and BOl4 (Added per Modification POD239)

Contract Data Requirements List (DO Form 1423) Exbibit A, Data Item Nos. 8004 (Added per Modification PO02S7)

"Added statement below to address weekendsIHoJidays: (In Mod POO143)

Revised 20 Mar 09

Revised 30 Aug 11

Reviscd,31 Jul12

24 October 07

DASG60-98-C-000I P00257

Page 6 of 15

60

2

·Per a mutual agreement between Raytheon and JLENS Product Office all Contract Data Requirements List (CDRL's) (DO Fonn 1423) are due on the next business day after the required due date if the due date falls on Saturday. Sunday or a Government Holiday, In addition, for any CDRL with a requirement to resubmit within 10 days or less after receipt of comments, where Raytheon receives the conuncnts on a Friday. the time frame for resuhmittal will begin on the next business day, Statement added in Mod POD 143 on 24 Oct. 2007,

GFElGFP/GFS List for SOD Replaced with Rev. B List "Add items below For record-keeping purposes (Per Mod POO143) Replaced with Revision C List (per Modification POOl 83) Replaced with Revision 0 List (Per Modification P00207)

28 Nov 06 15 Oct 07 Revised 22 Oct 07

09 Mar 09

23 Feb 10

2 6

12

1 1

•• Per the ,DCMA is authorized rent tree use on a non-interference use of the equipment listed below on JLENS Fire Control Radar Prime Contract DASG60-98-C- (b)(4) 0001 for the period from 19 April 2007 through 30 September 2011.

Originated in Basic Contract: Government Furnished Equipment - Spiral I (Spiral 1 Equipment Transferred to Government

20 Jun 03 1 List 25 Mar 07* 34 pages

(b)(3) (A)

1149 (attached) (b)(6)

(b)(4)

DASG60·98·C·000I POO257

Page7ofl5

(Revised 21 Nov 07)'" 34 pages

*NOTE: (terns 1·1060 transferred to Contract DASG60...(){)..c;-0091 per revised GFE list dated 21 Nov 07. Items 1061 - 1116 GFE items retained on Contract DASG60-98·C-000 I for Spiral 2 per GFE list dated 25 Mar 07.

JLENS Perfonnance Specification, MIS·PRF·55628, Revision A

(Added by reference per Modification POO 168)

Annex A to the JLENS Perfonnance Specification, MIS-PRF.55628, Revision A

(Added by reference per Modification POO 168)

JLENS SOO 00250 Plan (Added per Modification P00207)

Engineering Change Proposal (ECP) MI·N3893, Revision 2, CDRL B039·oo5b

Engineering Cbange Proposal (ECP) MI-N3894. CDRL 9039-006

Engineering Change Proposal (ECP) MI-N3895, CORL 8039-007

Engineering Change Proposal (ECP) JL 1359 (Added per Modification P00240)

Flat Zone Perfonnance Criteria for JLENS SOD Contract, Section H·19(c)

(Added per Modification P00242)

Revised Flat Zone Performance Criteria ror JLENS SOD Contraet, Section H·I9(e)

(Added per Modifieation P002S?)

Test Spares List (Added per Modification P00247)

CLINs 0023 and 0024 JLENS Simulation Support SOW dat d 28 J 2008

> •. , >,., .~ ... (Added per Mod POOI60)

CLIN 0025

(b)(3)(A)

JLENS Integrated Fire Control Demonstration Program

27 Jun 08 136

27 Jun 08 10

II Dec 09 5

15 Nov 10 IS

18 Aug JO 16

28 Sep to 50

20 Jun II 7

01 Nov I I 4

10 Aug 12 7

Undated 8

28 January 2008 2

14 Sep 09 3

Statement of Work, Revision 5 (Added per Modification P002Il)

JLENS Integrated Fire Control Demonstration Program Program and Technical Clarification Description, incorporated herein by reference (Added per Modification P00211)

Contract Data Requirements List (DD Form 1423) Exhibit B, Data Items Nos. BOO 1 through B004, with Data Item Descriptions (Added per Modification POO 165)

Contract Data Requirements List (DD Form 1423), CLIN 0028, Exhibit B, Data Item Nos. BOOI through B006 (Added per Modification P002Il)

CLIN0027

JLENS System Integration Lab (SIL) Equipment List (Added per Modification P00196)

Revision to System Integration Lab (SIL) Equipment List (Added per Modification P002I7)

30 Mar 10

16 Oct 07

16Iun 10

Undated

02 Aug 10

DASG60-98-C-000 1 P002S7

Page 8 of15

26

19

6

6

6


ACRN FUNDING

AA 440,100.00 AB 2,298,235.00 AC 17,832,987.00 AD 0.00 AE 7,500,000.00 AF 3,300,000.00 AG 17,192,400.00 AH 700,000.00 AI 200,000.00 AK 85,000.00 AL 45,000.00 AM 17,045,000.00 AN 5,800.00 AP 20,779,000.00 AQ 105,000.00 AR 35,000.00 AS 0.00 AT 6,984,678.52 AU 7,970,000.00

OOaS4a

DASG60-98-C-000 1 P00257

Page 9 of15

AV 0.00 AW 100,000.00 AX 3,396,000.00 AY 550,000.00 AZ 19,412,000.00 BA 24,527,878.00 BB 146,000.00 BC 72,000.00 BD 85,000.00 BE 100,000.00 BF 100,000.00 BG 1,975,321.00 BH 38,018 j 908.00 BJ 7,896;673.34 BK 260,000.00 BL 0.00 BM 125,000.00 BN 103,000.00 BP 10,199,288.50 BU 350,000.00 BV 9,000.00 BW 84,896,852.00 BX 1,146,000.00 BY 3,880,000.00 BZ 190,000.00 KL 118,250.00 KM 192,793,000.00 KN 0.00 KQ 92,811.00 KR 0.00 KS 0.00 KT 386,377,998.00 KU 2,203,183.00 KV 65,000.00 KW 20,000.00 KX 60,000.00 KY 25,000.00 KZ 25,000.00 LA 13,508.00 LB 12,500.00 LC 200,000.00 LD 7,943,648.00 LE 1,173,850.00 LF 10,000.00 LG 62,000.00 LH 400,000.00 U 7,476.00 LK $281,575,897.00 LL $173,798.00 LM $1,410,376.00

C'()~j4 3

DASG60-98-C-OOO 1 P002S7

Page 10 of15

LN $630,061.00 LP $83,200.00 LQ $235,566.00 LR $125,000.00 LS $6,069,616.00 LT $530,377.00 LU $9,100,000.00 LV $1,957,265.00 LW $255,567.00 LX $68,000.00 LY $264,807,424.52 LZ $1,751,384.00 MA $2,982,442.00 MB $375,000.00 MC $2,283,481.00 MD $8,573.00 ME $0.00 MF $270,514,880.00 MG $6,262,095.00 MH $213,390.00 MJ $858,495.00 MK $56,076.00 ML $116,044.00 MM $1,618,600.00 MN $2,573,000.00 MP $250,000.00 MQ $691,421.00 MR $0.00 MS $700,000.00 MT $16,289,524.00 MU $7,864,499.00 MY $39,921,199.75 MW $10,000,000.00 MX $85,699,161.00


CLINOOOI CLINOOOI

CLIN0003 CLIN0003 CLINOOO3 CLINOOO3 CLIN0003

AA AD

AB AC AD AE AF


440,100.00 0.00 _____ _

2,298,235.00 17,832,987.00

0.00 7,500,000.00 3,300,000.00

440,100.00

DASG60-98-C-000 1 P00257

Page 11 of15

CLINOO03 AG 17,192,400.00 CLINOO03 AH 700,000.00 CLINOO03 AM 17,045,000.00 CLINOOO3 AN 5,800.00 CLINOO03 AP 20,779,000.00 CLINOO03 AS 0.00 CLINOOO3 AT 6,984,678.52 CLINoo03 AW 100,000.00 CLINOO03 AY 550,000.00

94,288,100.52

CLINOOO5 BA 24,527,878.00 CLINOO05 BB 146,000.00 CLINOO05 BC 72,000.00 CLINOO05 BD 85,000.00 CLINoo05 BE 100,000.00 CLINOO05 BF 100,000.00 CLINOO05 BG 1,975,321.00 CLINOO05 BH 38,018,908.00 CLINOOO5 BL 0.00 CLINOO05 BZ 0.00

65,025,107.00

CLINOO07AA BP 10,199,288.50

10,199,288.50

CLINOO09AA AQ 45,106.00 CLIN0009AA AV 0.00 CLINOO09AA BK 256,545.00 CLINOO09AA BM 125,000.00 CLINOOO9AA BN 21,315.00

447,966.00

CLINOOO9AB AI 200,000.00 CLINOO09AB AK 85,000.00 CLINOO09AB AL 45,000.00 CLINOO09AB AQ 59,894.00 CLINOO09AB AR 35,000.00 CLINoo09AB BK 3,455.00 CLINOOO9AB BN 81,685.00 CLINOOO9AB BU 350,000.00 CLINOO09AB BV 9,000.00

869,034.00

CLIN 0013 AU 7,970,000.00 CLINOO13 AX 3,396,000.00 CLIN0013 AY 0.00

OO~545

DASG60-98-C-000 1 P00257

Page 12 of15

CLINOOI3 AZ 19,412,000.00 CLINOO13 BJ 7,896,673.34

38,674,673.34

CLIN 0017 BW 0.00 CLINOO17 K.M 0.00

0.00

CLINOO17AA BY 3,880,000.00 CLIN 0017AA BX 1,146,000.00 CLINOO17AA BW 84,896,852.00 CLINOO17AA BZ 0.00 CLINOO17AA K.M 192,793,000.00 CLINOO17AA KN 0.00 CLINOO17AA KQ 66,151.00 CLINOO17AA KS 0.00 CLINOO17AA KT 386,204,200.00 CLINOO17AA KU 2,203,183.00 CLINOO17AA KY 0.00 CLINOO17AA LC 200,000.00 CLINOO17AA LD 7,943,648.00 CLINOO17AA LE 0.00 CLINOO17AA LH 400,000.00 CLINOO17AA LJ 7,476.00

CLINOO17AA LK 281,575,897.00


CLINOO17AA LS 6,069,616.00


CLINOO17AA LU $9,100,000.00

CLINOO17AA LV $1,957,265.00



CLINOO17AA LY $264,807,424.52

CLIN 0017AA MB $375,000.00

CLINOO17AA MC $2,283,481.00


CLINOO17AA ME $0.00

CLINOO17AA MF $270,514,880.00





CLINOO17AA MM $1,618,600.00

CLINOO17AA MN $2,573,000.00


~54lQ

CLINOO17AA MQ CLINOO17AA MR

CLINOO17AA MS CLINOO17AA MT CLINOO17AA MY

CLINOO17AA MW CLINOO17AA MX

CLINOO17AB KL

CLINOO17AC BZ


CLINOO17AE LL

CLINOO17AH KT

C[IN0020AA KN CLIN 0020AA KQ

CLIN0021AA KW

CLIN0021AB KV CLIN0021AB LB CLIN0021AB KX CLIN 002 lAB KY


$691,421.00 -==== ...... _=== $0.00 -==-....... _====

$700,000.00 ====== $16,289,524.00 _====-=== $39,921,199.75 _____ _

$10,000,000.00 ====== ...... $85,699,162.00 ========

1,676,509,068.27

118,250.00

118,250.00

190,000.00

190,000.00

0.00 0.00

0.00

173,798.00 173,798.00

173,798.00

173,798.00

0.00 26,660.00

26,660.00

0.00

0.00

0.00 0.00 0.00 0.00

0.00

0.00 0.00

0.00

coa.54'J

DASG60-98-C-OOO 1 P00257

Page 13 of 15

DASG60-98-C-000 1 P00257

Page 14 of 15

CLIN 0022 KW 0.00

0.00

CLIN0023 KX 60,000.00 CLIN 0023 KY 25,000.00 CLIN0023 KV 65,000.00 CLlN0023 LB 12,500.00 CLIN 0023 LF 10,000.00 CLIN 0023 LR $125,000.00

297,500.00

CLIN0024 LA 13,508.00 CLIN0024 LG 62,000.00 CLlN0024 KZ 25,000.00 CLIN0024 KW 20,000.00

CLlN0024 LP 83,200.00

203,708.00

CLIN0025 LE 1,173,850.00 CLIN0025 LM 1,080,404.00

CLIN 0025 MA 0.00

2,254,254.00

CLIN0026 LN 630,061.00

630,061.00

CLIN0027 LZ 1,751,384.00

1,751,384.00

CLIN0028 LM 329,972.00

CLIN0028 MA 2,982,442.00

CLIN0028 MG 6,262,095.00

CLIN0028 MU $7,864,499

17,439,008.00

CLIN 003001 * MX $52,974,283.00

CLIN003002* MX $719,132.00

CLIN 000303* MX $5,747.00

eLIN 000304· MX 516,000,000.00

85,699,162.00

* CLIN 0030 has been established for the sole purpose of obligating GFEBS funding for performance of SubCLIN 0017AA. Informational SubCLINs under CLIN 0030 will be established each time additioanl GFEBS funding is obligated. For proposes of this funding update, funding obligated under CLIN 0030 will also be reflected under SubCLIN 0017 AA and should not be counted twice with regards to the total contract funding obligated.



Page 15 of15

OO~S50

lorA ....

INSERT IN

SECT.B

8 $V(J1 CIt -

,---, T SPOT INCENTIVE CRITERIA FOR JLENS SOD (y '\RACT, SECTION H-19(C), DATED 10 AUG 1;

'T SPOT INCENTIVE CRITERIA FOR JLENS SOD' r r---~TRACTI SECTION H-19(C)1 DATED 10 AUG 1:

I ::!::w I -

.---T SPOT INCENTIVE CRITERIA FORJlENS SOD c: ';RACT, SECTION H-19(C), DATED 10 AUG 1:

------ ----.. . ~ T SPOT INCENTIVE CRITERIA FOR JLENS SOD. (" ""RACT, SECTION H-19(C), DATED 10,AUG 1:

G>~ ...-0-........... ...-~ ...........

L~)ff~

---'TSPOT INCENTIVE CRITERIA FORJLENSSDD r "fRACT, SECTION H":19(C), DATED 10 AUG 1:

T SPOT INCENTIVE CRITERIA FOR JLENS SOD ( TRACT; SECTION H-19(C)1 DATED 10 AUG 17

1===' -

.- · .... T SPOT INCENTIVE CRITERIA FOR-JLENS SODCr ~RACT,.sECTION Hr.19(C), DATED 10 AUG 1:

,=::1 __ d

AMENDMENT OF SOLiCITATIONIMODMCATION OF CONTRACf

NO.

AND ADDRESS OF CONTRAcrOR (No .• !it recto COIIIty. &lIe ud Zip Code) RAYTHEON CCMPNrf 311DLOE.L8r. MOOU!iJ'IMAOI81004«lO

_ .. abo""'~ solldlalon I • ...cIed as 111II1II11 ... 1_14. 11M hDllr .... dale IpCCiIed IItNCdpl oro. 0 I. _ded. Is __ ended

O._leeknowled ..... pl Dfdrill8alll_1 prior 10 IIIcbOllf'IIId ~qNlClhd I. IIMsoIlcilallaa or as ..-dcd by _ oRlle 1»11ow1 .. lII:lhods: (I'll)' caap, ..... , ..... mIlIS •• d Rlumilll copM oldie MaId_: (II)BJ ldlnowled.lq _lpI Df .. 111 """_1011 acb copy onlle oltr lu""'"ed: or(c:) By .. _lanaror ICIqnmwblcb hld~lo lIIolCllld"'oo II1II ......... nntJcn. FA R.U RE OF YOUR ACXNOWLEOOMBNTlO BE REa!JVED AT1HE PLACE DBSIONAlED fOR lIIE REaJPTOFOfFERS PRlOR1011I8 HOU1AHD DAlE SPECIFIED Nt. Y RESULTIN REJEC'JlON OP YOUR OfFER. Ilby "111 .. 0 ..... 1.--..1 you dalMIO ..... III ........ J lubnflled.sucll ell .... n.)' buaddy ....... or 'e" •• pIO\'IdId~IeI._hmer""' __ IDIII .. oIlri .. IORudchl.~.ORdII.-lwedpriorlal"" ... I·lbour""dllClped.ed.

12. A<X'OUNTING AND APPROPRIATION DATA (Ir recpUecI) .... 8dwdule

13. THIS ITEM IT

OF CONTRACT9'ORDERS. IN ITEM 14.

THISOtANCIi ORDER IS IBJED PURAJANT TO: (~fy allhority) THE OIAN<ESSET RJRTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM lOA.

,,","'''.~ (SQCh IS cblllFS In pa)'lnl

IMPORT ANT: Conlr8CIor 0 is 1101. is required 10 Ii .... Ibis cb:umenl IIDd ret.,. c:opies 10 ahe issuing office.

14. DEDIPTION OF AMENDMENTIMODIFICATION (Orpnized by OCFscc:tion heMinp. includinl solicilltionlcontrac:t suI!Iec:t mluer lIofIere fasible.) " . ModiflCltion Control Number: •••••••

The PI.II'JIOS8 d .. II trodflcallon Is to hlreae the esttratad cost 0/ SlbCl.fi 0017AA tAle to a cos1 overrun resuDlg from 1he delayad s1art elate d Deve/cpmBn1a1 Test 2 (DT·2) and to provide Incremental furdlg II tie arrounI 0/ $38,266,043.

AI oller tem'8 and ccndlllon8 AII1IIt"I unchlngad.

PA<lES

13

30·105-04 APPROVED BY OIRM 11·84

Sf ANDARD FORM:30 (Rev. 10.13) Prescribed by C&\ FAR (48 CPR) 53.243


SUMMARY OF CHANGES


DASG60-98-C-OOO 1 P00258

Page 2 of 13

The total cost of this contract was increased by $34,309,700.00 from $1,920,928,309.00 to $1,955,238,009.00.


SUBCLIN 0017AA The estimated cost has increased The estimated fee has decreased The total estimated cost plus fee of

to $1,717,489,562.00.

rlhis includes an increase in estimated cost 0 7000 consisting of in cost and _ increase in facilities capital cost of money, and a decrease in estimated fee These

estimated values incorporate the Integrated Fire Control (IFC) incentive recognized in Modification P00257.

The target cost and target fee set forth in the table below reflects the negotiated Section B values prior to any adjustments made resulting from estimated cost overruns and share ratio impacts to the fee. Any differences between the Estimated Cost values provided above in Section B and the Target Cost values shown on the table below are as a result of estimated cost overruns. Any differences between the Estimated Fee values provided above in Section B and the Target Fee values shown on the table below are a result of reductions based on current share ratio impacts to the Target Fee and do not include any allocation for yet to be earned incentives as set forth in Section H-I9. As of the date of this modification, the target cost and target fee are as follows:

The Target Cost is ••••• ,consisting o •••••• n cost and •••• tt, facilities capital cost of money.

The Target Fee is ~~~~==~ •••. Total Target Cost plus Fee is

Pursuant to FAR 16.405-1, the target cost and target fee will be finally determined and adjusted after contract performance.

The table below provides 'a summary of the target cost, target fee, and total:

CLIN 0030 The total cost of this line item has increased by $38,000,000.00 from $85,699,162.00 to $123,699,162.00.


(~)(~

\$J'{If) ~i't) l'-->1f)

DASG60-98-C-000 1 P00258

Page 3 of 13


GFEBS funding for SubCLlN 0017 AA

CPIF

FOB: Destination



• As stated in Modification P002S1, CLlN 0030 has been established for the sole purpose of obligating GFEBS funding for performance of SubCLIN 0017 AA. The value of CLIN 0030 equates to the amount of GFEBS funding obligated for performance of SubCLIN 0017 AA and should not be considered additional contract value. Informational SubCLINs under CLIN 0030 will be established each time additional GFEBS funding is obligated. CLIN 0030 and its SubCLINS will not be segregated from SubCLIN 0017 AA, identified, accounted for, analyzed, or reported separately from SubCLlNOO 17, including EVMS. All scope remains under SubCLIN 0017 AA with associated incentive events and flat zones.

B-17. INCENTNE FEE FOR SUBCLIN 00 17AA1CLIN 0018 (SEE H-19):

In accordance with FAR 52.216-10, entitled "Incentive Fee", the total amount originally negotiated, adjusted in accordance with paragraph d. of this clause, for target cost and target fee for performance under SubCLIN 0017 AAlCLIN 0018 are set forth below:

Target Cost Target Fee

Incentive Arrangement: Maximum Fee: Minimum Fee:

(Share Ratio: Government/Contractor)

Underrun: _or the amount by which the total allowable cost is less than the estimated cost until maximum fee is attained.

Overrun: ~r the amount by which the total allowable cost exceeds the estimated cost until minimum fee is attained.

FAR 52.216-10, INCENTIVE, paragraph (e)(1), is stated as follows:

(e) Fee Payable.

(1) The fee payable under this contract shall be the target fee increased b_ents for every dollar that the total allowable cost is less than the estimated cost or decreased b_ents for every dollar that the total allowable cost exceeds the estimated cost. In no event shall the fee be greater th~rcentt (Maximum fee) or less th~ percent (Minimum fee) of the estimated cost.

B-18. ESTIMATED COST, ESTIMATED INCENTIVE FEE, MINIMUM INCENTIVE FEE, MAXIMUM INCENTIVE FEE, AND INCENTIVE ARRANGEMENT FOR SUBCLIN 0017AA1CLIN 0018:

SUBCLIN0017AA-ITwo SDDJLENS Systems)

a. Estimated cost:

b. Estimated fee:


d. Maximum incentive fee:

e. Total estimated cost and estimated fee:




• .... .--51,717,489,562

DASG60-98-C-000 1 P00258

Page 4 of13

(b )(4)

(b )(4) (b )(4)

(b )(4)


SUBCLIN 0017AA:

MF: 21 12040 5L 5L68 Pl72419E555L 255Y 4MIJ730000 S010214MIJ730000/14MJLEl4M5 was increased by $266,043.00 from $270,514,880.00 to $270,780,923.00

Estimated Cost, Estimated Fee, and Estimated total for the above increase includes an increase in estimated co_st of $£ 3 _of cost and and an increase in estimated fee oti

SUBCLIN 003006 (GFEBS Funding for SubCI,.IN 0017AA): Funding on SUBCLIN 003006 is initiated as follows:

ACRN:MX


Acctng Data: 0212012201320400000 I 171722550030003242A.OOOOO 13.1.1

Increase: $38,000,000.00

Total: $38,000,000.00

Cost Code: A5XFJ

Estimated Cost Estimated Fee Total

distributed as follows and IllCllllUI=S capital cost of money)

6100.9000021001

IMPLEMENTATION OF AND EXPLANATION OF THE RELATIONSHIP OF THE LIMITATION OF FUNDS

(b )(4)

(b )(4)

(b )(4)

(LOF) CLAUSE TO FEE OBLIGATIONS, subparagraph C., is revised to read as follows:

SUBCLIN 0017 AA : THIS

DASG60-98-C-000 1 P00258

Page 5 of 13

CUMULATIVE PRIOR MODIFICATION TOTAL·

(1) Amount Required for Full Funding, Including Fee: $1,683,179,862 534,309,700 51,717,489,562

(2) Amount Allotted Under the LOF Clause for Payment of Costs:


(4) Total Amount Allotted and Obligated: $1,676,509,068.27 538,266,043 51,714,775,111.27 (5) Net Amount Required for Full Funding $ 6,670,793.73 ($ 3,956,343) 5

• These figures take into consideration the negotiated total value of SubCLIN 00 17 AA (This does not include SubCLIN 17 AH)


ParagraphH-19, INCENTIVE FEE STRUCTURE AND PAYMENT FORCLIN 0017. SYSTEM DEVELOPMENT AND DEMONSTRATION (SDD), subparagraphs a., b., and C., are revised as follows:

a. General.

2,714,450.73

SubCLIN 0017AA, System Development and Demonstration (SDD), is a cost-plus-incentive-fee (CPIF) Line Item with cost and schedule incentives as described below. Paragraph H-19(b) applies only to the Cost Incentive and Paragraph H-19( c) applies only to the Schedule Incentive. The contract price r ount If $lfS,OOS,39S includes a target cost 0 (which includes cost alid facilities capital cost of money) and a target incentive fee of of estimated cost less facilities capital cost of money.

b. Cost Incentive.

(I) The tarlilfee ranle under SUbCLIN._0.O.17 •• money an amount equall~

estimated cost less facilities capital cost of

(2) Th~e under SubCLIN 0017 AA it Iof the estimated cost less facilities capital cost of money~ount equal to

(3) Th~able under SubCL~fthe estimated cost less facilities capital cost of mone~an amount equal to __

(4) Fee will be adjusted for ac!1 cost that is less than or more than the estimated cost stated above using a share ratio 0 overnment :ontractor for actual costs less than the estimated cost, and a ratio of. Government ~ontractor for actual costs greater than the estimated cost range applied according to Paragraph H-19(c)(l);

(5) Nothing stated in this clause shall take precedence over the clause 52.216-10 - Incentive Fee contained in this contract.


(1) A maximum flat zone" will be established at the estimated cost value of-. with the conduct of milestones below. The "flat zone" over which the contractor will earn target fee IS for eligible costs from

&,1Y

lb~_

~iL{) Q;,)4)

l>)l~)

LbJl.#)

~)(t.t) L\o.)[1-'

DASG60-98-C-OOO 1 P00258

Page 6 of13

(8) I of the maximum benefit of the "flat zone", earned by the conduct of the SDD System Functional Review NL T 2nd Quarter, Fiscal Year 2007. (It is hereby acknowledged by the government that Raytheon completed the requirement for this flat zone and earned the "Flat Zone" schedule incentive of ••••• , Final determination of incentive fee payment the "Flat Zone" amount will be made at the ~ct. Reference letter, dated 5 March 2007

(I Df the maximum benefit of the "fl~t zone", earned by the conduct of SDD Orbit Critical Design review NL T 2nd Quarter, Fiscal Year 2009. (It is hereby acknowledged by the government that Raytheon completed the requirement for this flat zone and earned the "Flat Zone" schedule incentive of $' Final determination of incentive fee payment utilizing the "Flat will be made at the conclusion of the contract. Reference letter, dated 12 January 2009, frOI ••

(c) ~ of the maximum benefit of the "flat zone", earned by the conduct of the Developmental Test I (DT -1) in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SOD Contract, Section H-19(c), dated 08/10112. (It is hereby acknowledged by the government that Raytheon completed the requirement for this flat zone and earned a "Flat Zone" schedule incentive of ? 01 of the available Final determination of incentive fee p~yment utilizing the "Flat Zone" amount will be made at the conclusion of the contract.)

(d) 1 of the maximum benefit of the "flat zone", earned by the conduct of the Electromagnetic Environmental Effects (E3) Testing in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDD Contract, Section H-19(c), dated 08/10/12.

(e) , _ of the maximum benefit of the ''flat zone", earned by the conduct of the Integrated Fire Control Event in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SOD Contract, Section H-19(c), dated 08/10/12. (It is hereby acknowledged by the government that Raytheon completed the requirement for this flat zone and earned a f'Flat Zone" schedule incentive of ." ••• or _ of the available .• Final determination of incentive fee payment utilizing the "Flat Zone" amount will be made at the conclusion of the ·NOTE: Th ..... "' . ,: , ., . - ... , from to movement of the for

(f) • if the maximum benefit of the "flat zone", earned by the conduct of the Functional Configuration Audit (FCA) #1 in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SOD Contract, Section H-19(c), 08110/12. ·Note:

(b)(3)(A)

(i)&Title 10 Sec 130 (a)(b)

(b)(3)(A) (i)&Titie 10 Sec 130

(7)(1{) L'Ox-~: O'J)lG-.-O:;.~)

C!;>)L1f;

(bX-IQ) C1~: \D"j..",

Lb)O()

(g) _ ~ of the maxinium benefit of the "flat zone", earned by the conduct of Developmentaia)(b) Lb)L.'1) Test 2 (DT-2) in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SOD Contract, Section H-19(c), dated 08/10112. •

(h) of the maximum benefit of the "flat zone", earned by the conduct of the Early User Test ~ )LIIJ (previously as Limited User Test) in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDO Contract, Section H-19(c), dated 08/10112. *

OASG60-98-C-000 1 P00258

Page 7 of 13

(i) _ of the maximum benefit of the ".flat zone", earned by the conduct of the Final Functional Configuration Audit (FCA) in accordance with the criteria set forth in Section J attachment entitled Flat Zone Perfonnance Criteria for JLENS SOD Contract, Section H-19(c), dated 08/10112 ....

(3) For Earned Value and cost reporting purposes, the estimated cost value of be used.

d. Changes is.sued under FAR 52.243-2, Changes - Cost Reimbursement

In the event of a change issued under FAR 52.243-2, Changes - Cost Reimbursement, it is agreed that changes to the perfonnance and schedule incentive may be considered a part of the equitable adjustment. In the event that any Options to CLIN 0017 are added and exercised, the incentive fee for cost and schedulelperfonnance applicable to the Option will be incorporated in accordance with the incentive fee structure of this provision.


ACRN FUNDING

AA 440,100.00 AB 2,298,235.00 AC 17,832,987.00 AD 0.00 AE 7,500,000.00 AF 3,300,000.00 AG 17,192,400.00 AH 700,000.00 AJ 200,000.00 AI( 85,000.00 AL 45,000.00 AM 17,045,000.00 AN 5,800.00 AP 20,779,000.00 AQ 105,000.00 AR 35,000.00 AS 0.00 AT 6,984,678.52 AU 7,970,000.00 AV 0.00 AW 100,000.00 AX 3,396,000.00 AY 550,000.00 AZ 19,412,000.00 BA 24,527,878.00 BB 146,000.00 BC 72,000.00 BD 85,000.00 BE 100,000.00 BF 100,000.00 BG 1,975,321.00

roa5loY

DASG60-98-C-000 1 POO258

Page 8 ofl3

BH 38,018,908.00 BJ 7,896,673.34 BK 260,000.00 BL 0.00 BM 125,000.00 BN 103,000.00 BP 10,199,288.50 BU 350,000.00 BV 9,000.00 BW 84,896,852.00 BX 1,146,000.00 BY 3,880,000.00 BZ 190,000.00 .KL 118,250.00 KM 192,793,000.00 KN 0.00 KQ 92,811.00 KR 0.00 KS 0.00 KT 386,377,998.00 KU 2,203,183.00 KV 65,000.00 KW 20,000.00 KX 60,000.00 KY 25,000.00 KZ 25,000.00 LA 13,508.00 LB 12,500.00 LC 200,000.00 LD 7,943,648.00 LE 1,173,850.00 LF 10,000.00 LG 62,000.00 LH 400,000.00 LJ 7,476.00 LK $281,575,897.00 LL $173,798.00 LM $1,410,376.00 LN $630,061.00 LP $83,200.00 LQ $235,566.00 LR $125,000.00 LS $6,069,616.00 LT $530,377.00 LU $9,100,000.00 LV $1,957,265.00 LW $255,567.00 LX $68,000.00 LY $264,807,424.52 LZ $1,751,384.00

(X)~5105

DASG60-98-C-000 1 POO258

Page 9 of 13

MA $2,982,442.00 MB $375,000.00 MC $2,283,481.00 MD $8,573.00 ME $0.00 MF $270,780,923.00 MG $6,262,095.00 MH $213,390.00 MJ $858,495.00 MK $56,076.00 ML $116,044.00 MM $1,618,600.00 MN $2,573,000.00 MP $250,000.00 MQ $691,421.00 MR $0.00 MS $700,000.00 MT $16,289,524.00 MU $7,864,499.00 MY $39,921,199.75 MW S.10,OOO,OOO.00 MX $123, 699,162.00


CLINOOOI CLINOOOI

CLINOO03 CLINOO03 CLINOO03 CLINOO03 CLINOO03 CLINOO03 CLINOO03 CLINOO03 CLINOO03 CLIN 0003 CLINOO03 CLINOO03 CLIN0003 CLINOO03

AA AD

AB AC AD AE AF AG AH AM AN AP AS AT AW AY


440,100.00 0.00 _____ _

2,298,235.00 17,832,987.00

0.00 7,500,000.00 3,300,000.00

17,192,400.00 700,000.00

17,045,000.00 5,800.00

20,779,000.00 0.00

6,984,678.52 100,000.00

440,100.00

550,000.00 _____ _

94,288,100.52

DAS060-98-C-000 1 P00258

Page 10 of 13

CLINOO05 BA 24,521,818.00 CLIN 0005 BB 146,000.00 CLINOO05 BC 12,000.00 CLINOO05 BD 85,000.00 CLINOO05 BE 100,000.00 CLINOO05 BF 100,000.00 CLINOO05 BO 1,915,321.00 CLIN 0005 BH 38,018,908.00 CLIN 0005 BL 0.00 CLINOO05 BZ 0.00

65,025,101.00

CLINOO07AA BP 10,199,288.50

10,199,288.50


447,966.00

CLINOO09AB AI 200,000.00 CLINOO09AB AK 85,000.00 CLINOO09AB AL 45,000.00 CLINOO09AB AQ 59,894.00 CLINOO09AB AR 35,000.00 CLINOO09AB BK 3,455.00 CLINOO09AB BN 81,685.00 CLINOO09AB BU 350,000.00 CLINOO09AB BV 9,000.00

869,034.00

CLINOO13 AU 7,970,000.00 CLINOO13 AX 3,396,000.00 CLINOO13 AY 0.00 CLIN 0013 AZ 19,412,000.00 CLINOO13 BJ 7,896,673.34

38,674,673.34

CLIN 0017 BW 0.00

CLINOO17 KM 0.00

0.00

CLINOO17AA BY 3,880,000.00 CLINOO17AA BX 1,146,000.00

CLINOO17AA BW 84,896,852.00

(J:)Q'Sb1

DASG60-98-C-000 1 P00258

Page 11 of 13

CLIN 0017AA BZ 0.00 CLIN 0017AA KM 192,793,000.00 CLIN 0017AA KN 0.00 CLINOO17AA KQ 66,151.00 CLINOO17AA KS 0.00 CUN 0017AA KT 386,204,200.00 CLINOO17AA KU 2,203,183.00 CLINOOI7AA KY 0.00 CLINOO17AA LC 200,000.00 CLINOO17AA LD 7,943,648.00 CLINOO17AA LE 0.00 CLINOO17AA LH 400,000.00 CLINOO17AA LJ 7,476.00 CLINOO17AA LK 281,575,897.00 CLINOOl7AA LQ 235,566.00 CLINOO17AA LS 6,069,616.00 CLINOO17AA LT 530,377.00 CLINOO17AA LU $9,100,000.00 CLINOOl7AA LV $1,957,265;00



CLINOO17AA LY $264,807,424.52


CLINOO17AA MC $2,283,481.00

CLIN 0017AA MD $8,573.00

CLINOOl7AA ME $0.00

CLINOOl7AA MF $270,780,923.00



CLIN 0017AA MK $56,076.00


CLINOO17AA MM $1,618,600.00

CLINOO17AA MN $2,573,000.00


CLINOO17AA MQ $691,421.00

CLINOO17AA MR $0.00

CLINOO17AA MS $700,000.00

CLINOO17AA MT $16,289,524.00

CLIN 00 I 7AA MV $39,921,199.75

CLIN 0017AA MW $10,000,000.00

CLINOO17AA MX 5123,699,162.00

1,714,775,111.27

CLIN0017AB KL

CLINOO17AC BZ


CLIN0017AE LL

CLIN0017AH KT

CLIN0020AA KN CLIN0020AA KQ

CLIN0021AA KW

CLINOO21AB KV CLIN0021AB LB CLINOO2lAB KX CLINOO21AB KY


CLIN0022 KW

CLIN0023 KX CLINOO23 KY CLIN0023 KV CLIN0023 LB CLIN0023 LF CLIN0023 LR

118,250.00

190,000.00

0.00 0.00

173,798.00

173,798.00

0.00 26,660.00

0.00

0.00 0.00 0.00 0.00

0.00 0.00

0.00

60,000.00 25,000.00 65,000.00 12,500.00 10,000.00

$125,000.00

())~5109

118,250.00

190,000.00

0.00

173,798.00

173,798.00

26,660.00

0.00

0.00

0.00

0.00

297,500.00

DASG60-98-C-000 1 P00258

Page 12 of 13

CLIN0024 LA CLIN0024 LG CLIN0024 KZ CLlN0024 KW

CLIN0024 LP

CLIN0025 LE CLIN0025 LM

CLIN0025 MA

CLIN0026 LN

CLIN0027 LZ

CLIN0028 LM

CLIN0028 MA

CLIN0028 MG

CLIN0028 MU

CLIN 003001 * MX

CLIN003002* MX

CLIN 000303* MX

CLIN 000304* MX

CLIN 000305* MX

eLIN 003006* MX

13,508.00 62,000.00 25,000.00 20,000.00

83,200.00

1,173,850.00 1,080,404.00

0.00

630,061.00

1,751,384.00

329,972.00

2,982,442.00

6,262,095.00

$7,864,499

$52;974,283.00

$719,132.00

$5,747.00

$16,000,000.00

$16,000,000.00

538,000,000.00

203,708.00

2,254,254.00

630,061.00

1,751,384.00

17,439,008.00

123!699,162.00

DASG60-98-C-000 1 P00258

Page 13 of 13

... CLIN 0030 has been established for the sole purpose of obligating GFEBS funding for performance of SubCLIN 0017 AA. Informational SubCLINs under CLIN 0030 will be established each time additioanl GFEBS funding is obligated. For pruposes of this funding update, funding obligated under CLIN 0030 will also be reflected under SubCLIN 0017 AA and should not be counted twice with regards to the total contract funding obligated.


~S70

AMENDMENT OF SOUCITATIONIMODIFICATION OF CONTRACT

ADMINISTERED BV (If'oIhcrtbua ltan6) DCMARAYTHalN SI N'FLE HIJ.DRM! t.MS13'R2 ~NAInIJ8

8. NAME AND ADDRESS OF CONTRACTOR (No., Street, Cowly, Stlde and Zip Code) RA'miEDN COMPANY 3IIIl.CMI!lLsr. AI'IO(M!Il MA01I1~

oerlJllltacknow!odaeleCdPl orthi ..... ftIIlpriDl'IO thclaounnd doIe.pcdlcd In IhClOllcUI.loIIoru _lied by oneor.Iae .. UowIDI acchods;

I. not P1a1cicd.

II) By co .... IClln.I ...... snd IS ...... -Ina copies 1Ifl1le._dln"u: (II) By ICknowled,;n,lB:dp! anh" .-ndmenl on ..... copy anbcal:rlu~"'ncd; or(c) By •• me letlerortel .... wbl~ l..chldes --;;;ti ... cc 10 \lie solicitation ud --"'11I\IatJcn. FAILUR!! OF YOUR ACKNOWLI!DOMENTTO BE RECEIVED ATnll! PLACE DESIONA TED FOR nil! Rl!CElPTOFOFfERS PRIOR 10 nil! ROUP. AND DA 11: SPEClfll!D MA VIlI!IlULT IN

IlI!JECOON OF VOUR OFfI!R. lilly vlltueonhl. ~'fOll desl.to ct.acMloeulMCly 1IIbni\l" llIel1 cblnp ... y be ndcby JeI....,...r 1 .. 1 .... PlDylded cecil ........... orletler .. ka ........ to dtcHllclhtlon.ad"1t ....... I.aad Is IeCdved plio. to tlIcapeR1nll h_InddMespcclled.

12. ACCOUNTING AND APPROPRIATION DATA (lfrequked)

a.. Sch.dule

13. THIS ITEM APPLIES ONLY TO MODIflCATIONSOFCONTRACTS'ORDERS. IT MODlFJESTHE CONTRACTIORDERNO. AS DElDUBED IN ITEM 14. .

A. THIS CHANGE ORDER IS I~D PURSUANT TO: (lipeci/Y ... hority) THE CHANCES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM lOA.

TO REFLECT THE ADMINlSfRATIVE ~""""lJ=(lIICh u chlftFS m payma TOTHE AUTHORITY OF

E.IMPOKTANT: Contractor Is required to sian this documeal and retwn copies 10 the iauinloffic:e.

14. DESCItJPTION OF AMENDMENTIMODlFlCATION (Orpizedby UCF section headings, includingsoHcillltionlconlncl sul!iec:t mailer v.tacre feasible.) MacUle.lion Control Number. ••••••

See OJntlnuallon Page

IIIIu. aad COtIdllloM 0"_ dOCIIlllltlt rdnmcId ID 1I1III9A or lOA. u hClClO ....

PAGES

20

APPROVED BYOIRM 11-84

COcl. S '11 Sl'ANDARD FORM 30 (Rev. 10-83) Prs:ribed by CBA FAR(48 CFR) 51.243

)

DASG60-98-C-OOO 1 P00259

Page 2 of20


The purpose of this modification is:

1. Settlement of the proposal submitted by the contractor in response to Change Order Modification P00236 for JLENS 14 Day Endurance Test. The target cost, target fee,and total contract value will be adjusted as follows to account for the difference in the order value and the final negotiated amount: target cost decreased b~get fee decreased . total contract value decreased by $640,600.

2. Settlement of the proposal submitted by the contractor in response to Change Order Modification P00239 to delete paragraph 3.12.4, System Capability Reviews, from the System Development and Demonstration (SOD) Program Statement of Work, SW-JLENS-SDD-2006. The target cost, target fee, and total contract value will be adjusted as follows to account for the difference in the change order Wue and the final negotiated amount for costs incurred: target cost increased by target fee increased b. and total contract value increased by $660,095.

3. P00246 i

The target cost, target fee, and total contract value will be adjusted as follows to account for the difference in the change order value and the final negotiated amount: target cost decreased by ~get fee decreased ~ and total contract value decreased by $199,804.

4. Settlement of the proposal submitted by the contractor in response to Change Order Modification P00247 tor JLENS System Development and Demonstration (SDD) Spares. The target cost, target fee, and total contract value will be adjusted as follows to account for the difference in the change order value and the final negotiated amount: target cost decreased b~ target fee decreased by _ and total contract value decreased by $600,733.

5. Settlement of the proposal submitted by the contractor in response to Directorate B, Contract Operations Division 2, letter JLENS-2012-001, dated Januray 19,2012, subject: Contract DASG60-98-C-OOOI, "Joint Land Attack Cruise Missile Defense Elevated Netted Sensor (JLENS)," for de-scope offour functionalities from MIS-PRF-55628, Revision B, dated 18 August 2009. The target cost; target fee, and value will be adjusted as follows to account for the final negotiated amount: target cost decreased by target fee decreased by and total contract value decreased by $931,707.

6. Settlement of the proposal submitted by the contractor in response to Directorate B, Contract Operations Division 2, letter JLENS-2011-036, dated July 1,2011, requesting an update to Contract Data Requirements List (CDRL) BOI7, Integrated Support Plan, Sub-Plan entitled Deployment Transition Plan. The target cost, target fee, and total contract value will be adjusted as follows to account for the fmal negotiated amount: target cost increased by £ 3 target fee increased by _ and total contract value increased by $2,091,048.

7. To provide incremental funding in the amount of$I,096,I96.

SUMMARY OF CHANGES


(b )(4) ~1(

(b)(3)(A) (i)&Title 10 Sec 130 (a) (b)

DASG60-98-C-000 1 P00259

Page 3 of20

The total cost of this contract was increased by $378,299.00 from $1,955,238,009.00 to $1,955,616,308.00.


SUBCLIN 0017 AA

The target cost has increased by •••• om •••••• '0 •••••••

The target fee has increased by

The total target cost plus fee of this line item has increased by $378,299.00 from $1,595,005,395.00 to $1,595,383,694.00.

This includes an increase in target cost of consisting of __ 1r.rl'!lI'1.l'! in cost and ••• increase in facilities capital cost of money, and an increase in target fee

The target cost and target fee set forth above and in the table below reflects the negotiated ~ection B values prior to any adjustments made resulting from estimated cost overruns and share ratio impacts to the fee. Any differences between the Estimated Cost values provided below and the Target Cost values provided above and shown on the table below are as a result of estimated cost overruns. Any differences between the Estimated Fee values provided below and the Target Fee values provided above and shown on the table below are a result of reductions based on current share ratio impacts to the Target Fee and do not include any allocation for yet to be earned incentives as set forth in Section H-19. As oftl:}e date of this modification, the estimated cost and estimated ~~asfu~~: •

The Estimated Cost is •••••• consisting of $ •••• 1 in cost and •••• lm facilities capital cost of money.

The Estimated Fee is ••••••

Total Estimated Cost plus Fee is $1,717,867,861.

Pursuant to FAR 16.405-1, the target cost and target fee will be finally determined and adjusted after contract performance.

The table below provides a summary of the target cost, target fee, and total:

eLIN MOD TARGET COST FQCM TARGET FEE

$1,594,280,516.00

17AA

17AA P00254 ,005,395.00

17AA P00258 1,595,005,395.00

17AA P00259 1,595,383,694.00

oo~5'73

lb~A \\?)L~

l'C')L ~:

09)L{

~)L~

CLIN 0030

DASG60-98-C-000 I P00259

Page 4 of20

The total cost of this line item has increased by $1,096,196.00 from $123,699,162.00 to $124,795,358.00.



GFEBS Funding for SubCLIN 0017AA CPIF

FOB: Destination



... As stated in Modification P00251, CLIN 0030 has been established for the sole purpose of obligating GFEBS funding for performance of SubCLIN 0017 AA. The value of CLIN 0030 equates to the amount of GFEBS funding obligated for perfonnance of SubCLIN 0017 AA and should not be considered additional contract value. Informational SubCLINs under CLIN 0030 will be established each time additional GFEBS funding is obligated. CLIN 0030 and its SubCLINS will not be segregated from SubCLIN 0017 AA, identified, accounted for, analyzed, or reported separately from SubCLINOO 17, including EVMS: All scope remains under SubCLIN 0017 AA with associated incentive events and flat zones.

B-17. INCENTIVE FEE FOR SUBCLIN OOI7AA1CLIN 0018 (SEE H-19):

In accordance with FAR 52.216-10, entitled "Incentive Fee", the total amount originally negotiated, adjusted in accordance with paragraph d. of this clause, for target cost and target fee for performance under SubCLIN 0017 AAlCLIN 0018 are set forth below:

Target Cost

Target Fee

Incentive Arrangement: Maximum Fee: ---Minimum Fee: -(Share Ratio: Government/Contractor)

Underrun: _or the amount by which the total allowable cost is less than the estimated cost until maximum fee is attained.

Overrun: _or the amount by which the total allowable cost exceeds the estimated cost until minimum fee is attained.

FAR 52.216-10, INCENTIVE, paragraph (e)(I), is stated as follows:

(e) Fee Payable.

DASG60-98-C-000I P00259

Page 5 of20

(I) The fee payable under this contract shall be the target fee increased by_or every dollar that the total allowable cost is less than the estimated cost or decreased b) every dollar that the total allowable cost exceeds the estimated cost. In no event shall the fee be greater than t 1aximum fee) or less th~

inimum fee) of the estimated cost.

B-18. ESTIMATED COST. ESTIMATED INCENTIVE FEE. MINIMUM INCENTIVE FEE.

MAXIMUM INCENTIVE FEE. AND INCENTIVE ARRANGEMENT FOR SUBCLIN 0017 AAlCLlN 0018:

SUBCLIN 0017 AA - ITwo SDD JLENS Systems)

a. Estimated cost:

b. Estimated fee:

c; Minimum incentive fee: $---d. Maximum incentive fee: s

e. Total estimated cost and estimated fee: 51,717,867,861






ACRN:MX


Acctng Data: 02120122013204000001 1 71722550030003242A.0000013. 1.1 6100.9000021001

Increase: $1,096,196.00

Total: $1,096,196.00

Cost Code: A5XFJ

Estimated Cost, Estimated Fee, and Estimated total for the above increase of $1 ,096, 196 is distributed as fo lIows and includes an increase in estimated cost of_ (_ of cost an~ facilities capital cost of money) and an increase in estimated fee ~

oo~'5 '75

~)lq

~i~J

~1t£

~t~

(b)~)

'rJ~

Estimated

Cost

Estimated Fee

Total ,096,196

DASG60-98-C-000 1 P00259

Page 6 of20

IMPLEMENTATION OF AND EXPLANATION OF THE RELATIONSlllP OF THE LIMITATION OF FUNDS (LOF) CLAUSE TO FEE OBLIGATIONS, subparagraph c., is revised to read as follows:

SUBCLIN 0017 AA : THIS CUMULATIVE

PRIOR MODIFICATION TOTAL'"

(1) Amount Required for Full Funding,

Including Fee: -(2) Amount Allotted Under the LOF Clause

for Payment of Costs:

(3) Amount Separately Obligated for

Payment of Fee: S

(b )(4) ltll

(b )(4)

\.\;l)~

(b )(4) lV.>~

(4) Total Amount Allotted and Obligated: $1,714,775,111.27 51,096,196 $1,715,871,307.27

(5) Net Amount Required for Full Funding $ 2,714,450.73 ($ 717,897) $

... These figures take into consideration the negotiated total value of SubCLIN 0017 AA (This does not include

SubCLIN 17 AH)


Paragraph H-19, INCENTIVE FEE STRUCTURE AND PAYMENT FOR CLIN 0017. SYSTEM DEVELOPMENT AND DEMONSTRATION (SDD), subparagraph a., b., and c., are revised as follows:

a. General.

1,996,553.73

SubCLIN 0017AA, System Development and Demonstration (SDD), is a cost-plus-incentive-fee (CPIF) Line Item with cost and schedule incentives as described below. Paragraph H-19(b) applies only to the Cost Incentive and

Paragraph H-19(c) applies only to the Schedule Incentive. The target contract price amount 0($1,595,383,694 includes a target cost of which includes & .2 of cost and 5 »f facilities capital

(b )(4) (b)C


Page 7 of20

cost of money) and a target incentive fee of.S •••• 'which is.oftarget cost less facilities capital cost of money.

b. Cost Incentive.

(1) The target fee payable under SubCLIN 0017 AA estimated cost less facilities capital cost of mOlley

money

an amount equal

under SubCLIN 0017 AA is8 of the estimated cost less facilities capital cost of an amount equal to_

(3) The minimum fee payable under SubCLIN 0017AA is "'the estimated cost less facilities capital cost of ~)C'f an amount equal ~ ,

(4) Fee will be adjusted for actual cost that is less than or more than the estimated cost stated above u~ share ratio o~ovenunent ~ontractor for actual costs less than the estimated cost, and a ratio o~ ~ 1 Government _ Contractor for actual costs greater than the estimated cost range applied according to Paragraph H-19(c)(1). Q?11

(5) Nothing stated in this clause shall take precedence over the clause 52.216-10 - Incentive Fee contained in this contract,

c. Schedule and Perfonnance Incentive.

(1) A maximum "flat zone" will be established at the target cost value of 'lith the conduct of milestones below. The "flat zone" over which the contractor will earn target fee is for eligible costs from S to $ once the program milestones set forth below are conducted. (Note: As of the effective date of Modification P00259, onl~fthe maximwi "flat zone" has been acknowledged as earned.)

(a) , ~fthe maximum benefit of the "flat zone", earned by the conduct of the SDD System Functional Review NLT 2nd Quarter, Fiscal Year 2007. (It is hereby acknowledged by the government that Raytheon completed the requirement for this flat zone and earned the "Flat Zone" schedule incentive of .Ii •••• Final detemiination of incentive fee payment the "Flat Zone" amount will be made at the conclusion of the contract. Reference letter, dated 5 March 2007

(b) of the maximum benefit of the "flat zone", earned by the conduct of SDD Orbit Critical Design review NL T 2nd Quarter, Fiscal Year 2009. (It is hereby acknowledged by the government that Raytheon completed the requirement for this flat zone and earned the "Flat Zone" schedule incentive a Final detennination of incentive fee payment utilizing the "Flat Zone" amount will be made at the conclusion of the contract. Reference letter, dated 12 January 2009, front .................. .

7 (c) 2 _ of the Inaximum benefit of the "flat zone", earned by the conduct of the Developmental

Test I (DT -I) in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDD Contract, Section H-19(c), dated 08/10112. ([t is hereby acknowledged by the government that Raytheon completed the requirement for this flat zone and earned a "Flat Zone" schedule incentive of ••••• or of the available Final determination of incentive fee payment utilizing the "Flat Zone" amount will be made at the conclusion of the contract.)

\])'0 U)i(g) (nLIq)

~t't

0D)~

(PX1o ~lo)

(b)(~'


Page 8 of20

(d) ,fthe maximum benefit of the "flat zone", earned by the conduct of the Electromagnetic Environmental Effects (E3) Testing in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDD Contract, Section H-19(c), dated 08110/12.

(e) • _ of the maximum benefit of the "flat zone", earned by the conduct of the Integrated Fire Control Event in accordance with the criteria set forth in Section J attachment entitled Flat Zone PerfoI'IIlance

Criteria for JLENS SDD Contract, Section H-19(c), dated 08/10112. (It is hereby acknowledged by the government that Raytheon completed the requirement for this flat zone and earned a "Flat Zone" schedule incentive of

the available S ____ inal determination of incentive fee payment utilizing the

"Flat Zone" amount will be made at the conclusion of the contract.) ·NOTE: The potential has been decreased from _ lue to movement of the centive for "JLENS tracks interceptor when it

enters the FCR Field-of-View (FOV)" from the IFC event to the FCA #1 event

(f) 7 ~ of the maximum benefit of the "flat zone", earned by the conduct of the Functional Configuration Audit (FCA) #1 in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDD Contract, Section H-19( c), dated 08/10112. ·Note: The potential has been increased frOIl to 'ue to movement of the ncentive for "JLENS tracks interceptor when it enters the FCR Field-of-View (FOV)" from the IFC event to the FCA # 1 event.

(g) , ~ of the maximum benefit of the "flat zone", earned by the conduct of Developmental

Test 2 (DT -2) in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDD Contract, Section H-19(c), dated 08/10/12 ....

(h) l _of the maximum benefit of the "flat zone", earned by the conduct of the Early User Test (previously defined as Limited User Test) in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDD Contract, Section H-19(c), dated 08/10112 ....

(i) ,_ of the maximum benefit of the "flat zone", earned by the conduct of the Final Functional

Configuration Audit (FCA) in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SOD Contract, Section H-19(c), dated 08/10/12. •

(3) For Earned Value and cost reporting purposes, the estimated cost value of $1,464,660,290 will be used.


In the event of a change issued under FAR 52.243-2, Changes - Cost Reimbursement, it is agreed that changes to the performance and schedule incentive may be considered a part of the equitable adjustment. In the event that any Options to CLIN 0017 are added and exercised, the incentive fee for cost and schedule/performance applicable to the Option will be incorporated in accordance with the incentive fee structure of this provision.


FUNDING

OO~57R

l'o)L~

DASG60·98·C-OOO 1 P00259

Page 9 of20

AA 440,100.00

AB 2,298,235.00

AC 17,832,987.00

AD 0.00

AE 7,500,000.00

AF 3,300,000.00

AG 17,192,400.00

AH 700,000.00

AJ 200,000.00

AK 85,000.00

AL 45,000.00

AM 17,045,000.00

AN 5,800.00

AP 20,779,000.00

AQ 105,000.00

AR 35,000.00

AS 0.00

AT 6,984,678.52

AU 7,970,000.00

AV 0.00

AW 100,000.00

AX 3,396,000.00

AY 550,000.00

AZ 19,412,000.00

BA 24,527,878.00

BB 146,000.00

BC 72,000.00

OO~ rs79

DASG60-98-C-Ooo 1 P00259

Page 10 of20

BD 85,000.00

BE 100,000.00

BF 100,000.00

BG 1,975,321.00

BH 38,018,908.00

BJ 7,896,673.34

BK 260,000.00

BL 0.00

BM 12~,()()O.00

BN 103,000.00

BP 10,199,288.50

BU 350,000.00

BV 9,000.00

BW 84,896,852.00

BX 1,146,000.00

BY 3,880,000.00

BZ 190,000.00

KL 118,250.00

KM 192,793,000.00

KN 0.00

KQ 92,811.00

KR 0.00

KS 0.00

KT 386,377,998.00

KU 2,203,183.00

KV 65,000.00

KW 20,000.00

(joci5iO

DASG60-98-C-000 1 P00259

Page II of20

KX 60,000.00

KY 25,000.00

KZ 25,000.00

LA 13,508.00

LB 12,500.00

LC 200,000.00

LD 7,943,648.00

LE 1,173,850.00

LF 10,000.00

LG 62,000.00

LH 400,000.00

LJ 7,476.00

LK $281,575,897.00

LL $173,798.00

LM $1,410,376.00

LN $630,061.00

LP $83,200.00

LQ $235,566.00

LR $125,000.00

LS $6,069,616.00

LT $530,377.00

LU $9,100,000.00

LV $1,957,265.00

LW $255,567.00

LX $68,000.00

LY $264,807,424.52

LZ $1,751,384.00

00 a es«J

DASG60-98-C-000 1 P00259

Page 12 of20

MA $2,982,442.00

MB $375,000.00

MC $2,283,481.00

MD $8,573.00

ME $0.00

MF $270,780,923.00

MG $6,262,095.00

MH $213,390.00

MJ $858,495.00

MK $56,076.00

.ML $116,044.00

MM $1,618,600.00

MN $2,573,000.00

MP $250,000.00

MQ $691,421.00

MR $0.00

MS $700,000.00

MT $16,289,524.00

MU $7 ,864,499.00

MY $39,921,199.75

MW $10,000,000.00

MX SI14,795,358.00


CLIN 0001 AA

CLINooOI AD

CLIN 0003 AB

CLINOO03 AC

CLINOO03 AD

CLINOO03 AE

CLINOOO3 AF

CLINOO03 AG

CLINOOO3 AH

CLINOOO3 AM

CLINOOO3 AN

CLINOO03 AP

CLINOOO3 AS

CLINOOO3 AT

CLINOOO3 AW

CLINOO03 AY

CLINOO05 BA

CLINOO05 BB

CLIN 0005 BC

CLINOO05 BD

CLIN 0005 BE


440,100.00

0.00

440,100.00

2,298,235.00

17,832,987.00

0.00

7,500,000.00

3,300,000.00

17,192,400.00

700,000.00

17,045,000.00

5,800.00

20,779,000.00

0.00

6,984,678.52

100,000.00

550,000.00

94,288,100.52

24,527,878.00

146,000.00

72,000.00

85,000.00

100,000.00

OOd..583

DASG60-98-C-OOOI P00259

Page 13 of20

CLIN0005 BF

CLIN0005 BO

CLIN0005 BH

CLINOO05 BL

CLIN0005 BZ

CLIN0007AA BP

CLINOO09AA AQ

CLINOOO9AA AV

CLINOO09AA BK

CLINOO09AA BM

CLINOO09AA BN

CLINOO09AB AJ

CLINOO09AB AK

CLINOO09AB AL

CLlNOO09AB AQ

CLINOO09AB AR

CLINOO09AB BK

CLINOO09AB BN

CLINOO09AB BU

CLINOO09AB BV

100,000.00

1,975,321.00

38,018,908.00

0.00

0.00

10,199,288.50

45,106.00

0.00

256,545.00

125,000.00

21,315.00

200,000.00

85,000.00

45,000.00

59,894.00

35,000.00

3,455.00

81,685.00

350,000.00

9,000.00

oo~~~tt

65,025,107.00

10,199,288.50

447,966.00

DASG60-98-C-OOO 1 P00259

Page 14 of20

CLINOO13 AU

CLINOO13 AX

CLIN 0013 AY

CLINOO13 AZ

CLIN 0013 BJ

CLIN 0017 BW

CLIN0017 KM

CLINoo17AA BY

CLINOOl7AA BX

CLINOO17AA BW

CLINOO17AA BZ

CLINOO17AA KM

CLINOO17AA KN

CLINOO17AA KQ

CLINOO17AA KS

CLINOOl7AA KT

CLINOO17AA KU

CLINOO17AA KY

CLINoo17AA LC

CLINOO17AA LD

CLINOO17AA LE

7,970,000.00

3,396,000.00

0.00

19,412,000.00

7,896,673.34

0.00

0.00

3,880,000.00

1,146,000.00

84,896,852.00

0.00

192,793,000.00

0.00

66,151.00

0.00

386,204,200.00

2,203,183.00

0.00

200,000.00

7,943,648.00

0.00

CO~5<j?5'

869,034.00

38,674,673.34

0.00

DASG60-98-C-000 1 P00259

Page 15 of20

DASG60-98-C-000 1 , P00259

Page 16 of20

CLINOO17AA LH 400,000.00

CLINOO17AA LJ 7,476.00

CLINOO17AA LK 281,575,897.00


CLINOO17AA LS 6,069,616.00


CLINOO17AA LV $9,100,000.00

CLINOO17AA LV $1,957,265.00



CLINOO17AA LY $264,807,424.52


CLINOO17AA MC $2,283,481.00


CLINOO17AA ME $0.00

CLINOO17AA MF $270,780,923.00





CLINOO17AA MM $1,618,600.00

CLINOO17AA MN $2,573,000.00


CLINOO17AA MQ $691,42l.00

CLINOO17AA MR $0.00

CLIN0017AA MS

CLIN0017AA MT

CLIN0017AA MY

CLIN0017AA MW

CLIN0017AA MX

CLIN0017AB KL

CLIN0017AC BZ

CLINOO17AD KN

CLIN0017AD KS

CLIN0017AE LL

CLIN0017AH KT

CLIN0020AA KN

$700,000.00

$16,289,524.00

$39,921,199.75

$10,000,000.00

$124,795,358.00

118,250.00

190,000.00

0.00

0.00

173,798.00

173,798.00

0.00

1,715,871,307.27

118,250.00

190,000.00

0.00

173,798.00

173,798.00

DASG60-98-C-OOO 1 P00259

Page 17 of20

CLIN0020AA KQ

CLIN0021AA KW

CLIN0021AB KV

CLIN0021AB LB

CLIN0021AB KX

CLIN0021AB KY

CLIN0021AC KZ

CLIN0021AC LA

CLIN0022 KW

CLIN0023 KX

CLIN 0023 KY

CLIN0023 KV

CLIN0023 LB

CLIN0023 LF

CLIN0023 LR

26,660.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

60,000.00

25,000.00

65,000.00

12,500.00

10,000.00

$125,000.00

OO~S~~

26,660.00

0.00

0.00

0.00

0.00

297,500.00


Page 18 of20

CLIN0024 LA

CLIN0024 LG

CUN0024 KZ

CLIN0024 KW

CLIN0024 LP

CLINOO25 LE

CLINOO25 LM

CLINOO25 MA

CLIN0026 LN

CLINOO27 LZ

CLINOO28 LM

CLINOO28 MA

CLINOO28 MG

CLIN0028 MU

CLIN 00300 I '" MX

13,508.00

62,000.00

25,000.00

20,000.00

83,200.00

1,173,850.00

1,080,404.00

0.00

630,061.00

1,751,384.00

329,972.00

2,982,442.00

6,262,095.00

$7,864,499

$52,974,283.00

203,708.00

2,254,254.00

630,061.00

1,751,384.00

17,439,008.00

DASG60-98-C-0001 P00259

Page 19 of20

CLIN003002'" MX

CLIN 000303* MX

CLIN 000304'" MX

CLIN 000305* MX

CLIN 003006'" MX

eLIN 003007* MX

$719,132.00

$5,747.00

$16,000,000.00

$16,000,000.00

$38,000,000.00

51,096,196.00

124,795,358.00

DASG60-98-C-000 1 P00259

Page 20 of20

'" CLIN 0030 has been established for the sole purpose of obligating GFEBS funding for perfonnance of SubCLIN 0017 AA. Infonnational SubCLINs under CLIN 0030 will be established each time additioanl GFEBS funding is obligated. For pruposes of this funding update, funding obligated un.der CLIN 0030 will also be reflected under SubCLIN 0017 AA and should not be counted twice with regards to the total contract funding obligated.

8. In consideration of the modification agreed to herein as complete equitable adjustment for the following proposals submitted by Raytheon, the contractor hereby releases the Government from any and all liability under the contract for further equitable adjustments attributable to such facts or circumstances giving rise to the proposals for adjustment:

JLENS System Capability Review (SCR) Proposal, submitted via Raytheon letter JLENS-SDDI2-016, dated 2 March 2012.

the Surveillance System (SuS) Proposal, submitted via Raytheon letter JLENS-SDD-12-008, dated 16 February 2012.

JLENS 14 Day Endurance Test Proposal, submitted via Raytheon letter JLENS-SDD-12-026, dated 16 March 2012.

JLENS Capability De-Scope Proposal, submitted via Raytheon letter JLENS-SDD-12-035, dated 9 April 2012.

JLENS Deployment Transitiion Plan Proposal, submitted via Raytheon letter JLEN8-SDD-12-001, dated 23 January 2012.

JLENS System Development and Demonstration (SDD) Spares, Proposal, submitted vai Raytheon letter JLENSSDD-12-012, dated 22 February 2012.

(b)(3)(A) (i)&Title 10Sec 130 (a) (b)


\MENDMENT/MODIFICATION NO.

0260

6. ISSUED BY

USASMOCIARSTRAT SMOC·ROC POBOX11!OO HUNTS\IIU.E Al358D7·3B(»

CODE

4. REQUlSrnON/PURCHASE REQ. NO.

7. ADMINIS'lERED BY (Ifothor Iban itcm6) '--------1 OCMARAYTHEON

SOAPPl.E HILL ORNE MIST2FR2 TElM<S8URY MA 01876

8. NAME AND ADDRES';OF CONTRACTOR (No., Street, Co1Dlty, Statc and Zip Code) RAYTHEON COMPANY 31!0 LOV\8.L ST. ANDOVER MA D181D-4400

lOA. MOD. OF CONTRACf/ORDERNO. ~SG60-98-C-0001

"",A ahnvA nUnDeRd lolicitlllion is amonded .. let tbrth in Item 14. Thebour IIId datespeciied ilr receipt oroSe D i. not extended.

OSrIlll.t acknowledge receipt ofthi. amendment prior to the hoW' lad date .peciJied io thOlolicitation or .. _ded by one ofth .. tbllowing mb.od.:

(a) By oo .... l.ting Items 8 and H, IIId ",turning copiea ofthalDllnd"""t; (b) By acknowledging receipt ofthi. _dlIlOllt on each copy ofth. 01& aubnitted; or (c) By .epara/e.' .. t ... or telelJr&lll which includea arofon:nce to the solicitation and _dlIlOlt nuni>e<s. FAILURE OF YOUR ACKNOWLEDOMENT1O BE RECEIVED ATlHE PLACE DESIGNA mD FOR lHB RECEIPT OF OFFERS PRIOR 10 mE HOUR AND DA'IE SPECIFIED MAY RESUL TIN

REJEcnON OF YOUR OFFER,. ifby virtue ofthi. amend ....... t you dOlit" to change ali oSr'oIroady lubuitted, such change lIllY boOBda by telognunor letter, provided OIcb tclograJDorietterrtllkOl ... ironce to the solicitation and this urad"""'t, and i. received prior to tho opcming hour sod date speciliod.

12. ACCOUNTING AND APPROPRIA nON DATA (If TCcPrcd)

See Schedule

13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACfS'ORDERS IT MODIFIES THE CONTRACTIORDERNO. AS DESCRIBED IN ITEM 14 .

. THIS CHANGE ORDER IS I~D PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACf ORDER NO. IN ITEM lOA.

'YlUIJ1C1DIJ TO REFLECr THE ADMINISfRA TlVE ~""""~'''''03(such as cbanges in paying TO THE AIJTHORITY OF FAR

(Specify type of modification and authority) TffiAL: FAR 52.243-2, Changes and FAR 52.232-22 Urrlation of Funds

E. IMPORT ANT: Contractor [R) is not, 0 is to sign this docl.II1cllt and return copies to the issuing office.

14. DBSCRIPT ION OF AMENDMENT IMODIFICA nON (Organized by UCF section hcadings, including solicitation/contract subject matter where feasible.) Modification Control Number:

See SF3Q, block 14, continuation page.

Except as herein,lll tClJU,ll and cooditions ofthe docum:nt ro&oDeod in Item 9A or lOA, as beman", chang.d, romIin. unchanged and in flll nree and •• 1.

15A. NAME AND TITLE OF SIGNER (Type or print)

:ONTRACfORIOFFEROR lSC. DATE SIGNED

at.tborized to sign)

(b )(6)

30-105·04

ooaSq I APPROVED BY OIRM 11·84 Sf ANDARD FORM 30 (Rev. 10·83) Prescribed by GSA FAR (48 CFR) 53.243

SBCTIONSF30BLOCKI4CO~ATIONPAGE

The purpole or tills modification Is to:


Page 2 0(20

1. Issue Change Order Modification P00260 for JLENS based on restructure letter JLENS-2012·03Idated 20 September, 2011. CeDing of contract will incJ'C8se by a total ofSS9,034,271.

2. This Change Order Modification will also incrementally fund this increase by $16,145,.226.39.

SUMMARY OF CHANGES

I. SECTIqN A - SOLICITATION/CONTRACT FORM

The total cost of this contract was increased by $S9,034,271from $1,955,616,308,00 to $2,014,650,579.00.


SUBCLIN OOt7AA

The target cost has increased by~

The tarset fee has increased

Tho total target cost plUB fee ofthialine item has increased by 159,034,271 from $1,595,383,694 to $1,654,417,965.

11tJs includos an increase in target cost o~isting ofa _crease in facilities capital cost of money, and an increase in target inrn'OMUlfI in cost and a

The target cost and tarlot fee set forth above and in the table below reflects the negotiated Section B values prior to any adjustments made resulting from estimated cost ovemms and share ratio impacts to the fee. Any dift'erences between the Estimated Cost values provided below and the Target Coat values provided above and shown on the table below are as a result of estimated cost overruns. Any dift'erenllCS between the Estimated Fee values provided below and the Targot Pee values provided above and shown on the table below are a result of reductions based on current sharo ratio impacts to the Target Fee and do not include any allocation for yet to be eamed incentives as sot forth in Section H-19. As of the date of this modification, the estimated cost and estimated fee are as follows:

The Estimated Cost is $ facilities capi~ cost of money. .. -.--

The Estimated Fee is

Tota,l Estimated Cost plus Fee Is S I ,776.902,132 ..

Pursuant to FAR 16.405-1, the target cost and target fee will be finally detennined and adjusted after contract performance.

The table below provides a swiunary of the target cost, target fee, and total:

DASG60-98-C-OOO 1 POO260

Page 3 of20

CLIN MOD FCCM

17AA 1,594,280,516.00

1,594,280,516.00

17AA

P00259

17AA POO260 .00

CLIN0030

The total cost of this line item has increased by $16,000,000.00 from $124,795,358.00 to $140,795,358.00.


\ ~~)

~JL+)

(}JX-~)

~)L*) cp)l~)

Cb'(4)

ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT 003008


CPIF FOB: Destination

ACRNMX CIN: GFEBSOO lO2467oo0000 1

$16,000,000.00

• As stated in Modification P00251, CLIN 0030 has been established for the sole purpose of obligating GFEBS funding forperfonnance ofSubCLIN 00 17AA. The value ofCLIN 0030 equates to the amountofGFEBS funding obligated for perfonnance of SubCLIN 0017 AA and should not be considered additional contract value. Infonnational SubCLINs under CLIN 0030 will be established each time additional GFEBS funding is obligated. CLIN 0030 and its SubCLINS will not be segregated from SubCLIN 0017 AA, identified, accounted for, analyzed, or reported separately from SubCLINOO 17, including EVMS. All scope remains under SubCLIN 0017 AA with associated incentive events and flat zones.

B-1 7. INCENTIVE FEE FOR SUBCLIN 0017 AAlCLIN 0018 (SEE H-19):

In accordance with FAR 52216-10, entitled "Incentive Fee", the total amount originally negotiated, adjusted in accordance with paragraph d. of this clause, for target cost and target fee for performance under SubCLIN 0017 AAlCLIN 0018 are set forth below:

Target Cost 51,518,857,479

DASG60-98-C-OOO 1 P00260

Page 4 of20

Target Fee $---Incentive Arrangement Maximum Fee:

Minimum Fee: & (Share Ratio: Government/Contractor)

Underrun: maximum fee is attained.

the amount by which the total allowable cost is less than the estimated cost until

Overrun: £ minimum fee is attained.

.r the amount by which the total allowable cost exceeds the estimated cost until

FAR 52.216-10, INCENTIVE, paragraph (eX 1 ), is stated as follows:

(e) Fee Payable.

8-18. ESTIMATED COST. ESTIMATED INCENTIVE FEE. MINIMUM INCENTIVE FEE. MAXIMUM INCENTIVE FEE. AND INCENTIVE ARRANGEMENT FOR SUBCLIN OOI7AA1CLIN 0018:

SUBCLIN QO 17 AA - (Two SDO JLENS Systems)

a. Estimated cost:

b. Estimated fee:


d. Maximwn incentive fee: $£ e. Total estimated cost and estimated fee: SI,776,902,132


ACCOWlting and Appropriation



SUBCLIN 0017 AA:

(b)(4) ~~ @li\ lb'1~

(b )(4) ~'0

(b )(4) (\;b

~)Ltf-

DASG60-98-C-000 1 P00260

Page 5 of20

MF: 21 12040 5L 5L68 Pl72419E555L 255Y 4MIJ730000 SOl0214MIJ730000114MJLEl4M5 was increased by $126,899.39 from $270,780,923.00 to $270,907,822.39

Estimated Cost, Estimated Fee, and Estimated total for the above increase of$126,899.39 is distributed as follows and includes an increase in estimated cost of I ,F:' f cost and of f~ci1ities capital cost of money) and an increase in estimated fee of 3

Estimated Cost

Estimated Fee

Total

MY: 21 12040 5L 5L68 PI72419E555L 2516 4MlMMICST3 S010214M1MMICST3114MJMM/4M5 was increased by $18,327.00 from $0.00 to $18,327.00

The contract ACRN MY has been added.

Estimated Cost, Estimated Fee, and Estimated total for the above increase of $18,327 is distributed as follows and includes an increase in estimated cost cost and ~ffacilities capital cost of money) and an increase in estimated fee of •••

Cost

Estimated Fee

Total 18,327

CLIN0030:


ACRN:MX

CIN: GFEBSOO1024670000ool

Acctng Data: 0212012201320400000 1171722550030003242A.OOOOO 13.1.1 6100.9000021001

Increase: $16,000,000.00

Total: $16,000,000.00

Cost Code: A5XFI

Estimated Cost, Estimated Fee, and Estimated total for the above increase of$16,OOO,OOO is distributed as follows and includes an increase in estimated cost of _ ( of cost and 2 of facilities capital

006..595

(b )(4) Cbi; lbu ~JUl

cost of money) and an inCrease in estimated fee ot ••••

Estimated Cost

DASG60-98-C-OOO 1 PO0260

Page 6 of20

(b )(4)

Estimated Fee (b )(4)

Total

IMPLEMENTATION OF AND EXPLANATION OF THE RELA TIONSIDP OF THE LIMITA nON OF FUNDS (LOF) CLAUSE TO FEE OBLIGATIONS. subparagraph c., is revised to read as follows:

SUBCLIN 0017 AA : THIS CUMULATIVE

PRIOR MODIFICATION TOTAL·

(1) Amount Required for Full Funding.

Including Fee:

(2) Amount Allotted Under the LOF Clause



(b)(4) ~

(9):.Y

Payment of Fee: $ ~)~) ~l'

(4) Total Amount Allotted and Obligated: $1,715,871,307.27 SI6,145,226.39 SI,732,016,533.66

(5) Net Amount Required for Full Funding $ 1,996,553.73 $ 42,889,044.61 S 44,885,598.34

• These figures take into consideration the negotiated total value of SubCLIN 00 17 AA (This does not include SubCLIN 17 AH)


Paragraph H-19, INCENTIVE FEE STRUCTURE AND PAYMENT FOR CLIN 0017. SYSTEM DEVELOPMENT AND DEMONSTRATION (SOD), subparagraph a., b., and c., are revised as follows:

a. General.

SubCLlN 0017AA, System Development and Demonstration (SOD), is a cost-plus-incentive-fee (CPIF) Line Item with cost and schedule incentives as described below. Paragraph H-19(b) applies only to the Cost Incentive and

hrqrIph 8-19(0) oppilleo .>Diy .. melUd. • tIrJIIC COlt _ of.....,,) ond. lalPi'iiiCiiiiiiiW .....".

b. Coot 1nccnIlvc.

8-19(eXI).

DAS060-9a-COOO1 POO260

PoP~'6f20

• 'I"

(5) Notbinc ItUed in this cia&ale Ihall tab precedeoce over me claiM 52.216-10 - Inceatlve Foe contaioed in &i • .........

"&t DlIMI" wiU be eatabliabed ... the IIrpt coC value "flU zone" over- which the c.ootruor wUl

owcimum 1

iiiil;~". FIIc:ol V", complclled the requirmDeot for thla o.t ZOM I

cIoIomI_or~ .. ftIe __ udlIz

_" ....... _ 12 J .. ""Y'

ICII: bib below 11'0

1>0 SDD S,...........

)0 Orbit Critbl .II1II R.Iytbcca

_Final llionorebe

muimum. be )ewIopmonIaI Tat I witb lbecriteria .. tbr1h in Scctioa J.u.:imeat ooddod F1UZonD PatG:ciOlilCO em.;. fur JLI!NS SDD ~ _8-19«). _01110112. (I' is bon>by _todpcI bylbo 110-"'" Rlylboon comp_1bo __ I fur Ihlo fill """ ODd _ • "FIII_rr __ YO Of

,, "., ,

(b)(4)~ "1 "''11_ ~m ~)J/

i!>:£.~;

~~ @YI: Ili'j.q

~)b (b)(f

(b)(4) t~

~(fi l5>Xli ll')u.~ MoO'\)

Ijl/.!J'

(b"X~) Q,o")dJ) . blL.<{\ ,

I

OASG60-98-C-OOOl PO0260

Page 8 of20

••••• or of the available . Final detennination of incentive fee payment utilizing the "Flat Zone" amount will be made at the conclusion of the contract.)

Cd) of the maximum benefit of the "flat zone", earned by the conduct of the Electromagnetic Environmental Effects (E3) Testing in accordance with the criteria set forth in Section J attachment entitled Fiat Zone Perfonnance Criteria for JLENS SOD Contract, Section H-19(c), dated 08/10/12.

(e) of the maximum benefit of the "flat zone", earned by the conduct of the Integrated Fire Control Event in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDO Contract, Section H-19(c), dated 08110/12. (It is hereby acknowledged by the government that Ra1eon completed the requirement for this flat zone and earned a "Flat Zone" schedule incentive of

i i or_of the available 2 Final detennination of incentive fee payment utilizing the "Flat Zone" amount will be made at the conclusion of the contract.) "'NOTE: The ...... , ; •. .J. .... ~.... . .' •

, , , I • •

. (b)(3)(A)

. . (i)&Title 10 (10 " ~ (f) . U of the maxunum benefit of the "flat zone", earned by the conduct of the Functional Sec 130 (a) (b) IJ; ]v .

Configuration Audit (FCA) #1 in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SOD Contract, Section H-19(c), dated 08110/12. increased from (b)(3)(A)

(i)&Title 10 Sec

(g) of the maximum benefit of the "flat zone", earned by the conduct of Developmental 130 (a) (b) li?x.. -(, Test 2 (DT-2) in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDD Contract, Section H-:19(c), dated 08/10/12. •

.-.... \I~V"JI (h) ~ of the maximum benefit of the "flat zone", earned by the conduct of the Early User Test \Y J-.'-t (previously defined as Limited User Test) in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDD Contract, Section H-19(c), dated 08/10112. *

(i) ~ of the maximum benefit of the "flat zone", earned by the conduct of the Final Functional (,,;,/.--4) Configuration Audit (FCA) in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SOD Contract, Section H-19(c), dated 08/10/12. •

(3) For Earned Value and cost reporting purposes, the estimated cost value of $1,518,857,479 will be used.


In the event of a change issued under FAR 52.243-2, Changes - Cost Reimbursement, it is agreed that changes to the performance and schedule incentive may be considered a part of the equitable adjustment. In the event that any Options to CLIN 0017 are added and exercised, the incentive fee for cost and schedule/perfonnance applicable to the Option will be incorporated in accordance with the incentive fee structure of this provision.

5. The following is an update to Modification P00259 showing a sununary offunding by ACRN through Modification POO260:

FUNDING

AA

AB

AC

AD

AE

AF

AG

AH

AI

AK

AL

AM

AN

AP

AQ

AR

AS

AT

AU

AV

AW

AX

AY

AZ

BA

BB

440,100.00

2,2~8,235.00

17,832,987.00

0.00

7,500,000.00

3,300,000.00

17,192,400.00

700,000.00

200,000.00

85,000.00

45,000.00

17,045,000.00

5,800.00

20,779,000.00

105,000.00

35,000.00

0.00

6,984,678.52

7,970,000.00

0.00

100,000.00

3,396,000.00

550,000.00

19,412,000.00

24,527,878.00

146,000.00

OO~5q~


Page 9 of20

BC

BD

BE

BF

BG

BH

BJ

BK

BL

BM

BN

BP

BU

BV

BW

BX

BY

BZ'

KL

KM

KN

KQ

KR

KS

KT

KU

KV

72,000.00

85,000.00

100,000.00

100,000.00

1.975,321.00

38,018,908.00

7,896,673.34

260,000.00

0.00

125,000.00

103,000.00

10.199.288.50

350,000.00

9,000.00

84,896,852.00

1,146,000.00

3,880,000.00

190,000.00

118,250.00

192,793,000.00

0.00

92,811.00

0.00

0.00

386,377,998.00

2,203,183.00

65,000.00

OO~(oOO

DAS060-98-C-Oool P00260

Page 10 of20

KW

KX

KY

KZ

LA

LB

LC

LD

LE

LF

LG

LH

LJ

LK

LL

LM

LN

LP

LQ

LR

LS

LT

LV

LV

LW

LX

LY

20,000.00

60,000.00

25,000.00

25,000.00

13,508.00

12,500.00

200,000.00

7,943,648.00

1,173,850.00

10,000.00

62,000.00

400,000.00

7,476.00

$281,575,897.00

$173,798.00

$1,410,376.00

$630,061.00

$83,200.00

$235,566.00

$125,000.00

$6,069,616.00

$530,377.00

$9,100,000.00

$1,957,265.00

$255,567.00

$68,000.00

$264,807,424.52

(X)cl&20 [

DASG60-98-C-OOO 1 P00260

Page 11 of20

DASG60-98-C-000 I P00260

Page 12 of20

LZ $1,751,384.00

MA $2,982,442.00

MB $375,000.00

Me $2,283,48 LOO

MD $8,573.00

ME $0.00

MF $270,907,822.39

MG $6,262,095.00

MH $213,390.00

MJ $858,495.00

MK $56,076.00

ML $116,044.00

MM $1,618,600.00

MN $2,573,000.00

MP $250,000.00

MQ $691,421.00

MR $0.00

MS $700,000.00

MT $ 16,289,524.00

MU $7,864,499.00

MV $39,921,199.75

MW $10,000,000.00

MX $140,795,358.00

MY $18,327.00

6. The following is an update to Modification P00259 showing a summary of funding by eLIN by ACRN through Modification P00260:

CLIN 0001 AA

CLIN 0001 AD

CLINOO03 AB

CLINOO03 AC

CLINOOO3 AD

CLINOOO3 AE

CLINOO03 AF

CLIN 0003 AG

CLIN 0003 AH

CLINOO03 AM

CLINOO03 AN

CLINOO03 AP

CLlN 0003 AS

CLlN 0003 AT

CLINOO03 AW

CLINOO03 AY

CLINOO05 BA

CLINOO05 BB

CLIN 0005 BC

CLINOO05 BO

CLINOO05 BE


440,100.00

0.00

440,100.00

2,298,235.00

17,832,987.00

0.00

7,500,000.00

3,300,000.00

17,192,400.00

700,000.00

17,045,000.00

5,800.00

20,779,000.00

0.00

6,984,678.52

100,000.00

550,000.00

94,288,100.52

24,527,878.00

146,000.00

72,000.00

85,000.00

100,000.00

()O~~O3

OASG60-98-C-000 1 P00260

Page 13 0[20

CLIN0005 BF

CLIN 0005 BG

CLIN0005 BH

CLIN 0005 BL

CUN0005 BZ

CLIN0007AA BP

CLINOOO9AA AQ

CLIN 0OO9AA AV

CLINOO09AA BK

CLINOO09AA BM

CLINOO09AA BN

CLINOO09AB AJ

CLINOOO9AB AK

CLINOO09AB AL

CLINOO09AB AQ

CLIN 0009AB AR

CLINOO09AB BK

CLIN 0009AB BN

CLINOOO9AB BU

CLINOO09AB BV

100,000.00

1,975,321.00

38,018,908.00

0.00

0.00

10,199,288.50

45,106.00

0.00

256,545.00

l25,000.00

21,315.00

200,000.00

85,000.00

45,000.00

59,894.00

35,000.00

3,455.00

81,685.00

350,000.00

9,000.00

()O~u04

65,025,107.00

10,199,288.50

447,966.00

DASG60-9 8-C-000 1 P00260

Page 14 of20

CLINOOl3 AU

CLINOO13 AX

CLINOOl3 AY

CLINOO13 AZ

CLIN 0013 BJ

CLIN0017 BW

CLIN 0017 KM

CLIN 0017AA BY

CLIN 0017AA BX

CLINOO17AA BW

CLIN 0017AA BZ

CLIN 0017AA KM

CLIN 0017AA KN

CLIN 0017AA KQ

CLINOO17AA KS

CLINOO17AA KT

CLIN 0017AA KU

CLINOO17AA KY

CLIN 0017AA LC

CLIN 0017AA LD

CLIN OO17AA LE

7,970,000.00

3,396,000,00

0.00

19,412,000,OQ

7,896,673.34

0.00

0.00

3,880,000.00

1,146,000.00

84,896,852.00

0.00

192,793,000.00

0.00

66,151.00

0.00

386,204,200.00

2,203,183.00

0.00

200,000.00

7,943,648.00

0.00

OOd-laOS

869,034.00

38,674,673.34

0,00

DASG60-98-C-OOO 1 P00260

Page 150[20

DASG60-98-C-OOO 1 P00260

Page 16 of2D

CLIN OO17AA LH 400,000.00

CLIN 0017AA LJ 7,476.00

CLIN 0017AA LK 281,575,897.00

CLIN 0017AA LQ 235,566.00

CLIN 0017AA LS 6,069,616.00

CLIN 0017AA LT 530,377.00

CLINOOl7AA LV $9,100,000.00

CLIN OO17AA LV $1,957,265.00

CLIN OOl7AA LW $255,567.00

CLIN 0017AA LX $68,000.00

CLIN OO17AA LY $264,807,424.52

CLIN 0017AA MB $375,000.00

eLIN OOl7AA Me $2,283,481.00

eLIN 0017AA MD $8,573.00

eLIN 0017AA ME $0.00

CLINOO17AA MF $270,907,822.39

CLIN 0017AA MH $213,390.00

CLINOOl7AA MJ $858,495.00

CLIN 0017AA MK $56,076.00

CLIN OO17AA ML $116,044.00

CLINOOl7AA MM $1,618,600.00

CLIN OO17AA MN $2,573,000.00

CLIN 0017AA MP $250,000.00

CLIN 0017AA MQ $691,421.00

CLINOOl7AA MR $0.00

CO&loOto

CUN0017AA MS

CLIN 0017AA MT

CLIN 0017AA MV

eLIN 0017AA MW

CLIN 0017AA MX

CLINOOl7AA MY

CLIN 00 17AB KL

CLIN 0017AC BZ

eLIN OOl7AD KN

eLIN 0017AD KS

eLIN 0017AE LL

eLfN 0017AH KT

$700,000.00

$16,289,524.00

$39,921,199.75

$10,000,000.00

$140,795,358.00

$18,327.00

118,250.00

190,000.00

0.00

0.00

173,798.00

173,798.00

OO~(.QO'7

1,732,016,533.66

118,250.00

190,000.00

0.00

173,798.00

173,798.00

DASG60-98-C-000 1 P00260

Page 17 of20

CLIN0020AA KN

CLIN0020AA KQ

CLIN 0021AA KW

CLIN 002lAB KV

CLIN 002lAB LB

CLIN 0021AB KX

CLfN 002lAB KY

CLIN 0021AC KZ

CLIN0021AC LA

CLIN 0022 KW

CLIN0023 KX

CLIN 0023 KY

CLINOO23 KV

CLIN0023 LB

CLIN0023 LF

CLIN 0023 LR

0.00

26,660.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

60,000.00

25,000.00

65,000.00

12,500.00

10,000.00

$125,000.00

00611908

26,660.00

0.00

0.00

0.00

0.00

DASG60-98-C-000 I P00260

Page 180(20

CLIN 0024 LA

CLIN0024 LG

CLIN 0024 KZ

eLIN 0024 KW

CLIN 0024 LP

CLIN0025 LE

CLIN 0025 LM

CLIN 0025 MA

CLIN0026 LN

CLIN0027 LZ

CLIN 0028 LM

CLIN 0028 MA

CLIN 0028 MG

CLIN 0028 MU

13,508.00

62,000.00

25,000.00

20,000.00

83,200.00

1,173,850.00

1,080,404.00

0.00

630,061.00

1,751,384.00

329,972.00

2,982,442.00

6,262,095.00

$7,864,499

297,500.00

203,708.00

2,254,254.00

630,061.00

1,751,384.00

17,439,008.00

DASG60-98-C-OOO 1 P00260

Page 190[20

CLIN 003001* MX

CLIN003002* MX

CLIN 000303 * MX

CLIN 000304* MX

CLIN 000305 * MX

CLIN 003006* MX

CLIN 003007* MX

eLIN 003008* MX

$52,974,283.00

$719,132.00

$5,747.00

$16,000,000.00

$16,000,000.00

$38,000,000.00

$1,096,196.00

$16,000,000.00

140,795,358.00

DASG60-98-C-OOO 1 P00260

Page 20 of 20

* CLIN 0030 has been established for the sole purpose of obligating GFEBS funding for performance of SubCLIN

0017 AA. Informational SubCLINs under CLIN 0030 will be established each time additioanl GFEBS funding is obligated. For pruposes of this funding update, funding obligated under CLIN 0030 will also be reflected under

SubCLIN 0017 AA and should not be counted twice with regards to the total contract funding obligated.


OO~lo(O


6. ISSUED BY

USASMDCIAASTRAT SMDC·RDC PO BOX ISlO HUNTSVILLE AI. 351107·3801

NO.

CODE

EFFECTIve DAlE 4. REQUISmON/PURCHASE REQ. NO.

13-Nov-2012

1.ADMINISlERED BY (lfotb .. lblll il .... 6) """';;"O"';='-----i DCMARAYTHEON

50 APPl£ Hi\.L DRIVE M/sT2FA2 TEW<SBURY MA 01818

8. NAME AND ADDRESS OF CONTRACTOR (No., Street. COUDty, SUte and Zip Code) RAYTHEON COMPANY 350LOWEU.ST. ANDOVER MAOla'l).44oo

9A.

98. DATED (SEE ITEM II)

Olh ..... ' ocknowtodg. receip' oflhi ........ dm:nl prio, to Ih. hour and dale 'p",iled in 'he sotici'ation o,.J _dod by on. ortbe.lltowlnH IIIdhods:

(a) 9y co .... lelin~ 1t0lll5 8 and t S, and n:lumiaG ___ copies oRh • ....,.d ..... l; (b) By ocknowl.dllias roceipl oflhi ...... eImonl on each copy .fthe 01& .u_IIed;

or (c) By •• panteleller 0' leteararftwhich includc. a ....... " 10 the loli<ilolion and • .-end .... 1 nuatl.n. FAILURE OF YOUR ACKNOWLEDGMENT TO BE RECEIVED A TTIlE PLACE DESIGNA lED FOR THE RECEIPT OF OFFERS PRIOR 1'0 TIlE HOUR AND DAlE SPEClFlED MAY RESULTIN

REJECTION OF YOUR OFFER. Ifby Ylltue ofthi. _dRnt you d •• ire 10 chonaean o .... lready subnittod. such chlllK.aay be mad. by t.I.Il ..... o' leller. p,ovidod _h leleamno,Iellcrmokcs ",&m"1a Ihu.licitalion and this _dmmt,lAd iJ n:ceIvod prior to theop .. in" houraod dal •• peeiiod.

AND APPROPRIATION OAT A (If required)

13.

THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Speciry authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM lOA.

(Scleciry type of modification and authority) ~L; FAR 52.232-22

E. IMPORT ANT: Contractor is not. 0 is required 10 sign Ihis document and reI urn

"nn"'~JI'." (such as chllJlges in pDying

copies to the issuing office.

14. DESCRIPTION OF AMENDMENT !MODIFICATION (Organized by UCF section headings. inch..!ing solicitation/contract subject matter where feasible.) M

SOdi

F3'ficalion Control Number: 12 •••••

See 0, block 14, contrrualion page.

OO~{; {I

ST ANDARD FORM 30 (Rev. 10-83) Prescribed by GSA FAR (48 C'FR) 53.243


SUMMARY OF CHANGES

I. SECTION B - SUPPLlliS OR SERVICES AND PRICES

CLIN 0030

DASG60-98-C-000 I P00261

Page 2 of 15

The total cost of this line item has decreased by $2,000,000.00 from $140,795,358.00 to $138,795,358.00. ,.,

,. As stated in Modification P00251, CLIN 0030 has been established for the sole purpose of obligating GFEBS funding for performance of SubCLIN 0017 AA. The value of CLIN 0030 equates to the amount of GFEBS funding obligated for pertonnance of SubCLIN 0017 AA and should not be considered additional contract value. Informational SubCLINs under CLIN 0030 will be established each time additional GFEBS funding is obligated. CLIN 0030 and its SubCLINS will not be segregated from SubCLIN 0017AA, identified, accounted for, analyzed, or reported separately from SubCLINOO 17, including EVMS. All scope remains under SubCLIN 0017 AA with associated incentive events and flat zones.




As a result of this modification, the total funded amount for this document was decreased by $2,000,000.00 from $1,965,219,224.02 to $1,963,219,224.02.

SUBCLIN 003008:

NIX: 02120122013204000001171722550030003242A.0000013.1.1 6100.9000021001 A5XFJ (CIN GFEBSOO 102467000000 I) was decreased by $2,000,000.00 from $16,000,000.00 to $14,000,000.00

Estimated Cost, Estimated Fee, and Estimated total for the above decrease of $2,000,000 is distributed as follows and includes a decrease in estimated cost ( (' of cost and .f facilities capital cost of money) and a decrease in estimated fee of

Estimated Cost

Estimated Fee

Total ($2,000,000.00)

IMPLEMENT A TION OF AND EXPLANA nON OF THE RELA TIONSfllP OF THE LIMIT A TION OF FUNDS

OO:tlo (a

DASG60-98-C-000 1 P00261

Page 3 of 15

(LOF) CLAUSE TO FEE OBLIGATIONS, subparagraph C., is revised to read as follows:

SUBCLIN0017AA : TillS CUMULATIVE

PRIOR MODIFICATION TOTAL *

(1) Amount Required for Full Funding,

Including Fee: SO ~ (2) Amount AlIotted Under the LOF Clause



Payment of Fee: S

(4) Total Amount Allotted and Obligated: $1,732,016,533.26 ($2,000,000.00) $1,730,016,533.26

(5) Net Amount Required for Full Funding $ 44,885,598.34 $ 2,000,000.00 $ 46,885,598.34

* These figures take into consideration the negotiated total value of SubCLIN 0017 AA (This does not include SubCLIN 17 AH)

3. The following is an update to Modification P00260 showing a summary of funding by ACRN through Modification P00261 :

FUNDING

AA 440,100.00

AB 2,298,235.00

AC 17,832,987.00

AD 0.00

AE 7,500,000.00

AF 3,300,000.00

AG 17,192,400.00

OOd-Lo{3

Lloj-l)

lVJ~ct~

lb\L~

DASG60-98-C-000 1 P00261

Page 4 of 15

AH 700,000.00

AJ 200,000.00

AK 85,000.00

AL 45,000.00

AM 17,045,000.00

AN 5,800.00

AP 20,779,000.00

AQ 105,000.00

AR 35,000.00

AS 0.00

AT 6,984,678.52

AU 7,970,000.00

AV 0.00

AW 100,000.00

AX 3,396,000.00

AY 550,000.00

AZ 19,412,000.00

BA 24,527,878.00

BB 146,000.00

BC 72,000.00

BD 85,000.00

BE 100,000.00

BF 100,000.00

BG 1,975,321.00

BH 38,018,908.00

Bl 7,896,673.34

BK 260,000.00

DASG60-98-C-0001 P00261

Page 5 of 15

BL 0.00

BM 125,000.00

BN 103,000.00

BP 10,199,288.50

BU 350,000.00

BV 9,000.00

BW 84,896,852.00

BX 1,146,000.00

BY 3,880,000.00

BZ 190,000.00

KL 118,250.00

KM 192,793,000.00

KN 0.00

KQ 92,811.00

KR 0.00

KS 0.00

KT 386,377,998.00

KU 2,203,183.00

KV 65,000.00

KW 20,000.00

KX 60,000.00

KY 25,000.00

KZ 25,000.00

LA 13,508.00

LB 12,500.00

LC 200,000.00

LD 7,943,648.00

OOd-lt 15

DASG60-98-C·000 1 POO261

Page 6 of 15

LE 1,173,850.00

LF 10,000.00

LG 62,000.00

LH 400,000.00

LJ 7,476.00

LK $281,575,897.00

LL $173,798.00

LM $1,410,376.00

LN $630,061.00

LP $83,200.00

LQ $235,566.00

LR $125,000.00

LS $6,069,616.00

LT $530,377.00

LV $9,100,000.00

LV $1,957,265.00

LW $255,567.00

LX $68,000.00

LY $264,807,424.52

LZ $1,751,384.00

MA $2,982,442.00

MB $375,000.00

Me $2,283,481.00

MD $8,573.00

ME $0.00

l'v1F $270,907,822.39

MG $6,262,095.00

OO:lu I ~

DASG60-98-C-OOO 1 P00261

Page 7 of 15

MH $213,390.00

MJ $858,495.00

tvJK $56,076.00

IvIL $116,044.00

MM $1,618,600.00

MN $2,573,000.00

MP $250,000.00

MQ $691,421.00

l\.1R $0.00

MS $700,000.00

MT $16,289,524.00

MU $7,864,499.00

MV $39,921,199.75

MW $10,000,000.00

MX $138,795,358.00

MY $18,327.00

4. The following is an update to Modification P00260 showing a summary of funding by CLIN by ACRN through

Modification P0026 I :


CLIN 0001 AA 440,100.00

CLIN 0001 AD 0.00

440,100.00

CLIN 0003 AB 2,298,235.00

DAS060-98-C-000 1 P00261

Page 8 of 15

CLIN 0003 AC 17,832,987.00

CLIN 0003 AD 0.00

CLIN 0003 AE 7,500,000.00

CLIN 0003 AF 3,300,000.00

CLIN 0003 AO 17,192,400.00

CLIN 0003 AH 700,000.00

CLIN 0003 AM 17,045,000.00

CLIN 0003 AN 5,800.00

CLIN 0003 AP 20,779,000.00

CLIN 0003 AS 0.00

CLIN 0003 AT 6,984,678.52

CLIN 0003 AW 100,000.00

CLIN 0003 AY 550,000.00

94,288,100.52

CLlN 0005 BA 24,527,878.00

CLINOO05 BB 146,000.00

CLIN 0005 BC 72,000.00

CLIN 0005 BD 85,000.00

CLlN 0005 BE 100,000.00

CLlN 0005 BF 100,000.00

CLIN 0005 BO 1,975,321.00

CLIN 0005 BH 38,018,908.00

CLIND005 BL 0.00

CLIN 0005 BZ 0.00

65,025,107.00

CLIN0007AA BP

CLINOO09AA AQ

CLINOO09AA AV

CLINOO09AA BK

CLINOO09AA BM

CLINOO09AA BN

CLINOO09AB AJ

CLINOO09AB AK

CUNOO09AB AL

CLIN 0009AB AQ

CLINOO09AB AR

CLINOO09AB BK

CLIN 0009AB BN

CLIN 0009AB BU

CLINOO09AB BV

CLIN0013 AU

CLIN 0013 AX

CLIN 0013 AY

CLIN 0013 AZ

CLIN 0013 BJ

10,199,288.50

45,106.00

0.00

256,545.00

125,000.00

21,315.00

200,000.00

85,000.00

45,000.00

59,894.00

35,000.00

3,455.00

81,685.00

350,000.00

9,000.00

7,970,000.00

3,396,000.00

0.00

19,412,000.00

7,896,673.34

OOG-~ 19

10,199,288.50

447,966.00

869,034.00

DASG60-98-C-OOO 1 P00261

Page 9 of 15

CLIN 0017 BW

CLIN 0017 KM

CLIN 0017AA BY

CLINOOI7AA BX

CLIN 0017AA BW

CLIN 0017AA BZ

CLINOO17AA KM

CLIN 0017AA KN

CLIN 0017AA KQ

CLIN 0017AA KS

CLIN 0017AA KT

CLIN 00 I 7AA KV

eLIN 0017AA KY

eLIN 0017AA LC

eLIN 0017AA LD

CLIN 0017AA LE

CLINOO17AA LH

CLIN 0017AA LJ

CLINOO17AA LK

eLIN 0017AA LQ

CLIN 0017AA LS

CLIN 0017AA LT

CLIN 0017AA LV

0.00

0.00

3,880,000.00

1,146,000.00

84,896,852.00

0.00

192,793,000.00

0.00

66,151.00

0.00

386,204,200.00

2,203,183.00

0.00

200,000.00

7,943,648.00

0.00

400,000.00

7,476.00

281,575,897.00

235,566.00

6,069,616.00

530,377.00

$9,100,000.00

00 ~&d-O

38,674,673.34

0.00

DASG60-98-C-000 I P0026 I

Page 10 of 15

DASG60-98-C-000 1 P0026 I

Page II of 15

CUN 0017AA LV $1,957,265.00

CLIN 0017AA LW $255,567.00

CLIN 0017AA LX $68,000.00

CLIN 0017AA LY $264,807,424.52

CLIN 0017AA MB $375,000.00

CLIN 0017AA MC $2,283,481.00


CLlNOOl7AA ME $0.00

CLIN 0017AA MF $270,907,822.39

CLIN 0017AA MH $213,390.00

CLIN 00l7AA MJ $858,495.00


CLIN 0017AA ML $116,044.00

CLIN 0017AA tvIM $1,618,600.00

CLINOO17AA MN $2,573,000.00


CUNOOl7AA MQ $691,421.00

CLIN 0017AA MR $0.00

CUNOO17AA MS $700,000.00

CLINOOl7AA MT $16,289,524.00

CLlN 0017AA MY $39,921,199.75

CLINOO17AA MW $10,000,000.00

CLlNOOl7AA MX $138,795,358.00

CLIN OOl7AA MY $18,327.00

1,730,016,533.26

CLIN0017AB KL

CLIN0017AC BZ

CLIN 0017AD KN

CLIN 0017AD KS

CLIN0017AE LL

CLIN0017AH KT

CLIN0020AA KN

CLIN0020AA KQ

CLIN0021AA KW

118,250.00

190,000.00

0.00

0.00

173,798.00

\73,798.00

0.00

26,660.00

0.00

118,250.00

190,000.00

0.00

173,798.00

173,798.00

26,660.00

0.00

DASG60-98-C-OOO 1 P00261

Page 12 ofl5

CLIN 0021AB KV

CLIN 0021AB LB

CLIN 0021AB KX

CLIN 0021AB KY

CLIN0021AC KZ

CLIN 0021AC LA

CLIN 0022 KW

CLIN 0023 KX

CLIN 0023 KY

CLIN 0023 KV

CLIN 0023 LB

CLIN 0023 LF

CLIN 0023 LR

CLIN0024 LA

CLIN0024 LG

CLIN 0024 KZ

CLIN 0024 KW

CLIN0024 LP

0.00

0.00

0.00

0.00

0.00

0.00

0.00

60,000.00

25,000.00

65,000.00

12,500.00

10,000.00

$125,000.00

l3,508.00

62,000.00

25,000.00

20,000.00

83,200.00

0.00

0.00

0.00

297,500.00


Page 13 ofl5

CLIN 0025 LE

CLIN0025 LM

CLIN 0025 MA

CLIN0026 LN

CLIN0027 LZ

CLIN 0028 LM

CLIN 0028 MA

CLIN 0028 MG

CLIN 0028 MU

CLIN 00300 1* MX

CLINOO3002* 1\1)(

CLIN 000303 * MX

CLIN 000304* MX

CLIN 000305 * MX

CLIN 003006* MX

CLIN 003007* MX

1,173,850.00

1,080,404.00

0.00

630,061.00

1,751,384.00

329,972.00

2,982,442.00

6,262,095.00

$7,864,499

$52,974,283.00

$719,132.00

$5,747.00

$16,000,000.00

$ I 6,000,000.00

$38,000,000.00

$1,096,196.00

CO~~~~

203,708.00

2,254,254.00

630,061.00

1,751,384.00

17,439,008.00

DASG60-98-C-000 1 P00261

Page 14 of 15

CLIN 003008* MX $14,000,000.00

138,795,358.00

DASG60-98-C-OOO 1 P00261

Page 15 of 15

* CLIN 0030 has been established for the sole purpose of obligating GFEBS funding for performance of SubCLlN 0017 AA. Informational SubCLINs under CLIN 0030 will be established each time additioanl GFEBS funding is obligated. For pruposes of this funding update, funding obligated under CLIN 0030 will also be reflected under SubCLIN 0017 AA and should not be counted twice with regards to the total contract funding obligated.


Page Intentionally Left Blank

Not a Contract Document












USASMDCIAASTRAT SMDC·RDC POBOX 1500 fiUNTSVJlI.EAL 35807·3801

l. EFFEC"nVE DATE REQUISITION/PURCHASE REQ. NO.

. ADMlNlSlERED BY (Ifother than it .... 6) t..:.:.;:;.;..="-___ ; OCMA RAYTHEON

!IIAPPlE HIll. DRIVE MIS T2FR2 TEWKSBURY MA 01878

8. NAME AND ADDRESS OF CONTRACfOR (No., Streel, COWlly. Stale and Zip Code) RAYTHEON COMPANY 3!5IILO~ST. ANDOVERMAOI81().4400

9A. AMENDMENT SOLICITATION NO.

98. DATED (SEE ITEM II)

(SEE ITEM \3)

n ..... md solicit.tion is _dcd os set (nth in It .... 14. The ho.r and date spcciicd ilr ...,.ipt oro lir 0 i ••• 1 ntendod.

Oli:r I1IISlacknowledt:. receipt oflhi ........ dll"Cnt prior to Ih. ho.r and dlle 'pcci!cd in th. solicilltioo or as ...... dod by one oflhel>lIowi.llll:lbods:

(a) By c:oJq)leting hems 8 and I S. and I'dumin" __ copJes o(the iU'IEIldnau; (b) By adcnowlcdging ~cejpl aflhis am:ndDall on each copy orthc 0 .... stlbnitted;

or (c) By sopanl.lelter or I.I.g ..... wbich i.clud ... reference to th. solicitation IOd IIDmdJnCrIl nu .... .,.. FAILURE OF YOUR ACKNOWLEDOMENT1O BE

RECEIVED ATlHE PLACE DESIGN A lED FOR THE RECEIPT OF OFFERS PRIOR 10 lliE HOUR AND DAlE SP ECIFIED MAY RESULT IN

REJECTION OF YOUR OFFER. l(by vlnu. oflbi, _d .... t you desire to cbongc an olJ:r.lrcady ,ab"lled, such chanKe ny bellINI. by tel.gromor I",Ier.

eacb te-Ie-edlnar letterrmkes reamce to Ihesolicill1ioD IIId tbis ~ndlll:llt,lDd IS ~ci¥t!d priorlD Ihe openinG hOlUlDd dilte specilcd.

12. ACCOUNTING AND APP ROP RIA nON DATA (I r required}

13.

THISCHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM lOA.

L""""U,,"" \!RICn as changes in paying

OTHER (Specify type of modification and aUlhority)

E. IMPORTANT: Contraclor 0 isnot, is required to sign Ihis docwnent and return copies to Ihe issuing office.

14. DESCRIPTION OF AMENDMENTIMODIFICATION (Organized by UCF seclion headings, includingsolicilationlconlract subject matter where feasible.) Modification Control Nmnber:

See SF30, block 14, contlnuaHon page.

0J/i0\ ~~ ___ ,'-.:. )1..')

ST ANDARD FORM 30 (Rev. 10-83) Prescnbcd by GSA FAR (48 CFR) 53.243

SECTION SF 30 BLOC'"<' . ~ CONTINUATION PAGE

St:MMAR~ ~) F CH A "I(·:~S

SECTION .:, SOLICIT n - IONiCONTRACI' FORM

The foHowmg h.ave bee,. ":ded by full text: PURPOSE

SECTION SF 30 BLOCK 4 COhfTlNUATION PAGE

Tile purpost of this mr.di~ca tiOfl is to:

I. Correct admin istr'::tive errors to Modification P()0260.

2. Summary of Changes for Modification P00260 should have read as follows:

3. All corrections ar..: shown in bold red.

SUMMARY Of CHA~G'£S

I. SECfl O"l A - SOLl CI! ATION/CONT!lACT FORM

DASG60-98-C·OOO I POO262

Page 2 of21

Change Order Modification P00260 for JLENS based on restructure letter lLENS-20 12-03 I dated 27 September, 2012 Ceiling of conlract will increase by a tOlal of$59,034.271.

The total cost or this contract was increased by $59,034,271 from $ I ,955,6 16,308.00 to $2,01 4,650,579.00.

2. SECTlO:-'; B - SUP!·~.E.S OR SER VICES AND PRICES

SUBCLfN 0017AA

Tho; tuget CC5i r::s increased by "~,ro"," """"~Ot~'''''''''''1I The targel fee hz.s increased byl •••

The tetal targ~, cost plus fee oftbis line item has increased by $59,034,271 from $ 1.595 ,3 83,694 to

$1,654,41 7,';165.

This includes all Increase in target cost o~f •••• T~consistillg of a • ",re,,, ," facilities capital cost of mOlley, and an increase III target fee

r increase ill cost and a

The target cost and ~arget fee set forth above and in the table below reflects the negotiated Section B valUes prior to any adjustments made resul ting from estimated cost overruns and share ratio impacts to the fee. Any differences between tht: Estimated Cost values provided below and the Target Cost values provided above and shown on the table below are as a result of estimated cost overruns. Any differences between the Estimated Fee

DASG50·93·C'()OO! P;)0262

Page 3 of21

vallles prov;!l.~'i be low ~r.d 'he Target Fee values provided above and shown on the table below are a result o.

reductions bllseci on cu're~: ihare ratio impacts to the Target Fee and do not include any allocat ion for yet to be

earned il1ccl. 'i"ts as se, ri..' -6 in Section H- t 9. As of the date of this modification, the estimated cost and estimated

fee are as foll ows:

The Estimated CO:-<I is •••••• consisl ing of S1 ••••• in cost and ••••• in facilities capital cost cfmoney.

The Estimatec ~~C is S •••••

Tot~ i Estimated r: '51 plus Fee is S 1.776,902, I 32.

Pursuant to ?AR 16.405-1. the target cost and target fee will be finally determined and adjusted after contract

perfonnance.

The t'lb le below p<ovides a summary ofthe target cost, target fee, and total:

CUN

17AA

CLIN 0030

T1;<,: total cost of his line item has increased by SI6,000,000.00 from S 124,795.358.00 to

S 140, 795,35:UC.

SUBCi...N 003003 is ::ldded as follows:

ITEM NO SUPPLIES/SER .... '::ES Q UANTITY 003008

GFEBS Funding 1cr SubCLIN OO l 7AA

CPIF

FOa. Destination

UNIT UNIT PRICE A.W: "

AC R.'J MX $16,OOO.O~, " CIt\. GFEBSOO : ')24S7000000 [

(lJ\W (!:» UI,)

t.b¥..1{)

C':JX9-) ('p)(4 ' ,

(1;,1'0

DA:-:;G6 '}3-C -I}'jl)!

P00262 ,'age loi2

• AS stated ' •... f:.difiea : . -'002! I, CL ll" 0030 has been establ ishecl fo r the so le purpose of obligatmg GPESS

fur,ding for .:.:'(Ntnan';.o 0'" S':bCL I:-" OO ! 7AA The value o!"CLfN 0030 equates to the amount of GFE.S S fur.dlng

obi igatco fo: ::~ 'iorm31 ,.: '. $ ut;CL/:-' DO \7 AA and should no t be considered additional eontTllct. v3Iut:.

lnforma1ior;a; SuoCLf:-:s~,dcr CUN 0030 will be established each time additional GFEBS funding is ohlig3ted

CLN 0030 (V";; IS Sub·-; '';$ "'II! not be ~egregated from SubCLfN OOI7AA, identified, accounted for, anaIYJ'd.

o r reponed ~~,:~~ately ;"J"" :-'ubCUNOGI7, l'1dudlng F, VMS . All sr.:ope remains unu~r SubCLlN OO] 7AA with

a:.socia ted jr~~"'I\"e c .. ~,;~' Jl\ d flat lones

8 -: 7, ,;-';CEt. ·; "'; FE!: [OK SUBCL[N OOt7ANCLIN 0018 (SEE H-19):

1. i;coord;. :'~'-"it.i FAR 52.2 16'10, entitled "Incentive Fee", the total amount originally ot:gol iated,

adjusted in accordance ·"It<". ~aragtaph d. of this clause, fur target COSI and targe t fee for performance under Sub<..UN

00 17 ANC Lil'- 00 18 are S~! forth below:

,r,~e ntive .'" ~ - 'Igcmcrrt: ·\lfax:iUlum F~e:

Minimum Fee:

"r,tjcrrun ' f the amount by which the tocal allowable oost is less than the estimated cost until

max:imum fe~ :S lItminea.

OllemJn: the arnoun, by which the total allowable cost exceeds the estimated COlI t );nli!

minimwr. fee is '!.ttained.

FAR. 52.216·1 0, r:-.;CENTIVE, paragraph (eX! ), is staled as follows :

(e) F'!c Pa.yaole.

{ \ The ree ;.y~ble under this ~ntnlCl shall be the the tola l aHo .... RIlle cost :3 less than the estimated cost or decreased

cost exceeds !~e ~timll.~d ··ost. In no event :lhall the fee be greater

.,ercent (Mir.;'num fee) ~fth.:: ~tjma:ed cost .

""."" dollar that roc " ~'l' iiOiii;;u~"th. total allowable ;;.,,,, (M;u;,""," r •• )., less than.

. I:J- i ~ EsrlMAT~D COST. ESTIMATED (NCENTJVE FEE. MllilMUM INCENTIVE FEE.

MAXIMUM ;NCEN!r\iC :;EE, AND INCENTIVE ARRANGEMENT FOR SUBCLIN 00 I 7ANCLCN 00 18:

S1i3CU NOO I k ,. (Two SPD ILENS Systems)

c. ....I.nimun: ·~r,;~r,tjve fee:

CXJ~3'5

(b)(4) (b)(4)

(b)(4) (b)(4)

l':>)(~,

Cbi~)

fb) l't

e. L~tal estJr-J -!". ' :;os;: and estimated ftt :

3. SECTIOi' G - CQj\:71..\CT ADMlNISTR..<I"TION DATA

Summary fer ':le Payr.ll;"".~ .. ) ffice

$1,776,902,132

DASG60·98·C-OOO 1 P00262

Page 5 0[ 21

As a "<!sult of ;" 1:5 modification, the total funded amount fo r this document was increased by

516,145,2215.:9 from $ .:1 "-9,073 ,997.63 to 51,965,219,224.02.

SUBCLIN 00' i AA:

MF: 21 I 2040 5L 3i.68 PI724 19E5S5L 25S Y 4MIJ7]OOOO 50 1021 4MI1730000i I4MJLE/4MS was increased by $ :26,899 39 from $270.780,923.00 to $270,907,822.39

Estimated Cost, Estimatd Fee, and Estimated and includes an increase ~stimated

;;'n.'"'~';'i',~O:f '~~~:=;.' d; ;;Stributed as follows (b)( 4) • and facilities capital (b)( 4)

cost of mOrley) and an i ncr~ase in estimated

Esti:nated Cost

Estimated -;: ee

Total $ I Z;' , S~9J9

MY: 2, 1204051. 5i..58 PI724 19E555 L 251 6 4M IMM[CSTJ S0 1021 4M 1MMICSTJ/14MJMW4M5 was increased by $18,327.00 from $0.00 to $18,327.00

The contract ACRe'.' MY has been added.

(b)(4)

(b)( 4)

Estimated Cost, Estimated Fell, and Estimated total for the above increase of S 18,]27 is distributed as follows and

includes an [:l.crease in e ' t mat.'dil'ilOii"lI0iif b S_fcost and '-'ffacilities capital cost of money) and (b)( 4) an increase ir. estimated f~e of

(b)(4) Cost

Estimated ~~e (b)(4)

Total

CLlNOO]O;

• SUBCLIN OG3008: Funding on S(;8CLfN 00:')08 is initiated as follows:

Ib' /;')

ACRl'\; MX


DASG60-98-C-OOOI POOl.2

Page6 of 21

Ac.:tng Dw.: 02120 \::201320400000 t 171712SS0030003242A.OOOOO13.1.1 6100.9000021001

Incrust: S [6,000.0;)(l ao

Tocal: $16,000,000 .00

Cost Code: A:lXFJ

Estimated Cosl. EstimlrttO. Fee, and E!timatcd and includes an il'LCrease ;n ~5timatcd cost C(lSl of money) and an increase in estimmd

~ ,""',~ ;,~~ ofSI6.000,OOO is distributed as foUo\Ol1i • • roo ... ", ~ffacil ities capital

IMPLEMEr-o'TATION OF ANDEXPLANAnON OF THE RELAnONSHIPOf 1HE UMITAll0N OF FUNDS CLOF) CLAli5E TO FEE OBLIGATIONS, s~h c., is revised to read as follows:

SUBCLIN 0011AA : nus CUMULATIV-~

MODIFICATION TOTAL-

( I ) Amou;r, Requirl:d fc Full Funding,

lnclud;ng Fee: SI.7l7,867.861 $ 59,034,271 S 1,716,902,132

(2) Amount Allotted. Tj r.der the LOF Clause

few Paym.ent of Cous:

(3) Amount Separatt.:y Obliaated for

Payment QfFee:

(4) Total A:nount Allc;;:ed and Obligated: 51,715,871,307.27 S16,J4S,226.39 Sl,7J2,016,533.t;

(5) Net Amount Requi7ed ror Full Funding S 1,~-:'1:J-S-42;U9;04it'.~611--';'-"';M5i598~

"' . .'

uP '4,". i't'(, .sti' . l o1 ~ -(I'" ~ 4 (" ,r; , , .,f. 1: 4

,

DASG6C-98-C·()OO l POQ::!62

Page 7of:,

" These fig · . 'J.ke int: "'sideration the negotiated total value of SubCLIN 00 17 AA (This does not indud-e S .... bCU N [7A;·:)

4. SECTIC~I ,.¥ - SPEC',. COi\. TRACT REQUlREMENTS is revised as follows:

Paragrapn j-' . 9. INCE?\T;'1E FEE STRUCTURE Al'\'O PAYMENT FOR eLIN OO ! 7. SYSTEM

DEVELOPY;J,T &'11; )Sy{ONSIRATION (SODl, subparagraph a., b., and c., are revised as fellows:

SubCLIN OO! 7 AA, Systel"" Development and Demonstration (SOO), is a cost-plus-incentive-fee (CPIF) Line Item with cost ar.c schedule i;:c~ntives as described below. Paragraph H· [9(b) appl ies only to the Cost Incentive and Paragraph H-! 9(c) app lie~ only to the Schedule Incentive. The price amount of51,654,417,965 includes a target cost ofi capital cost of rno:lty: dnd a tar:;e. ·r.centlve is~ftarget cost I cost of

money.

b. C;5t Incent"!':

(I ) The target fee payab le under SubCLIN ~ of the estimated cost less facilities capital cosl of money ( ,,1 amount equal 10_ (2) The ma..'<i r.l :.m fee p<:~"b[e under SubCLlN 00 11AA is .,flhe estimated cost less facili ties capital cos' ~f money P."1 amount equal to d

I under SlIbCL~thc estimated cost less facilit ies capital cost of

amount equal ~

(4) Fee will b~ adjuste(ll~r actual cost that is less than or more than the estimated cost stated above using a share ratio o. Govemment ~Contractor for actual costs less than the estimated cost, and a ratio of _ Government. ~ntra~,or for actual costs greater than the estimated east range applied according to Paragrapn H-I9(c)(l).

(5) Nothing stated in this dallse shall take precedence over the clause 52.216-10 - Incentive Fee contained in this

contract.

c. S';hedule and Performance Incentive.

~~~~~~~~~'~'fl~'~t~z~oo~:ot"~Wfil;j' b~o~,~stablished at the target cost value ofSI,5IS.BS7,379 WIth the The "flat zone" over which the contractor will eam taiget fee is for eligible costs from the set forth below ate conducted. (Note: As of the

effective date of Modifkation maximum lat zone" has been

acknow!edg~c as earned. )

P I the maximum benefit of the "flat zone", earned by the conduct of the SOD System

Functional Review "''L T 2nd Quarter, Fiscal Year 2007. (It is hereby acknowledged by the government that

iRi'IYithi'loioiOO.~IiPII'ttcd the rcquircmenl for this flat zone and earned the "Flat Zone" schedule incentive of inal cctennination of incentive fee payment uti lizing the "Flat Zone" amount will be made at the

IJut( ('oj. 4'

b)L~ O~~

tb.x.~ .(1,)(<1;

DrI.'jGG -"3·(.AI(!" I'lhI2,)~

~'!!!"l:!oC2'

.:.r. ,', SIU!" <: ..:on .•

b) •••• __ L ~ • ~ ;n3.ximur.1 oent',it oftfl" "nJ: ZOll.(', ealned by tile conduct of SOD Cr, ;( (n'lnl

',,;cslgn rc.v -':LT 2. .1. ~r ~i:;cill Yt'3r 2009. L,t; is ht'reby acknowledgeo by the !!o'emrr.ent Ihat {aytilco[1

~;;.Hj:'.eted - ~ '~qui-er ' J' ,Cjos na! ror.e and elf1ed the " 1: lat Z\Jn~" schedule incentive of Final

'eh'f,!],I1'1I" !11<.<:' ~. I~:t)nttnt u::h,/;mg the "Flal tOIl~" amount will be made at the conclusior. ·f '.he ,. ILL ~.;.t:< I';'" I anu : -:01)9 . .. ".. ....

tc) 1)1 ....... ' . tne maximull ht:llelit or the " nat 1-un""', c3.rn.::d by the .:onductofthe Devc opnlental T cst I (oT -. t, accor~'"' . , wim ,he cnter:a kt forth in Section J attachment emitled Flat Zone Perforwance

Critena for fL::-G SO!:: )'ltract, Sectiun H.19(c), dated OSI I0f12. (It is hereby acknowledged by the govemmcnt

1'~"j'I"I!i"iiiihi"l-t' ~e 'l1p[et~ . e (e<j;Jlrement for this flat lOne and eamerl a "Flat Zone" schedule incentive ) f ! -:1 of the available Final determinll1ion of Incentive fee payment LJ i{i;o;ing the

"f'at Zone" l··,)Unl W' _! ~~<lde at the conclusion of the contrac!.)

(d) .0 ~~the maximum benefit of the " flat zone", earned by the conduct of the Elecrtonag'letic

Er,vironmenl<" EfTeciS 'Ei :'-esting in accordance with the criteria set forth in S~ction J ilttachment crltlttcd flat Zone

f.>crformancc (- ,; teria f<1. ! ·,'+5 SDD Cuntra<;:t, Seellon H-19(c), dated 0811 0/1 2.

~ e) 1-_ ~"the maximum bem:fit of the "flat zone", ~afned by the tonduct of the 1 11teJ"'dt~ Fire

Control Eve"- ;, acco r:l~"" with the criteria SCI forth In Section J attachment entitl.:d Flal Zulli: ~er r<1nnance

Criteria for L 2'>I"S SO D -::'').~tr'l.CI, Section H·19(c), dated 081 10112. (It is hereby acknowl",dged by the gOHmmcnt : ;4 •• ~"~ ~ reliUlrement for th is flat lOne and earned a "Flat Lone" sciledule incentive of I ·he available Final detenmnatlon of inceutivc f« payment uti!lung the

11ade at the conclusion of the contract.) *NOTE:

(t , __ ~ oithe maximum benefit of the Unat zone", earned by the conduct of tile Functional

Configuration Audit (FCAj.1 in accordance with thc cntcrla set forth in Settion J attachn:enl mutled Flat tone r:,>:'NS SOD Contract, Section H·19(c), dated 08/ 10/1 2. · Note:

(g) the maximcm benefit of the " flat zoneH

, earr,ed by tho: conduct of rJeve 'opmcll ta!

fest 2 COT ·2) in accorcarce with tile criteria ~t fon:h in Section J anacl\ment entitled Flat Zone Perform~rlce

Crncria:or r:.E.~S SD!; "~;::::Itract, S«:1ion H·I 9(cJ. dated OS/ IOf I2. ~

(11) ~fth<:: maxi lllu m bt:ue{ic orth~ " fl at mne", earned by the conduct of the Eart" User Test

(previously je fined as l..':'l. ted Uscr Test) in aCCOTdan.:e with the criteria sel forth in Section 1 anachm':J" ~1I1itled

Flat Zone Pe~:~~mance C"l'eri~ for /LENS SOD Contract, Section H·19lc), daled 0811 0112 . •

(i) ,~~\he maximum b-enefit o rtne "fiat lone". earned by the conduct of the Fina: 1" H1ction:;.

CunfiguTaliv 'l Audi t (Fe;, lin accordance with the criteria set forth in Seclion J attachment enti tled flat (-une

Po;: rforman(;e - :te ria fo :.£~S SDD Contract, Section H- 19(c). dated 08110/12, •

(3) for £ant.~\l Value ~ "Gost reporting purposes, Ihe estimated cost valul:' of ., •••••• Wlll be used.

(b)(3)(A) (i)&Title

10 Sec 130 (,)(b)

(b)(3)(A) (i)&Title

10 Sec 130 (,)(b)

L\,'L~:

lbl")

Uo\L~

(!;)1-~

\.I9)U

l\?)G

o,H'

d. Cnanges issued under FAR 52.243-2, Changes - Cost Reimbursement

DASG61_~ ·98-C-OOO I P00262

°age 9 of21

In the event :l"" a change issued under FAR 52.243-2, Changes - Cost Reimbursement, it is agreed that changes to the

perfonnance and schedule incentive may be considered a pan of the equitable adjustment. In the event that any Options to CLiN 00 17 are added and exerclsed, the incentive fee for cost and schedulelperformance applicable to

the Option wilt oe incofro:ated in accordance with the incentive f« structure of this provision.

5. The ronowmg is all update to Modification PQ0259 showing a summary of fu nding by ACRN through

Modification P00260:

FUNPIt-G

AA 440,WO.00

AB 2,298,235.00

AC J 7,832,987.00

AD 0.00

A£ 7.500,000 .00

AF 3,300,000.00

AG 17,1 92,400.00

AH 700,000.00

"1 200,000.00

AI( 85,000.00

AL 45,000.00

AYI 17,045,000.00

AN 5,800.00

AF 20,779,000.00

AQ 105,000.00

AI( 35,000.00

AS 0.00

AT 6,984,678.52

OO~(pyo

DASG60-98··C-OOO 1 P002b2

Page 10 of21

7,970,000.00

<\, 0.00

,~ 100,000.00

\X 3,396,000.00

550,000.00

19,412,000.00

24,527,878.00

146,000.00

SC 72.000.00

K) 85 ;000.00

8"2 ]00,000.00

B17 100,000.00

R(' .< J 1,975,321.00

38,018,908.00

81 7,896,673.34

BK 260,000.00

.; J. , ~~ 0.00

BM 125,OOOO[)

8"\ 103,000.00

Dn u, 1O,199,28UO

Be 350,000.00

[3 9,000.00

84,896,852.00

X 1,146,000.00

3,880,000.00

190,000.00

K.L 118,25000

OOd.{, L( I

KV

IN

f' v ,',. ,

KY

KL

LB

LC

ID

LK

p

192.793.00000

0.00

92,811.00

0.00

0.00

386,377,998.00

2,203.183.00

65,000.00

20,000.00

60,000.00

25,000.00

25,000.00

13,508.00

t2,500.00

200,000.00

7,943,648.00

i,173,850.00

10,000.00

62,000.00

J()O,OOO.OO

7,476.00

'S28 l,575,897.()O

$173,798.00

$i,410,376.00

5630,06 t .00

$33,200.00

$235.566.00

DASG60-98-C-000 1 P00262

P'tgel1of2!

, L

LZ

'vID

!\11:.

'ill-j

ML

MM

'vIP

'viS

$125,000.00

$6,069,616.00

$530,377.00

S9,i 00,000.00

$1,957,265.00

$255,567.00

:568,000.00

$264,807,424.52

$1,751,384.00

$2,982,442.00

$375,000.00

$2,283,481.00

$8,573.00

$0.00

5270,907,822.39

$6,262,095.00

$213,390.00

$858,495.00

$56,076.00

$ t 16,044.00

$1,61S,600.00

$2,573,000.00

$250,000.00

$691,42[,00

$0.00

$700,000.00

$[6,289,524.00


Page 12 r>f21

M'J

"" MW

MX

MY

57,864,499.00

S39,92I, I99.75

S 1 0,000,000.00

5140,795,358.00

SI8,J27.00

DASG60-9S-C·OOO I POO262

Page 13 of2 1

6. The following is an update to Modification P00259 showing a summary of funding by CLfN by ACRi'1 through Modification P00260;

f1&'D(NG AMI CLIN TOTAL

CLIN 0001 440,100.00

CLIN 0001 0.00

440,100.00

CLIN 0003 -'" 2,298,235.00

e LlN 0003 ,'\C 17,832,987.00

CLlN 0003 , ) 0.00

CLIN 0003 ,- 7,500,000.00

CLIN 0003 AI 3,300,000.00

CU N 0003 >\'-T 17,192,400.00

CLIN 0003 ,.; 700,000.00

CLIN 0003 A~.1 17,045,000.00

CU N 0003 A 5,800.00

CLIN 0003 AP 20,179,000.00

CU NOOO) \. 0.00

CLlN 0003 AT 6,984,678.52

CUN OOO: .v

CLiNOOO J

CLfN 0005 '" CUN 0005 d.J

CLIN 0005 B::

CLIN0005 3D

CLlNOO05 .... :::

CLINOOO:: 3,

CLIN 0005 B.:J

CUNOOO5 B:t

C ... fNOQOS: ,

CLIN 0005 Bl

CLIN 0001AA S"

CLiN OOOSAA <I

CLJ:l'\ 0OO9AA \V

eLIN 0009AA B<

eLIN 0009AA B;"!

(LIN 0009AA Bi'

100,000.00

550,000.00

24,521,878.00

146,000.00

72,000.00

85,000.00

100,000.00

100,000.00

1,915,321.00

38,0 18,908.00

0.00

0.00

10,199,288.50

45,106.00

0.00

256,545.00

125,000.00

21.315.00

94,233,100.52

65,025,101.00

10,199,288.50

441,966.00


Page 14 of21

•

CLIK 0009",8

elI!\" 0009AB ,

CLIN OOO~AB ,. eLIN 0OO9A.B , )

CUN 0009AB '-'

CUN 0009AB i3;\

eLIN 0009.'1.8 "' CLIN 0OO9AB , .

eLIN 0OO9AB ::;

CLIN 0013 AC

CUNCOll AX

eLIN DOl] AY

CUN 0013 ., CLINOOIJ . ,

o .

(LIN 0017

eLIN OO[~

(LIN OOl7AA " CUNOO17AA "'. .,

C1INOO17AA ?.,

CUNOO 11AA J? ,

200,000.00

85,000.00

45,000.00

59,894.00

35,000.00

3,455.00

81,685 .00

350,000.00

9,000.00

7,970,000.00

3,396,000.00

0.00

19,412,000.00

7,896,673.34

0.00

0.00

],880,000.00

1,146,000.00

34,896,852.00

0.00

Cb~~y~

869,034.00

38,674,673 .34

0.00

DASG6<l-98-C-OOOI P00262

Page 15 of21

•

DASG6U·98·CJ)(IOI POO262

Pa6C 16of:l

C;"f.\I 001 AA , \92,793,000.00

G.'[N 001 ,V\ 0.00

Ci...lN 001 ~."'-.... , 66,151.00

CLlNOO17AA 0.00

CLIN OO(1A"" 386,204,200.00

CLIN OOI~.~.'\ 2,20),183 .00

CLiNOOI":.I>..A 0.00

CLINOO l 7AA 200,000.00

CLiNOO l 7AA 7,943,648.00

C" .... fN 00 17 AA 0.00

CLINOOI1AA 400,000.00

CLINOO,-,-\.A 7,476.00

CLIN 00: 7 • .l.A 281.575,897.00

Ct.!NOQI7.'v, 235,566.00

eLrN OO!7AA l 6,069,616.00

C!...IN 0011AA T 530,377.00

CUN oo\7AA L $9,100,000.00

CLIN 0017AA $1,957,265.00

CUNOOl7AA I \V $255,567.00

CLIN 0017AA , $68,000.00

CLfNOOl7AA L S264,807,424.S2

CL I}JOO17AA ' , S375,OOO.00

CLfNOOl7AA $2,283,481.00

eLf.'! 00 I '": A:\ . ) $8,573.00

(LIN 0017AA $0.00

CLiN 00 17AA .' F $270.907,822.39

:L r-". (>1: I -

CLI"'\ 001 -' CU'" 00 . -, :U'>. ;') \ '

)\" ;0' -,

':1.1'-1 nOli \ \

CU'-i OW - \.\

CI P\ on " 'L'~IJOI "

eLi).. 00 1 • \ \.

,.. I' 00 1 \.\

1.1"'\ OO'7A ~

u)..oo~,. ...... \

1"\.001- , Ill'; OUI \ ,'\.

, ,

, ,

-, ,

',' " ',Ip

'J

-, ,-,

\'

"\

, ~

-,

.\I \-

5213,390.00

$858,495.00

$56,076.00

$116,044.00

$1,6 18,600.00

$2,573,000.00

5250,000.00

$691 ,421.00

50,00

S700.000.00

SI6.289,524.00

539,921.199.75

510,000,000.00

S~795,J58,OO

f" " '" $I8,m.oo ------

I! 8,25000

190,000.00

1 .7ll';0 1 ~533.66 0<,<'

118,250,00

190,000,00

DASG6(\·99-C·(lCC, pe~)":IJ~

P~~O!:l7cf:!

c" ... fN OOI?AD

CLIN 00171\0

CLIN 0017AE

(LIN 00 I-t....O:;

(LIN oo20."A

CLIN0020AA

(UN 002iP."'" \

CLIN 002 lAS

CUN0021AB Lo

CLIN002:Aii

CUN0021 AB

CLN 002:AC

CUN 0021A( \

0.00

0.00

173,798.00

173,798.00

0.00

26,660.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

0.00

173,798.00

173,798 .00

26,660.00

0.00

0.00

0.00

DASG60-98-C-OOO; POO262

Page 18 of21

CLrN 002:"

c .... fl\ 00:· .' , CLIN 002J .(

CLiN 002j :<. /

CliN 0023 .8

CL,N 002: ,

l:UN (}I)2. ,

CLfN 0024-

CLf'I' 0024

CLIN 002 4 i<..l

CLIN 0024 '<' .\;

CLIN 0024 ,

CUN0025

CLiN 0025

CLIN 0025

CLf)I 0026 ,

0.00

60,000.00

25,000.00

65,000.00

12,500.00

10,000.00

S 125,000.00

13,508.00

62,000.00

25,000.00

20,000.00

83,200.00

1, 173,850.00

1,080,404.00

0.00

630,061.00

OO,U5D

0.00

297,500.00

203,708.00

2,254,254.00

630,06 1.00

DASG60-98·C·OOO j PQ(}262

Page 19 ofl,

CLN OC:"

cu~ Q02~

CLIN 002f

CUN OOlC') i ' <'IX

CLTNOO300: ·x CLfN oomn:; . . .. ; CUNOOO;, 'X

CUN 00031)5" 'AX

CLIN 0030G6' .\It. "'(

CLIN 003(1f\7· ~X

CLiN 603008· vp.

1,751,384.00

329,972.00

2,982,442.00

6,262,095.00

$7,864,499

$52,974,283.00

$719.132.00

S5,747.OO

$16,000,000.00

$16,000,000.00

$38,000,000.00

S I ,096, 196.00

SI6,OOO,000.00

1,751,3 84.00

17,439,008.00

140,795.)58.00

DASG60-98-C-OOOI POO262

Page 20 of2!

• CLIN 0030 nas been established for the sole purpose of obligating GFEBS funding for performance ofSubCUI'o 00 17 AA. Informational SuoCLINs IUlder CLIN 0030 will be established each time additioanl GFEBS funding is obligated. Fer proposes of tltis funding update, funding obligated under eLIN" 0030 ~ill also be reflected Wldcr SubCLlN 00 17 AA and silould not be counted twice with regards to the total contract funding obligated.

DASG6<. -')8-C-C1O POr,2S:

,-----.-~-··-·-------·---------·------------------TC__::_:_:_==_ __________ ~--,------'. CO"TRACT lD CODE

AMENDMENT OF SOLICITATION/1\'10DIFICATION OF CONTRACT

12. AME'IDME:-JTt'VIODIFICA nON "10

RJ0263

I, ISSliED BY

USASMDCIARSTRAT SMDC·RDC PO BOX 1500 HUNTSVIlLE AL 35807-3801

. EFFEC11VE DA TE 4. REOUIsmO"tPURCHASE REO NO

0010303589

7 ADMINISTI;:RED BY (Ifotherrhan ;temo) '---------1 DCMA RAYTHEON

50 APPlE HILL DRIVE MIS T2FR2 TEWKSBURY MA 01876

8. NAME AND ADDRESS OF CONTRACTOR (No., Street, County, State and Zip ('--ode) RAYTHEON COMPANY 350 LOWELL ST ANDOVER MA 0181 (}.4400

A. AMENDMEt-.T

lOA. MOD. OFCONTRACT/ORDER NO. ~SG60-98-C0001

111t: ahov~ nunb~red solicitation is arrended as set fOrth in Item 14. 1lle hour and date specified lOr-receipt ofOti':r 0 is cxtend~d, 0 is not extended.

Otkr 1T1lSt acknowledge n .. "Ccipt of this arrenulTl:nt pnor to the huur and date specifh.:u in the solicitation or as arremled by one ofthe Dilowing In::thods:

(a) By cOIll'leting Items 8 and 15, and returning copies ofthe arrendrrent; (b) By acknowledging receipt ofthis arrendrrent on each copy ofthe offer 5ubrritted;

or(c) Ry separate letteror te1egramwhich includ~nce to the ,"olicitation and arrendrrrnt nurrbers. FAlT,lJRE OF YOUR ACKNOWL EOGME~TTO BE

RECErVED ATTIlE PLACE DFSIGNATED FOR TIlE RECElPTOF OFFERS PRIOR TO THE HOURAND DA TE SPECIFIED MAY RESULTlN

REJECllON OF YOL:R OFFER Ifby virtue ofthis am:ndrrent you desire to change an ofi:r already submitted, such change may bc ITBdc by telegmmor letter,

provIded each telegrnmor letter rmkes rei;cence to the solicitation and this arrendrrent, and 15 received pnor to the opening hour and date specified

12. ACCOUNT ING AND Alry PROP RIA TION DAT A (If required)

See Schedule

13. THIS [TEM APPLIES ONLY TO MODIFlCATlONSOF CONTRAerSiORDERS. IT MODIFIES T HE CONT RACf 10RDER NO. AS DESCRIBED IN IT EM 14.

A. THISCHAl'lGE ORDER [S lSSlJED PURSUANT TO: (SpecifY authority) THE CHANGES SET FORTH [N ITEM 14 ARE MADE [N THE CONTRAer ORDER NO. IN ITEM lOA.

CONT RACT 10RDER IS MODIFIED TO REFLEer THE ADMIN1SfRA TIVE ,",nLn.l·'U<'~ (such as changes in paying .) SET FORTH [N ITEM 14, PURSUANT TO THE AUTHORITY OF FAR

THlS SUPPLEMENT AL AGREEi'VIENT [S ENTERED INTO PURSUANT TO AUTHORITY OF:

(SpecifY type of modification and authority) FAR 52.232-22 Increrrental Funding

E. IMPORT ANT: Contractor [R] is not, 0 is required to sign this dlcwnent and retWll copies to the issuing office.

14. DESCRIPTIOI'\" OF AMENDMENT IiVIODlFlCATION (Organized by UCF section headings, including solicitation/contract subject matter

where feasible.) 1...... (b)(6) Modification Control Number: •

The purpose of this rmdification is to increrrentally fund a..IN 0017AA via a..IN 0030 ACRN MZ in the armunt of $21,000,000.00. ACRN KM for SLlN 0017AA in section G is incorrect and should be disregarded. Funded arrount total as a result of thiS rrodification in section G is incorrect and should be disregarded.

herein, all tCITIli and conditions of the docurrent rererenct!d in ltem9A or lOA, as hereto lOre changed, remnns unchanged and In full /Orce and etrct.

4

~ 158. CONTRACTOR/OFFEROR 15C. DATE SIGNED 16C. DAT(bj~

14-Feb-2013 (1oX0

30-105-04 APPROVED BY OJRM 11-84 ooau53

Sf ANDARD FORIvl30 (Rev. 10-83) Prescribed by GSA FAR (48 CFR) 53.243


SUMMARY OF CHANGES

SECTION A - SOLICITATION/CONTRACT FORM

The following have been added by full text: PURPOSE

CLIN0030

UAe>vOV-'1/l-'-.--VVV I

P00263 Page 2 of4

* As stated in Modification P00251, CLIN 0030 has been established for the sole purpose of obligating GFEBS funding for perfonnance of SubCLIN 0017 AA. The value of CLIN 0030 equates to the amount of GFEBS funding obligated for performance of SubCLIN 0017 AA and should not be considered additional contract value. Infonnational SubCLINs under CLIN 0030 will be established each time additioanl GFEBS funding is obligated. CLIN 0030 and its SubCLINS will not be segregated from SubCLIN 0017 AA, identified, accounted for, invoiced, analyzed, or reported separately from SubCLIN 0017, including EVMS. AIl scope remains under SubCLIN 00 i 7 AA with associated incentive events and fiat zones.

The following have been deleted: PURPOSE PURPOSE PURPOSE PURPOSE

SECTION B - SUPPLIES OR SERVICES AND PRICES


U.t\.':)VOV-~/)-L-VVV 1

P00263 Page 3 of 4

ITEM NO SUPPLIES/SERVICES QUANTITY UNIT 003009

UNIT PRICE AMOt.JNT $0.00


CPIF

FOB: Destination

PURCHASE REQUEST NUMBER: 0010303589

TARGET COST

TARGET FEE

TOTAL TGT COST + FEE

MINIMUM FEE

MAXIMUM FEE

SHARE RATIO ABOVE TARGET

SHARE RATIO BELOW TARGET

$0.00

$0.00 $0.00

$0.00

$0.00

ACRNMZ $21,000,000.00 CIN: GFEBSOO 1 03035890000 I

SECTION E - INSPECTION AND ACCEPTANCE

The following Acceptance/Inspection Schedule was added for SUBCLIN 003009: INSPECT AT INSPECT BY ACCEPT AT N/A N/A N/A

SECTION G - CONTRACT ADMINISTRATION DATA



ACCEPT BY Government


SUBCLIN 0017 AA:

KM: 21 72040 5L 5L68 Pl7419E555L 255Y 4M7J730000 SOlO21 4M7J730000174MJLE/4M was increased by $192,793,000.00 from $0.00 to $192,793,000.00

The contract ACRN KP was changed to KM. The Cost Code' has been added.


ACRN:MZ

CIN: GFEBSOO 103035890000 1

OO<1lP 55

Acctng Data: 02120 132014204000001 17 1 722550030003242A.0009263. 1. 1

Increase: $21,000,000.00

Total: $21,000,000.00

Cost Code: A5XFJ


UA~vOV-':II:5-L-VVV 1

P00263 Page 4 of4

6100.9000021001

MOD00263 SECTIOl\i SF 30 BLOCK 14 CONTINUATION PAGE

SUMMARY OF CHANGES


CUN0030

The total cost of this line item has increased by $2 1,000,000.00 from $138,795,358.00 to $159,795,358.00. *

* As stated in Modification P00251, CLL'J" 0030 has been established for the sale purpose of obligating GFEBS funding for performance of SubCLIN 0017 AA. The value of CLIN 0030 equates to the amount of GFEBS funding obligated for performance of SubCLIN 0017 AA and should not be considered additional contract value. Informational SubCLINs under CLIN 0030 will be established each time additional GFEBS funding is obligated. CLIN 0030 and its SubCLINS will not be segregated from SubCLIN 0017 AA, identified, accounted for, invoiced, analyzed, or reported separately from SubCLIN 0017, including EVMS. All scope remains under SubCLIN 0017 AA with associated incentive events and flat zones.


ITEM NO SUPPLIES(SER VICES QUANTITY 003009


CPIF

FOB: Destination

UNIT

PURCHASE REQUEST NUMBER: 0010303589

UNIT PRICE AMOUNT

ACRNMZ $21,000,000.00 CIN: GFEBSOOI03035890000 1




As a result ofthi::; modification, the total funded amount for this document was increased by $21,000,000.00 from $1,963,219,224.00 to $1,984,219,224.00.


ACRN:MZ

CrN: GFEBSOO 103035890000 I

Acctng Data: 0212013201420400000 I 171722550030003242A.0009263.1.1 6100.9000021001

OO~lo51

Increase: $21,000,000.00

Total: $21,000,000.00

Cost Code: A5XFJ

Target Cost, Target Fee, and total for the above increase of $21 ,000,000 is distributed as follows and includes an increase in target cost of cost and 'facilities capital cost of money) and an increase in target fee


~ -. -==t [MPLEMENT ATION OF AND EXPLANATION OF THE RELATIONSHIP OF THE LIMITATION OF FUNDS (LOF) CLAUSE TO FEE OBLIGATIONS, subparagraph c., is revised to read as follows:

SUBCLIN 0017AA: THIS CUMULATIVE

PRIOR MODIFICATION TOTAL * (1) Amount Required for Full Funding,

Including Fee: $1,776,902,132 $ 0 $ 1,776,902,132 ,,-,, ~£) All10unt Allotted Under the LOF Clause

for Payment of Costs: • (3) Amount Separately Obligated for Payment of Fee: $

(4) Total Amount Allotted and Obligated: $1,732,016,533.66 421,000,000 $1,753,016,533.66 (5) Net Amount Required for Full Funding $ 46,885,598.34 ($21,000,000) $

* These figures take into consideration the negotiated total value of SubCLrN 0017 AA (This does not include SubCLIN 17 AH)


ACRN FUNDING

AA 440,100.00 AB 2,298,235.00 AC 17,832,987.00 AD 0.00 AE 7,500,000.00 AF 3,300,000.00 AG 17,192,400.00 AH 700,000.00

AJ 200,000.00

AK 85,000.00 AL 45,000.00 ANI 17,045,000.00 AN 5,800.00

25,885,598.34

(Pt4

(b~~)

AP 20,779,000.00

AQ 105,000.00

AR 35,000.00 AS 0.00

AT 6,984,678.52 AU 7,970,000.00 AV 0.00 AW 100,000.00

AX 3,396,000.00

AY 550,000.00

AZ 19,412,000.00

BA 24,527,878.00

BB 146,000.00

Be 72,000.00

BD 85,000.00

BE 100,000.00 BF 100,000.00

BG 1,975,321.00

BH 38,018,908.00 BJ 7,896,673.34

BK 260,000.00 BL 0.00 BM 125,000.00

BN 103,000.00 BP 10,199,288.50

BU 350,000.00

BV 9,000.00 BW 84,896,852.00

BX 1,146,000.00

BY 3,880,000.00

BZ 190,000.00 KL 118,250.00

KM 192,793,000.00

KN 0.00

KQ 92,811.00

KR 0.00 KS 0.00

KT 386,377,998.00

KU 2,203,183.00

KV 65,000.00

KW 20,000.00

KX 60,000.00 KY 25,000.00

KZ 25,000.00 LA 13,508.00

LB 12,500.00

LC 200,000.00 LD 7,943,648.00

LE 1,173,850.00

LF 10,000.00

CO&~59

LG 62,000.00 LH 400,000.00 LJ 7,476.00 LK $281,575,897.00 LL $173,798.00

LM $1,410,376.00

LN $630,061.00

LP $83,200.00

LQ $235,566.00

LR $125,000.00

LS $6,069,616.00

LT $530,377.00 LU $9,100,000.00 LV $1,957,265.00 LW $255,567.00

LX $68,000.00 LY $264,807,424.52

LZ $1,751,384.00 MA $2,982,442.00 ME $375,000.00 MC $2,283,481.00

MD $8,573.00 ME $0.00

MF $270,514,880.00

MG $6,262,095.00 MH $213,390.00 MJ $858,495.00 MK $56,076.00

ML $116,044.00

MM $1,618,600.00 MN $2,573,000.00 MP $250,000.00 MQ $691,421.00

MR $0.00 MS $700,000.00 MT $16,289,524.00

MU $7,864,499.00 MV $39,921,199.75 MW $10,000,000.00

MX $159,795,358.00

4. The following is an update to Moditlcation P00255 showing a summary of funding by CLIN by ACRN through Modification P00256:

CLIN 0001 CUN 0001

AA AD


440,100.00 0.00

440,100.00

CLIN 0003 AB 2,298,235.00

CLlN 0003 AC 17,832,987.00

CLlN 0003 AD 0.00

CLINOO03 AE 7,500,000.00 CLIN 0003 AF 3,300,000.00 CLIN 0003 AG 17,192,400.00

CLIN 0003 AH 700,000.00 CLlN 0003 AlV1 17,045,000.00

CLIN 0003 AN 5,800.00

CLIN 0003 AP 20,779,000.00

CLIN 0003 AS 0.00

CLIN 0003 AT 6,984,678.52

CLIN 0003 AW 100,000.00

CLIN 0003 AY 550,000.00

94,288,100.52

CLIN 0005 BA 24,527,878.00 CLIN 0005 BB 146,000.00

CLIN 0005 BC 72,000.00

CLIN 0005 BD 85,000.00

eLIN 0005 BE 100,000.00

CLlN 0005 BF 100,000.00

CLIN 0005 BG 1,975,321.00

CLIN 0005 BH 38,018,908.00

CLIN 0005 BL 0.00

CLINOO05 BZ 0.00

65,025,107.00

CLINOO07AA BP 10,199,288.50

10,199,288.50

CLINOO09AA AQ 45,106.00 CLINOO09AA AV 0.00

CLINOO09AA BK 256,545.00 CLINOO09AA BM 125,000.00

CLlNOO09AA BN 21,315.00

447,966.00

CLINOO09AB AJ 200,000.00 CLINOO09AB AK 85,000.00

CLINOO09AB AL 45,000.00

CLINOO09AB AQ 59,894.00

CLINOO09AB AR 35,000.00

CLIN 0009AB BK 3,455.00

CLIN 0009AB BN 81,685.00

CLINOO09AB BU 350,000.00

CLIN 0009AB BY 9,000.00

C()clb~l

869,034.00

CLIN 0013 AU 7,970,000.00 CLIN 0013 AX 3,396,000.00 CLINOO13 AY 0.00

CLI~0013 AZ 19,412,000.00

CLNOO13 BJ 7,896,673.34

38,674,673.34

CLIN 0017 BW 0.00

CLIN 0017 KM 0.00 0.00

CLIN 0017AA BY 3,880,000.00 CLIN 0017AA BX 1,146,000.00 CLIN 0017AA BW 84,896,852.00 CLINOO17AA BZ 0.00 CLINOO17AA KM 192,793,000.00 CLIN 0017AA KN 0.00 CLIN 0017AA KQ 66,151.00 CLIN 0017AA KS 0.00 CLIN 0017AA KT· 386,204,200.00 CLIN 0017AA KU 2,203,183.00 CLIN 0017AA KY 0.00 CLIN OOl7AA LC 200,000.00 CLIN 0017AA LD 7,943,648.00 CLIN 0017AA LE 0.00 CLIN 0017AA LH 400,000.00 CLINOOl7AA LJ 7,476.00

CLIN OOl7AA LK 281,575,897.00

CLIN 0017AA LQ 235,566.00

CLIN 0017AA LS 6,069,616.09

CLINOO17AA LT 530,377.00 CLIN 0017AA LV $9,100,000.00

CLIN 0017AA LV $1,957,265.00

CLIN 00I7AA LW $255,567.00

CLINOOl7AA LX $68,000.00

CLINOO17AA LY $264,807,424.52

CLIN 0017AA MB $375,000.00

CLIN 0017AA Me $2,283,481.00

CLIN 0017AA MD $8,573.00

CLINOO17AA ME $0.00

CLINOO17AA MF $270,514,880.00




CLIN 0017AA ML $116,044.00

CLIN 0017AA MM $1,618,600.00

CLIN 0017AA MN $2,573,000.00

CLIN 0017AA MP $250,000.00

CLIN 0017AA MQ $691,421.00

CLIN 0017AA MR $0.00

CLIN 0017AA MS $700,000.00

CLIN 0017AA MT $16,289,524.00

CLIN 0017AA MV $39,921,199.75

CLINOOl7AA MW $[0,000,000.00

CLIN 0017AA MX $140,795,358.00

CLIN 0017AA MY $18,327.00

CLIN 0017AA MZ $21,000,000.00

1,751,016,533.66

CLIN 0017AB KL 118,250.00

118,250.00

CLIN0017AC BZ 190,000.00

190,000.00

CLIN 0017AD KN 0.00 CLIN 0017AD KS 0.00

0.00

CLINOOI7AE LL 173,798.00 173,798.00

CLIN 0017AH KT 173,798.00

173,798.00

CLIN0020AA KN 0.00 CLIN 0020AA KQ 26,660.00

26,660.00

CLIN 0021AA KW 0.00

0.00

CLIN 002lAB KV 0.00 CLIN0021AB LB 0.00 CLIN0021AB KX 0.00 CLIN 002lAB KY 0.00

0.00

(x)~~(o3


0.00

CLIN 0022 KW 0.00

0.00

CLIN0023 KX 60,000.00 CLIN0023 KY 25,000.00 CLIN0023 KV 65,000.00 CLIN0023 LB 12,500.00 CLIN0023 LF 10,000.00 CLIN 0023 LR $125,000.00

297,500.00

CLIN0024 LA 13,508.00 CLIN0024 LG 62,000.00 CLIN 0024 KZ 25,000.00 CLIN0024 KW 20,000.00 CLI1'~ 0024 rn Lr 83.200.00

203,708,00

CLIN0025 LE 1,173,850.00 CLIN 0025 LM 1,080,404.00

CLIN0025 MA 0.00

2,254,254.00

CLIN0026 LN 630,061.00

630,06l.00

CLIN0027 LZ 1,751,384.00 1,751,384.00

CLIN 0028 LM 329,972.00

CLIN0028 MA 2,982,442.00

CLIN 0028 MG 6,262,095.00

CLIN0028 MU $7,864,499

17,439,008.00

CLIN 003001 * MX $52,974,283.00

CLIN003002* MX $719,132,00

CLIN 000303* MX $5,747.00

CLIN 000304* MX $16,000,000,00 CLIN 000305* MX $16,000,000.00

CLIN 003006* MX $38,000,000.00

CLIN 003007* MX $1,096,196.00

CLIN 003008* MX $14,000,000.00

eLIN 003009* MX $21,000,000.00

159,795,358.00

* CLIN 0030 has been established for the sole purpose of obligating GFEBS funding for performance of SubCLIN 0017 AA. Informational SubCLINs under CLIN 0030 will be established each time additional GFEBS funding is obligated. For purposes of this funding update, funding obligated under CLIN 0030 will also be reflected under SubCLIN 0017 AA and should not be counted twice with regards to the total contract funding obligated.




oa,;Z660


6. ISSUED BY

USASMOCfARSTRAT SMDC·RDC 1'0 BOX 1500 KUNTSW.I.E AI. 3S8OT.3801

NO.

CODE

llul""ruK'LH'''~REQ. NO.

L!.!::'..:..:=:....----1 .ADMINISTERED BY (Ifolherll .... il<lll6) - DC"'ARAYTHEOH

50 APPlE HIU. DRiVE M/sTlFA2 TEW<SBURYM ... D1878

8. NAME AND ADDRESS OF CONTRACTOR (No., SlTeet, County, Stale and Zip Code) RAYTHEON CQNPANY 350 LOYtSl. ST. ANDOI/ER "'AOl8'0' ... 00

9A.AM

98. DATED (SEE IT EM I!)

O"IIIISlI.knawlcdsc rccclpi oflhi. IIII:I1d"""l priOriO Ih. hour and d.,especllcd in Ih. SOUcillllion or u am:nded by one oflb, .. Uowlall_hod.: (I) By 00""letln8 II ... 8 Ind 15 •• ad Rlumlol __ copies oflhCln1Olldmcnl; (hJ By IckoowlqinllltCclpl oflhis ..... dlllt.' Dn .Icb copy orlhe a ..... builled; .r(c) By •• panlc loUer Drldearamwhich iDclud ..... hace 10 Ih •• olicilllloD and amomdlR!1l1 nuldtm. FAILURE OF YOUR ACKNOWLEDGMENTlO BE RECEIVED A TlH E PLACE DESIGNA -reO FOR me RECEIPT OF OfFERS PIUOR TO mE HOUIlAND DATE SPECIFIED MAY RESUL TIN

REJl!CnON Of YOUR OFFER. Ilby vlrtuc .flhi. 'lImd"""'l you desi", I. chanse Ill •• liready subuiUed.such Cblllie!MY be ... de by 'olOllramor leller, provided .Ich 1tlellTIDIo, leller nakes "'e .... celo Ihuolicililion ond Ihls ....... dnznl.llld '" .... elved prior 10 Iheopenlog b •• rlllddllespccifed.

12. ACCOUNTING AND APPROPRIATION DATA (If required)

13.

THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM lOA.

CHANGES (such as chanse! in paying

. OTHER (Specify type ofmodilication and authority)

E. IMPORT ANT: CQRlrac:lor 0 is DOt, ~ is required to silP1lhis document and return copies to the isslling office.

14. DESCRIPTION OF AMENDMENT !MODIFICATION (Organized by UCF seCI ion headings. including solicitation/contract subject matter where feasible.) Modification Control NlIII\ber: ...... ..

See ConUnuatlon Page

PAGES

10

NO.

Iii_~~~~ __ iiiiii~i<r;";~:--I~) ll9)

:"""'-6C-. -OA-T-E SJ-GN-ED---1 (10 yo)

• t MAR ZUll b1o)

sr ANDARD FORM 30 (Rev. 10·S3) Prescribed by GSA FAR(48 eFR) 53.243

SECTIO!,; SF 30 BLOCK 14 CONTI:-.lUATION PAGE

The following items are applicable to this modification:


SUMMARY OF CHANGES

SECTION A - SOLICIT A TION/CONTRACT FORM

The following have been added by full text: PURPOSE

The purpose of this modification is:

DASG60-9 8-C-OOO 1 P00264

Page 2 of 10

1. Settlement of P00260 Change Order Modification per the USD, AT &L NunnMcCurdy directed restructure of JLENS contract DASG60-98-C-OOOI submitted in letter JLENS-2012-031.

The target cost, target fee, and total contract value will not be adjusted from Change Order modification P00260 and subsequent modifications that make corrections or add incremental funding through modification P00263.

2. It is understood that P00260 Change Order amount of $59,034,271 shall not change from $59,034,271.00.

3. Attach GFE list dated 01124/2013 in section J of the contract.

4. Attach Contractor Furnished Property (CFP) list dated 01124/2013 which includes Cooperative

Engagement Capability (CEC) Hardware, and Revised additional test spares in section J ofthe contract. Note: Engineering units are acceptable for delivery so long as all components are form, fit and function equivalent.

5. Attach revised DD250 Plan dated 02-11-2013 in section J of the contract.

6. Attach revised Functional Configuration Audit (FCA) Plan dated 02/14/2013 in section J of the contract.

7. Attach revised Master Test Plan dated 02/0412013 to section J of the contract.


Pagc30flO

8. The requirement to change order is

nder this (b)(3)(A) (i)&Title 10 Sec 130 (a) (b)

(ROR) is (b)(3)(A)(i)&Title 10

will remain at Sec 130 (a)(b) (nX 4: values are included in the $59,034,271.00 change order P00260, llD)L'\-

but are to be documented in the modification for baselining purposes).

10. Aerostat Accident Recoup Direction

The Aerostat Accident shall be considered settled within this restructure settlement with no further intent by the Government to take further action in this matter. In consideration for this accident Raytheon shall provide (2) JLENS compliant Tethers in the amount of $2,316,819.00, as well as the Governments cost avoidance and other consideration. Agreement by Raytheon to this settlement relinquishes all claims for equitable adjustment by Raytheon, and the Government denies the increase to the Contract Budget Baseline (CBB) as requested by Raytheon. In consideration of the foregoing, the Government hereby releases Raytheon from any and all liability under the contract for further claims or liability attributable to the Aerostat Accident.

11. Upon execution of this contract modification, Raytheon will commence rebaselining the work to go including the FY'13 restructure as part of the SDD (CLIN 0017 AA). Raytheon will incorporate the changes for the restructured baseline in accordance with its documented process guidelines and procedures.

12. Flat Spot Opportunity Incentive Criteria


(1) A maximum ••••• "flat zone" will be established at the target cost value of •••••• with the conduct of milestones below. The "flat zone" over which the contractor will earn target fee is for eligible costs from 0 ••••••

once the program milestones set forth below are conducted. (Note: As of the effective date

(b)( 4)

of Modification P00260, the maximum 'flat zone" has (b)( 4) liv'£' been acknowledged as earned.)

(a) 7_0 of the maximum benefit of the "flat zone", earned by the

conduct of the SDD System Functional Review NL T 2nd Quarter, Fiscal Year 2007. (It is hereby acknowledged by the government that Raytheon completed the requirement for this


Page 4 of 10

flat zone and earned the "Flat Zone" schedule incentive of' •••••• Final

determination of incentive fee payment utilizing the "Flat Zone" amount will be made at

the conclusion of the contract. Reference letter, dated 5 March 2001 ,, __ -(b)\LP)

l\D )L~) (b) of the maximum benefit of the "flat zone", earned by the

conduct of SnD Orbit Critical Design review NLT 2nd Quarter, Fiscal Year 2009. (It is

hereby acknowledged by the government that Raytheon completed the requirement for this

flat zone and earned the "Flat Zone" schedule incentive of ••• Final (b)(4)U~ determination of incentive fee payment utilizing the "Flat Zone" amount will be made at

the conclusion of the contract. Reference letter, dated 12 January 2009, •••••••• l\r, 1~) Ll-:> )Clij

(c) Yo of the maximum benefit of the "flat zone", earned by the conduct of the Developmental Test 1 (DT-l) in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDD Contract, Section H-19(c), dated 08/10/12. (It is hereby acknowledged by the government that Raytheon completed the requirement for this flat zone and earned a "Flat Zone" schedule incentive

of r 2 fo of the available & I Final determination of incentive fee payment utilizing the "Flat Zone" amount will be made at the conclusion of the contract.)

(d) $_ ..... 0 of the maximum benefit of the "flat zone", earned by the conduct

ofthe Electromagnetic Environmental Effects (E3) Testing in accordance with the criteria

set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDD

Contract, Section H-19(c), dated 08/10/12.

(e) .g d ,....-0 of the maximum benefit of the "flat zone", earned by the conduct of the Integrated Fire Control Event in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDD Contract, Section H-19(c), dated 08/10/12. (It is hereby acknowledged by the government that Raytheon completed the requirement for this flat zone and earned a "Flat Zone" schedule

incentive of. or"l0 of the available • ): Final determination of incentive fee payment utilizing the "Flat Zone" amount will be made at the conclusion of

the contract.) *NOTE: The potential has been

(i)&Title 10 Sec

(f) 53 *~o of the maximum benefit of the "flat zone", earned by the 130 (a) (b)

conduct of the Functional Configuration Audit (FCA) #1 in accordance with the criteria set

forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDD

Contract, Section H-19(c), dated 08/10/12. *Note: The potential has been increased from

(b)C4-)

cbl(4j

(b)c+)


10

~!!!E:tio~===='ue to movement of the _ncentive fo

(g) .-' ~ of the maximum benefit of the "flat zone", earned by the conduct of Developmental Test 2 (DT -2) in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SOD Contract, Section H-19(c), dated 08/10/12. *

(b)(3)(A) (i)&Title 10 Sec 130 (a)(b)

~)Y-~

~J)(4

••• 1/0 of the maximum benefit of the "flat zone", earned by the conduct (b )(4) (1:1)( I of the Early User Test (previously defined as Limited User Test) in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDD Contract, Section H-19(c), dated 08/10/12. *

(i) ~ Sio of the maximum benefit of the "flat zone", earned by the conduct of the Final Functional Configuration Audit (FCA) in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SOD Contract, Section H-19(c), dated 08/10/12. *

(3) For Earned Value and cost reporting purposes, the estimated cost value of •••• Iwill be used.


In the event of a change issued under FAR 52.243-2, Changes - Cost Reimbursement, it is agreed that changes to the performance and schedule incentive may be considered a part of the equitable adjustment. In the event that any Options to CLIN 0017 are added and exercised, the incentive fee for cost and schedule/performance applicable to the Option will

be incorporated in accordance with the incentive fee structure of this provision.

SECTION J - LIST OF DOCUMENTS, EXHIBITS AND OTHER ATTACHMENTS

The following have been modified:

J.:l. SECTlO]\: J - LIST OF DOCUMENTS, EXHIBITS A~D OTHER ATT ACHME]\:TS

The following have been modified:

5. SECTION J - LIST OF ATTACHMENTS:

Section J is changed as shown below:

Contract Security Classification Specification (DO Form 254), Revision II (Added per Modification POO 187) (DO Form 254 mailed via US Postal Service)

Contract Security Classification Specification (DO Form 254), Revision 13 (Added per Modification P00235)

14 May 09

14 Apr II

JLENS Software Source Code Specifically Negotiated License, 04 Sep 08 License Number JLENS-SWLA-O 1

8

(Added per Modification POOI66)

CLIN 0017: JLENS System Development and Demonstration (SOD) Program Statement of Work (Revised by Incorporating CSDR Plans dated 20 Febr 2007 in Appendix C per Modification POOI36)

JLENS System Development and Demonstration (SOD) Program Statement of Work (Added per Modification POOI87)



JLENS System Development and Demonstration (SOD) Program Statement of Work (Added per Modification P00240)

Contract Data Requirements List (DO Form 1423) Exhibit A with Distribution List & Data Item Nos. BOOI through B062 (Replace Data Item Nos. 8026 and B027, only Per Modification POO 1 J6) (Replace Data Item Nos. B048 and B049, only Per Modification POO 143 & to add statement in Section A of Modification POOI4J) (Replace Data Item No. BOJJ only, per Modi fication POO 16/)

30 Nov 06-Revised 20 Feb 07

Revised 06 Apr 09

Revised 09 Mar 10

Revised 01 Sep 11

Revised 26 Sep II

01 Dec 06

Revised 05 Apr 07

Revised 24 Oct 07

Revised II Jul 08

DASG60-98-C-OOO 1 P00264

Page 6 of 10

#OF PAGES

11

13

37

38

36

36

J6

63

(b)(3)(A)(i)&Tillc 10 Sec 130 (a)(b)

Contract Data Requirements List (DO Form 1423) Exhibit A, Data Item Nos. B001 and B014 (Added per Modification roo 187)

Contract Data Requirements List (DO Form 1423) Exhibit A, Data Item Nos. 8 002 through 8062 (less 8014 ) (Added per Modification POOIS7)

Contract Data Requirements List (DO Form 1423) Exhibit A, Data Item Nos. BOOI and 8014 (Added per Modification P00239)

Contract Data Requirements List (DO Form 1423) Exhibit A, Data [tern Nos. 8004 (Addcd per Modification P002S7)

"Added statement below to address weekends/Holidays: (In Mod POO143)

Revised 07 May 09

Revised 20 Mar 09

Revised 30 Aug II

Revised 31 Jul 12

24 October 07

DASG60-98-C-Ooo 1 P00264

Page 7 of 10

2

60

2

"Per a mutual agrcement between Raytheon and JLENS Product Office all Contract Data Requirements List (CORL's) (DO Form 1423) are due on the next business day after the required due date if the due date falls on Saturday, Sunday or a Govemmcnt Holiday. In addition, for any CDRL with a requirement to resubmit within 10 days or less after receipt of comments, where Raytheon receives the comments on a Friday, the timeframe for rcsubmittal will begin on thc neit business day. Statement added in Mod P00143 on 24 Oct. 2007.

GFEiGFP/GF$ List for SOD Replaced wi th Rev. B List "'Add items below For record-keeping purposes (Pcr Mod PO0143) Replaced wi th Revision C List (Per Modification POO l 83) Replaced with Rcvision 0 List (Per Modification P00207)

28 Nov 06 15 Oct 07 Revised 22 Ocl 07

09 Mar 09

23 Feb 10

2 6

12

11

"'Per the D CMA is authorized rent free use on a non-interference use of the equipment listed below on JLENS Fire Control Radar Prime Contract DASG60-98-C-0001 for the period from 19 April 2007 through 30 September 20 11 .

OO~.!o'73

(b)(4)

Hereby added in Mod POO 148 for tracking purposes; Originated in Basic Contract: Government Furnished Equipment - Spiral 1 (Spiral I Equipment Transferred to Government Contract DASG60-00~ 1149 (attached)

_ (b)(6)

(b)(4 )

20 Jun 03 25 Mar 07·

(Revised 21 Nov 07)-


Page 8 of 10

I List 34 pages 34 pages

-NOTE: Items 1-1060 transferred to Contract DASG60-00-e.OO91 per revised GFE list daled 21 Nov 07. Items 1061 - 1116 GFE items retained on Contract DASG60-98-C-OOOI for Spiral 2 per aFE list dated 25 Mar 07.

J LENS Performance Specification, MIS-PRF-5S628. Revision A

(Added by rererence per Modification POO168)

Annex A to the JLENS Performance Specification, MIS-PRF-5S628, Revision A

(Added by reference per Modification P00168)

JLENS SOD 00250 Plan (Added per Modification P00207)

Engineering Change Proposal (Eep) MI-N3893. Revision 2, CORL B039-005b

Engineering Change Proposal (ECP) MI-N3894, CORL B039-006

Engineering Change Proposal (ECP) MI-N3895. CORL 8039-007

Engineering Change Proposal (ECP) Jl1359 (Added per Modification POO240)

Flat Zone Performance Criteria for JLENS SOD Contract, Section H-19(c) (Added per Modification P00242)

Revised Flat Zone Performance Criteria for lLENS SOD Contract, Section H-19(c) (Added per Modification P00257)

Test Spares List (Added per Modification POO247)

SubCLIN 0017AA

27 Jun 08

27 lun 08

II DeeM

15Novi0

18 Aug 10

28 Sep 10

20 lun 11

01 Nov 11

02 Aug 12

Undated

The following added by reference per Modification PO00264

136

\0

,

" 16

'0

7

4

7

8

'Government Furnished Equipment list (GFE) 24 Jan 13

..... Contractor Furnished Property list (CFP) 24 Jan 13 (Includes Cooperative Engagement Capability (CEC Hardware)

" SDD DD250 Plan

... Functional Configuration Audit (FCA) Plan

FY13 Master Test Plan, H492257 Rev b

" Flat Spot Opportunity Incentive Spreadsheet

, FY13 Final Test Spares List

CLIN s 0023 and 00024 JLENS Simulation Support SOW dated 28 January 2008 For JDEP, Nimble Fire and Simulation Suppon Tasks (Added per Mod POO 160)

CLIN 0025

JLENS Integrated Fire Control Demonstration Program Statement of Work, Revision 3 (Added per Modification POOI65)

JLENS Integrated Fire Control Demonstration Program Program and Technical Clarification Description, incorporated herein by reference (Added per Modification POOI65)

JLENS Integrated Fire Control Demonstration Program Statement of Work, Revision 5 (Added per Modification P002! I)

lLENS Integrated Fire Control Demonstration Program Program and Technical Clarification Description, incorporated herein by reference (Added per Modification P00211)

Contract Data Requirements List (DD Form 1423) Exhibit B, Data Items Nos. BOO 1 through B004, with Data Item Descriptions (Added per Modification POO \65)

Contract Data Requirements List (DO Form 1423), CLIN 0028, Exhibit B, Data Item Nos. BOOI through 8006 (Added per Modification P002Il)

11 Feb 13

14 Feb 13

04 Feb 13

N/A

04 Mar 13

28 January 2008

14 Jan 08

25 Jul 08

14 Sep 09

30 Mar 10

16 Oct 01

16 Jun 10


Page 9 of 10

1

1

4

28

62

7

6

2 pages

3

11

3

26

19

6

CLfN 0027

JLENS System Integration Lab (SIL) Equipment List (Added per Modification POD 196)

Revision to System Integration Lab (SIL) Equipment List (Added per Modification P00217)


Undated 6

02 Aug 10


Page 10 of 10

6

(b)(3)(A)(i)&Title 10 Sec 130 (a) (b)

(b) (3) (A) (i)& Title

10 Sec 130 (a) (b)

(b) (3) (A) (i)& Title 10 Sec 130 (a)

(b)

(b) (3)

(A)

(i)& Title 10 Sec 130 (a)

(b)

(b) (3) (A)

(i)&

Title 10 Sec 130 (a) (b)

(b)(3) (A)(i)&Title 10 Sec 130 (a)(b)

(b) (3) (A)

(i)& Title 10 Sec 130 (a)

(b)

(b) (3) (A) (i)& Title 10

Sec

130 (a)

(b)

(b)(3)(A)(i)&Titlc 10 Sec 130 (a)(b)

(h)(3)(A)(i)&Title 10 Sec 130 (a) (h)

(b)(3)(A)(i)&Title 10 Sec 130 (a)(b)

(b)(3)(A)(i)&Title 10 Sec 130 (a)(b)

(b)(3)(A)(i)&Title 10 Sec 130 (a)(b)

(b)(3)(A)(i)&Title 10 Sec 130 (a)(b)

G <:( cx::: IZ o u CI CI V)

Y"

(b)(3)(A) (b)(4)

FLAT SPOT INCENTIVE CRITERIA FOR SDD CONTRACT, SECTION H-19(C)

(b)(3) (A) (b)(4)

(b)(3) (A) FLAT SPOT INCENTIVE CRITERIA FOR

~ a:: Iz a u £:) £:) Vl . Vl -

Ia Q.. Vl

5 u..

(b)(4)

(b)(4)

(b)(4)

FLAT SPOT INCENTIVE CRITERIA FOR \jS SDD CONTRACT, SECTION H-19(C)

(b)(3)(A) (b)(4)

w > IZ w U Z I-a 0-Vl

S u..

(b)(4)

(b)(4)

(b)(4)

(b)(4)

(b)( 4)

(b)(3)(A)(i)&Titie 10 Sec 130 (a)(b)

(b)(4) iI

(b)(4)

(b)( 3)(A) (i)&Titlc to Sec 130 (a) (b)

(b)(3)(A) (i)&Title HJ Sec 130 (a)(bJ

(b)(3)( A) (iJ&Title \() Sec 130 (a) (b )

(b)(3)(A) (i)&Tillc 10 Sec 130 (a) (b)

(b) (4)

(bj(3)(A) (i)&Till l.' 10 Sec \30 (a)

,bl

(b)(4 )

(b)( 3)(A) (ij&Titlc 10 Sec 130 (a) (b)

(b)(3) (A) (i)&Titlc 10 Sec I ) U (a)

(b)

(b)(J) (A) (i)&Titlc 10 Sec UO (al (b)

(b)(4)

(b)(3) (A) (i)&Title 10 Se, 130 (a) (b )

(b) (3) (A) (j)& Title 10 S<, 130 (.) (b)

(b)(4)

(b)(4)

(h)(4)

(b)(3)(A) (i)&Titlc 10 See 130 (a)(b)

(b)(3)(A) (i)&Titie

10 Sec 130 (a)(b)

(h )(3)( A)

(i)&Title 10 Sec 130 (a) (b)

(b)(4)

Raytheon

Page 12 of62

OOd-'7DJ...

(b)(3)(A) (i)&Titic 10 Sec 130 (a)(b)

(b)(3)(A) (i)&Tille 10 Sec 130 (a)

(b)

(b)(3) (A) (i)&TiUe IOSee 130 (a) (n)

(b)(4)

CAGE Code 057 16 Doc H4 92257 Rev -

4 February 20 13

(h)(3)

IA) (i)&Title 10 Sec 130 (a) Ib)

(b)(3)(A) (i)&Tille 10 Sec 130 (a)(b)

(b)1 3)(A) (i)&Titlc 10 Sec 130 (a)(b )

(b )(4)

lbyw; \.klfo. lut-) Co'/}; (?l~)

(bl (4)

) 30 (a)(b)

(b)(4)

:, I

(b)(3)(A) (i)&Title 10 Se,130(a) (b)

(3)( A )

(b)14)

(i)&Title 10 St.'C 130 (a)(b)

(b)(4)


(" )(3)(A) (i)&Titie 10 Sec 130 (a) (b)

(b )(3)(A) (i)&Titlc \0 Sec 130 (a) (b)

(bJ(4)

(b)(3)(A)

10 See 130 (a)(b )

(b) (3) (A) (i)&Titlc IOSee no (a ) (b)

(b)(3)(A) (i)&Title III See 130 (a)(b)

(b)(4)

(b)(J,)( A j (ij&Title 10 Sec 130 (aj (bl

(bl('1

(b)(3)(A) (i)&Title 10 Sec 130 (a) (bl

(b)(3)(A) (i)&Titlc 10 Sec 130 (a)

(bl

(b)(4)

130

(i)&Titlc 10 Sec 130 (a)(b)

(i)&Til lc

(b)(3)(A) (i)&Titic 10 Sec 130(a) (hi

(b)( 4)

(b)(3)( AI ( i)&'Title 10 Sec 130 (a) (bl

(b) (J)(A) (i)&Tille 10 Sec 130 ( iI) (1I)

(h)(J)(A) (i)&Titlc 10 Sec 130 (a) (hi

(h)(3)(A) (i)&Title 10 See 130 (a)(b)

(h) (4)

(b)(3)(Al (i)&Titlc 10

Sec 130 (al (b )

(b )(3) (A) (i)&Titic 10 Sec 130 (a)

Ibl

(b)(3)(A) (i)&Tillc 10 Sec 130 (a)(b l

(b)(4)

(iJ&·fi". I. 130 (a)(b)

(b)(3)(A) (i)&Tille 10 Sec 130 (a) (b)

(b)(3)(A) (i)&Title 10 Scc 130 (a)(b)

(Il)(J)(A) (i)&Titie 10 Sec 130 (a)(b)

(b)(J)(A) (i)&-Titlc 10 Sec 130 (a) (b)

(b)(4)

(b)(3)(A) (i)&Titlc 10 Sec 130 (a)(b )

(b)(3)(A) (i)&Titlc 10 Sec 130 (a) (b)

(b)(3)(A) (i)&TitJe LO Sec

130 (a)(b)

(b )(3)(A) (i)&Title 10 Sec 130 (a) (b)

OOJ')/~

OOdl:L1

(b) (4)

(h)(3)( A) (i)&Titic 10

130 (a) (b)

(b)(4)

(b)(3)( A) (i)&Titlc \0 Sec 130 (a)(b)

(hJ(4)

(b)(3)(A) (i)&Title 10 Sec 130 (a) (b)

(h )(3)( A) (i)&TitJe 10 Sec 130

(,, )(b)

(b)(4)

(h)(4)

(bIl3I1A) (i)&Titic JO Sc, 130 (3)

(')

(')(4)

(b)[7)( E)

(b )(3)[ A) (i)&Titlc 10

Sec 130 (a) (bl

(b)(J) (A) (i)&Tillc 10 Sec 130 (a)(b)

(b)(4)

00;2'131

(b)(3)(A) (i )&Tille IOScc130 (a)(b)

(b) (3)(A) ( i)&Titie 10 Sec 130 (a)(b)

(b)(3)(A) (i)&Titlc

(b)(4)

(bj(3)(A) (i)&Titlc 10 SCI,:

L30 (a)(b)

(b) (4)

Page 48 of 62 (b)(4)

COD.'133

(b)(3)(A)


(b)(3)(A) (i)&Title 10 Sec 130 (a)(b)

(b)(3)(A) (i)&Title 10 Sec 130 (a)(b)

(b)(3)(A) (i)&Title IOxe 130 (a)(b)

(b) (3)(A) (i)&Tllle

IO S« 130 (a)(b)

(b)(3){A) (i)&Titie

10 51!' 130 (a) Ib)

Ib)(4)

(b )(3)

(AI (i)&Tille IU Sec 130 (a)

(b l

(b)(3)(A) (i)&Title 10 Sec 130 (a)(b)

(b )(3)(A) (i)&Titlc lOSe<: 130 (al (bl

(b)(4)

(b)(3)(A) (i)&Titic 10 Se, 130 (a)(b)

(b)(3) (A) (i)&Titlc 10 Sec 130 (a) (b)

(b)(3)(A) (i)&Title 10 Sec 130 Cal (b)

(h)(4)

(b)(3)(A) (i)&Title 10 Sec 130 (a)

Ib)

(b)(J)(A) (i)&Titlc 10 Soc 130 (al Ib)

(b)(3)(A) (i )&Title 10 Sec 130 (a )

Ib)

Ib)(4)

(h)(3)(A) (i)&Title 10 See 130 (a) (b)

(b) (3I1A) (i )&Titic 10 See 130 (a) (b)

(b)(3) (A) (i )&Till e 10 Sec 130 (a) (b)

(b)(4)

-OJ~'74Y

(b)(3) (A) (i)&Title 10 51:' 130 (a)

(b)

(b){3)(A) (i)&Titlc 10 SCI; 130 (a)(b )

(bJ(4)

(h )(3)(A) (i)&Title \0 Sec 130 (a) (bl

(b)(3)(A) (i)&Titlc 10 Sec 130 (a)(b)

(b )(3)(A) (i)&Titlc 10 Sec J 30 (a) (b l

(b)(4)

(b)(3)(A) (i)&Title 10 SC( 130 (a)

(h)

(b)(3) (A) (i)&Title 10 Se( 130 (a) (h)

(h)(3)(A) (i )&Title iO SC( 130 (a) (h )

(b)(4)

(b)(3)(A) (i)&Tillc 10 Sec 130 (a) (b)

(b )(3)(A )

(i)&Tit lc 10 Sec 130 (a) (b)

(b)(3)(A) (i)&Titlc 10 Sec 130 (a) (b)

(b)(4)

(b )(3) (A) (j)&Tille 10 Sec:: 130 (a) (b)

(b)(3) (A) (i)&Till c 10 Sec 130 (a) (b)

(b)(3) (A) (i)&Titl e 10 Sec 130 (a) (b)

(b)(4)

(b)(3) (A)

(i)&Ti tie 10

S" 130 (a)(b)

(b)(3) .

(AI (i)&Tit Ie 10 Se, 130 (a)

(bl

(b)(3) (AI (i)&Titl

e IV Sec 130 (a)

(hi

(b)(4)

(h )(3)(A) (i)&Tillc 10 Sec 130 (a)(b)

(b)(3)(A) (i)&Tille 10 Sec 130 (a)(b )

(b )(3) (A) (i)&Title 10 Sec 130 (a) (h )

(b)(4)

Documents

IERMA0181~ - EPIC · oo~S04 . Target Fee --Incentive Arrangement: Maximum Fee: Minimum Fee: (Share Ratio: Government/Contractor) DASG60-98-C-000 1 P00254 Page 3 of 12 (b )(4) (b )(4)